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A bstract
Impaired wound healing affects 3% of the population over 60 and costs over £1 billion 
annually in the UK. Chronic wounds are characterised by prolonged inflammation, 
impaired re-epithelialisation and defective extracellular matrix (ECM) remodelling. 
Fibroblasts play an important role in the closure of skin wounds, they replace and 
remodel the lost tissue and also influence both re-epithelialisation and angiogenesis. 
Numerous in vivo chronic wound animal models have been reported however, they fail to 
accurately model human chronic wounds.
This investigation aims to develop an in vitro chronic wound bioassay .Chronic wound 
fibroblast (CWF) and patient matched normal fibroblast (NF) cell strains (n=3) were 
retrovirally infected with a hTERT/puromycin construct. Population doubling levels 
(PDLs) were determined over an extended time in culture. RNA at defined time points 
was extracted and analysed using Asymetrix™ U133A microarrays. A cohort of gene 
expression changes were confirmed by QRT-PCR and the promoter regions of these 
genes used to construct fluorescent reporter human NF and CWF cell lines.
Population doubling levels indicated that, compared to primary (non-immortalised) CWF 
and NF, the hTERT infected fibroblasts had escaped replicative senescence and formed 
an immortalised cell line. Ajfjfymetrix™ microarray analysis of the CWF-hTERT with the 
NF-hTERT identified 247 genes that were significantly up- or down-regulated in CWF 
(validated by QRT-PCR). Upstream promoter regions of 13 genes of interest and a 
housekeeping gene have been identified by database searches/sequence analysis, 
amplified and cloned into the promoterless reporter vector pZsGreenl-DR. Reporter 
constructs have been transiently transfected into human NF and CWF cell lines and are 
currently being tested for efficacy.
CWF and NF cell lines have been created which demonstrated distinct gene expression 
profiles. The disease marker genes will form the basis of a low cost, highly reproducible 
fluorescent reporter cell-based bioassay which will be utilised in the discovery of novel 
therapeutics which have the potential to alter the chronic wound healing and, in turn, 
reduce unnecessary animal experimentation.
CHAPTER ONE
INTRODUCTION
1.1 The skin
The skin is, by volume, the largest single organ of the human body. It has multiple 
functions as diverse as temperature regulation and microbial protection. The skins 
primary function is as a barrier: it acts as the first line of defence against pathogens 
attempting to enter the body and as a water proof barrier preventing the loss of water 
from the body by evaporation. The skin protects underlying muscle and organs from 
mechanical, chemical and ultraviolet damage. The skin aids in the regulation of body 
temperature through the vasodilatation/vasoconstriction of blood vessels close to the 
skin, sweat glands and hair follicles. The skin also acts as a sensory system through 
nerve endings within the dermis allowing the detection of heat, cold, pressure and 
importantly tissue injury. The skin is also responsible for the body’s production of 
vitamin D.
The skin is not composed of a single cell type but is the result of multiple cell types 
working together. The skin can be separated into three discrete layers, the epidermis, 
dermis and the hypodermis. The epidermis and dermis are separated by the basement 
membrane (a collagen rich membrane allowing communication between the dermis 
and epidermis and anchoring the cells of the epidermis).
1.1.1 The Epidermis
The epidermis is the outermost layer of skin. It is this layer that forms the waterproof 
barrier protecting the body from water loss. The epidermis is composed of many 
layers o f cells forming a stratified epithelium with an underlying basement membrane. 
The epidermis contains four main cell types, keratinocytes, melanocytes, Merkel cells 
and Langerhans cells. The epidermis consists of five strata or sublayers, The outer 
stratum comeum is thickened in areas of the body with increased mechanical load
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such as the ball o f the foot. Below the stratum comeum are, in order, the stratum 
lucidum granulosum, spinosum and finally the stratum basale. The epidermis does not 
contain any blood vessels. Instead nutrients are supplied to the cells of the stratum 
basale by diffusion from the underlying dermis.
1.1.1.1 Keratinocytes
Keratinocytes are the most abundant cell of the epidermis and are responsible for the 
synthesis of keratin the main structural protein of the epidermis (Eckert et al., 1997). 
The type of keratin produced changes as the keratinocytes differentiate during 
keratinisation, with basal cells synthesising keratins 5 and 14 and the surface 
keratinocytes containing keratins 1 and 10 (Laijava et al., 1993). As well as keratin, 
keratinocytes are able to synthesise the components of the basement membrane such 
as collagen types IV and VII, laminin and fibronectin. This is important in wound 
healing as the keratinocytes are able to synthesize fresh basement membrane as they 
migrate during re-epithelisation (Romero-Graillet et al., 1996).
1.1.1.2 Melanocytes
Melanocytes are neural crest derived cells, which through melanogenesis produce the 
pigment melanin. Melanin acts to protect the skin against ultra violet radiation 
damage and is synthesised in specialist organelles called melanosomes. 
Melanogenesis occurs at basal levels in the skin leading to differences in skin tone, 
and is upregulated by exposure of the cells to UVB radiation leading to an increase in 
skin pigmentation (Kim and Holbrook, 2001, Iggo and Muir, 1969).
3
1.1.1.3 Merkel Cells
Merkel cells are neural crest derived oval shaped cells found within the stratum basale 
of the epidermis. The exact function of Merkel cells is disputed, however they appear 
to function as mechanoreceptors (Ginhoux et al., 2006).
1.1.1.4 Langerhans cells
Langerhans cells are found in the stratum spinosum of the epidermis and are the only 
dendritic cell type found within the epidermis. Langerhans cells are derived from 
monocytes (Eckert, 1989) and form the immune systems first barrier to invading 
pathogens. Langerhans cells are mobile; they ingest antigens present in the skin, 
migrate to the lymph node and present the antigens to T-lymphocytes.
1.1.1.5 Keratmisation
Mitosis occurs in the stratum basale. Keratinocytes formed in this layer move up 
through the strata changing shape and cellular composition (McMillan et al., 2003). 
The cells becoming progressively flatter as they move up through the strata, dying as 
they are separated from the diffused nutrients from the dermis. The cells synthesise 
more o f the protein keratin, a fibrous protein which replaces the cytoplasm within the 
cells, allowing them to become waterproof. Over this period these cells lose their 
nuclei and die. This gradual process of comification is called keratinisation and 
normally takes four weeks. The cells that reach the outer stratum comeum are dead 
and because of the high keratin content are consequently waterproof. These cells are 
subsequently constantly sloughed off by friction.
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1.1.2 The Basememt Membrane
The basement membrane zone is the junction between the epidermis and the dermis. 
The basement membrane is composed of a variety of different proteins including 
collagen type IV and type VII, perlecan and laminin (Metcalfe et al., 1997). The 
basement membrane allows the attachment of the epidermis to the underlying dermis.
1.1.3 The Dermis
The dermis is composed of a dense matrix of connective tissue known as the 
extracellular matrix (ECM). The ECM is predominantly made up of collagens 
however, it is also rich in proteoglycans, glycosaminoglycans and signalling 
molecules. The principle cell type of the dermis is the fibroblast. Fibroblasts are 
responsible for the synthesis and the remodelling of the ECM. In addition to 
fibroblasts, the dermis is also composed of macrophages and mast cells. The dermis 
contains an extensive network of blood capillaries supplying nutrients and growth 
factors to both the dermis and the stratum basale o f the epidermis. The dermis 
contains many of the skins nerve endings and mechanoreceptors providing sensory 
information about touch and temperature in addition to lymphatic vessels, hair 
follicles and sweat glands.
1.1.3.1 Fibroblasts
Fibroblasts are mesenchyme-derived cells; they have a bipolar, spindle shaped 
morphology in vivo and play a vial role in the skins response to injury. In normal 
uninjured skin, fibroblasts are in the GO phase of the cell cycle (quiescence), they do 
not actively proliferate, however they do still regulate the composition of the ECM.
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Quiescent fibroblasts are still able to secrete ECM components as well as matrix 
metalloproteinases (MMPs), which are able to modify the ECM and tissue inhibitors 
o f metalloproteinases (TIMPs) responsible for the control MMP activity. Upon 
wounding fibroblasts are activated by exposure to growth factors, re-enter the cell 
cycle and proliferate. Activated fibroblasts have an increased rough endoplasmic 
reticulum compared to quiescent fibroblasts and secrete a number of growth factors, 
cytokines and ECM protein components.
1.13.2 Macrophages
Macrophages are part o f the body’s innate immune system, giving a non specific 
response to pathogens. They are derived from monocytes, drawn into the dermis 
through the endothelium of the dermal blood vessels by chemotaxis. Monocytes are 
attracted to sites o f tissue damage by damaged cells, pathogens and signals released 
by mast cells. When in the dermis they differentiate into macrophages. Macrophages 
are phagocytes (as are the monocytes from which they are derived) and engulf cellular 
debris and pathogens. Macrophages are antigen presenting cells; they activate the 
specific immune response via T-helper cells generating antibodies to the antigen and 
aiding further macrophage phagocytosis. A further function of macrophages within 
the dermis is as a source of growth factors and cytokines, aiding in the recruitment of 
cells to the wound environment.
1.13.3 Mast Cells
Mast cells are bone marrow derived tissue based inflammatory cells acting as part of 
both the innate and the acquired immune response. Mast cells are characterised by the 
presence of cytoplasmic granules rich in histamine and heparin (Prussin and Metcalfe,
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2003). When activated through an IgE-dependent mechanism, mast cells release 
histamine and a number of cytokines (Watson et al., 2001, Smith et al., 1986). Mast 
cells play an important role in the wound response and in the defence against 
pathogens.
1.13.4 Extracellular Matrix
The ECM of the dermis like all ECM contains three classes of molecule, structural 
proteins, proteoglycans and adhesive glycoproteins all forming an interlocking mesh. 
The dermal ECM is generated and modified by dermal fibroblasts; it provides an 
anchorage for cells and a repository for growth factors.
1.13.4.1 Structural proteins of the ECM
The most abundant of the structural proteins in the ECM are the collagens,. Type I 
collagen is the most abundant of these structural ECM proteins, however collagen 
types III, V and VI are also present (Greenberg et al., 1991). Collagen fibres are made 
up of multiple collagen fibrils which are in turn made up of individual collagen 
molecules. Structurally collagen molecules are triple helices formed of three 
intertwined polypeptide chains. It is this multilayer quaternary structure, that gives 
ECM collagen fibres great mechanical strength. Collagen fibres are cross linked by a 
family o f proteins known as transglutaminases. The transglutaminases are a family of 
acyl-transferases that form bonds between glutamine residues and primary amines 
(Kielty et al., 2002, Kielty and Shuttleworth, 1997, Montes, 1996). With collagens, 
transglutaminases form bonds between glutamine and lysine residues of adjacent 
fibres forming a strong meshwork of collagen fibres. The collagen fibres impart great 
strength to the ECM however, the fibres are rigid and do not impart flexibility into the
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ECM. The skin must be able to flex and change shape to allow for movement of the 
body. This elasticity is provided by elastic fibres consisting of elastin and fibrillin rich 
microfibrils (Waller and Maibach, 2006, Lavker et al., 1986). Elastin molecules are 
cross linked by lysine-lysine covalent bonds, with the elastin network able to assume 
either an extended or compact configuration. This ability allows the elastin fibres to 
stretch giving the ECM the required flexibility. IN aged skin elastin fibres 
demonstrate signs of degradation and misfolding, thereby reducing the elasticity of 
the skin (Bernstein and Uitto, 1996).
1.13.4.2 Glycosaminoglycans, proteoglycans and glycoproteins of the ECM
Glycosaminoglycans (GAGs) are long unbranched polysaccharides consisting of 
repeating disaccharide units. The number and order of the different disaccharide units 
is unique to each GAG. In the dermis GAGs are important for the retention of water 
and the hydration of the skin. GAGs are able to bind many times their own volume of 
water (Choi et al., 1989). Glycosaminoglycans that are found in the dermis include 
hyaluronic acid (HA) and the chondroitin sulfate glycosaminoglycans. 
Glycosaminoglycans with a protein core are referred to as proteoglycans; this family 
includes the chondroitin sulphate glycosaminoglycans decorin and versican. One of 
the most abundant proteoglycan in the dermis is decorin, a member of the small 
leucine-rich proteoglycan family. Decorin is made up of a core protein with a single 
GAG chain containing either chondroitin sulfate or dermatan sulphate. In skin 
decorin GAG chain contains dermatan sulphate (Scott et al., 2003). Decorin is thought 
to be a dimer (Fleischmajer et al., 1991) that binds to type I collagen fibrils 
(Danielson et al., 1997, Corsi et al., 2002) and is thought to be involved in regulating 
the assembly of the collagen matrix. Decorin has been shown to inhibit collagen
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fibrillogenesis (Lochner et al., 2007). The expression of decorin has been shown to 
decrease both with age and with UV-irradiation, linking decorin levels with structural 
changes seen in the skin with increased age (Zimmermann et al., 1994b). Versican is a 
proteoglycan expressed by both fibroblasts and keratinocytes. It is a member of a 
family o f proteoglycans including aggrecan which is found in cartilage (du Cros et al., 
1995, Soma et al., 2005). Versican has many different roles within the ECM. It is 
involved in matrix assembly as well as playing a structural role in the ECM. Versican 
present in the dermis is linked with hair follicle morphogenesis and cycling (Sorrell et 
al., 1999). The percentage of the ECM made up of versican changes, with fetal skin 
containing higher levels of versican than adult skin (Zimmermann et al., 1994a). 
Within the dermis, versican is associated with elastin microfibrils (Hasegawa et al., 
2007). Versican has been shown to interact with other components of the ECM such 
as hyaluronan (HA) and elastin. Versican has a HA binding region at its N- terminus 
and a fibrillin binding domain at its C-terminus, which allows it to act as a connection 
between elastin microfibrils and HA (Sakai et al., 2000).
Hyaluronan (also referred to as hyaluronic acid or HA) is a major component of the 
extracellular matrix found in a variety o f tissues within the body including the skin. 
HA is a polymer made up of disaccharides varying in size from 5KDa to 20,000KDa. 
The disaccharides that make up HA are composed of D-glucuronic acid and D-N- 
acetylglucosamine, linked by glycosidic bonds with up to 25,000 disaccharide repeats 
in each HA molecule. HA in humans is synthesised by the hyaluronan synthases 
HAS1, HAS2 and HAS3. These membrane bound proteins synthesise HA by 
repeatedly adding D-glucuronic acid and D-N-acetylglucosamine as the HA molecule 
is extruded from the cell membrane. HA is degraded by another family of enzymes 
the hyaluronidases. HA is found throughout the skin and has been identified in the
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stratum comeum of the epidermis. The majority of the HA found in skin is, however, 
in the extracellular matrix of the dermis (Meran et al., 2007). HA has many roles 
within the dermis, with HA thought to play a role in the control of fibroblast adhesion, 
migration and differentiation. Studies have identified differences in HA synthesis 
between cells able to be stimulated by TGFp-1 and those that are resistant to 
stimulation. HA synthesis appears to be linked with activation of fibroblasts (Meran et 
al., 2008) and with fibroblast proliferation (Podolnikova et al., 2003).
1.1.4 The Hypodermis
The hypodermis is the lowest layer of the skin lying beneath the dermis and is often 
referred to as subcutaneous tissue. Multiple cell types are found within the 
hypodermis including fibroblasts, macrophages and adipocytes, with adipocytes being 
the most numerous. The primary function of the hypodermis is as a fat store; 
providing an energy reserve for the body as well as insulation against heat loss.
1.2 Wound Healing
1.2.1 Acute Wound Healing
Wound healing is a complex multi cellular process involving fibroblasts, 
keratinocytes and endothelial cells as well as inflammatory cells. The healing process 
follows an orderly sequence of events incorporating three distinct, yet overlapping 
phases: the inflammatory phase (I), the proliferation phase (II) and the remodelling 
phase (III). The phases of wound healing are regulated by crosstalk between at least 
three different groups of molecules growth factors, integrins and metalloproteases. 
Secreted growth factors such as IGF-1, EGF, TGF-P and PDGF are involved in 
recruitment of cells to the wound area as well as controlling proliferation and
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migration rates. Integrins allow for cells to interact with a wide variety of ECM 
proteins present in the wound bed, as well as at the wound margins. Differences in 
ECM makeup alter the way cells behave. MMPs promote degradation and 
modification of extracellular matrix proteins at the wound site, facilitating cell 
migration.
1.2.1.1 Inflammation
Inflammation is the first stage of the wound healing process. During the inflammatory 
phase o f wound healing the aim is to prevent blood loss, infection and to remove dead 
or dying tissue. Several different events are grouped within the inflammatory response 
including haemostasis, cellular recruitment and cellular differentiation.
1.2.1.1.1 Haemostasis (immediate)
Haemostasis is the process where blood loss is halted at the site of injury. Initially 
vasoconstriction of the local blood vessels takes place, reducing blood flow and 
therefore blood loss. Vasoconstriction is followed by vasodilation caused by 
histamine released from proximal mast cells, as well as components of the 
complement cascade. Vasodilation allows the influx of platelets to the wound site, at 
which point they come into contact with exposed collagen that activates them. 
Activated platelets adhere to each other and to the blood vessel walls forming a clot. 
They release clotting factors leading to the deposition of fibrin at the site of injury. 
The fibrin clot acts as a provisional matrix, providing a site for platelet (Gailit et al., 
1997, Farrell and Al-Mondhiry, 1997) and fibroblast binding (Kubo et al., 2001), but 
not keratinocyte binding (Laurens et al., 2006). Fibrin may provide a potential novel 
wound sealant to be used in poorly healing wounds (Heldin and Westermark, 1999).
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Platelets also release cytokines that are responsible for the recruitment of cells to the 
wound area and effectively initiate the wound healing response. Platelets release 
multiple different cytokines and growth factors, among those platelet derived growth 
factor (PDGF) and transforming growth factor beta (TGF0). PDGF is responsible for 
the chemotaxis o f neutrophils, macrophages, smooth muscle cells and fibroblasts to 
the wound area (Kim et al., 2008). TGFp is also involved in the chemotaxis of 
macrophages and enhances the chemotaxis of smooth muscle cells and fibroblasts. In 
addition, TGFp plays a role in the stimulation of collagen synthesis and the deposition 
of new ECM.
1.2.1.1.2 Early Inflammatory phase (24 - 48 hours)
The activation of the complement cascade and the release of cytokines from the 
activated platelets at the wound site, leads to the infiltration of the wound area by 
neutrophils (also referred to as polymorphonuclear leukocytes or PMNLs). The 
recruitment of Neutrophils to the wound site occurs rapidly after wounding, with 
neutrophils numbers increasing by five times in the wound area within 18 hours of 
wounding (Dovi et al., 2003). Neutrophils remove bacteria, infiltrated foreign 
material, dead cells and damaged ECM from the wound site by phagocytosis and the 
release o f lysozymes and oxygen free radicals. Though they play an important role in 
the prevention of wound infection neutrophils are not required for successful wound 
healing and have been shown to actually delay wound closure in animal models 
(Gillitzer and Goebeler, 2001, DiPietro et al., 1998). The neutrophils response lasts 
for 24 hours, at which time macrophages and lymphocytes have been successfully 
recruited to the wound site.
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1.2.1.1.3 Late inflammatory phase (48-72 hours)
Around 48 hours after wounding, circulating monocytes move into the wound area, 
become activated and undergo a phenotypic change, becoming macrophages. 
Monocytes are attracted to the wound area by a number of chemoattractants. These 
include complement proteins, degraded ECM products, immunoglobulin G fragments, 
cytokines and by changes in the tissue oxygen tension (Leibovich and Ross, 1975). 
Macrophages decontaminate the wound site, working with leukocytes to remove 
cellular debris, bacteria filled neutrophils, dead cells and bacteria, thereby preparing 
the wound site for the next stage of the wound healing process. Reduction of 
macrophage number from the wound site has been shown to delay wound healing, 
identifying them as an important cells within the wound healing process (Martin, 
1997). The continual recruitment of monocytes and their activation into macrophages 
is maintained by the production of pro-inflammatory cytokines at the wound site. 
These pro-inflammatory cytokines include interferon -  y (IFNy), tumour necrosis 
factor (TNF) and interleukins 1, 2 and 8 (IL1, IL2 and IL8). Macrophages release 
MMPs which allow them to degrade damaged ECM components such as collagen and 
elastin. The degraded ECM components are then removed by phagocytosis. When the 
wound debridement is completed, macrophages release PDGF and TGFp, which 
attract fibroblasts and smooth muscle cells to the wound site thereby beginning the 
proliferative phase of wound healing.
1.2.1.2 Proliferation (72 hours -  14 days)
The proliferative phase of wound healing begins approximately three days after the 
initial injury and continues for between two and four weeks. The predominant cell in 
the wound site during the proliferative phase is the fibroblast, which is responsible for
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the deposition of new ECM and the formation of granulation tissue. During the 
proliferative phase of wound healing a new network of blood vessels is formed within 
the wound area (neovascularisation). Towards the end of the proliferative phase of 
wound healing keratinocyte proliferation leads to epithelisation of the wound and the 
restoration of the epidermis (Drew et al., 2001).
1.2.1.2.1 Fibroblasts in the wound
Fibroblasts migrate into the wound area: once within the wound they proliferate and 
begin to express ECM proteins. Within the wound the provisional fibrin matrix 
generated during the first stage of wound healing acts as a binding site for fibroblasts. 
The fibrin matrix is not required for successful wound closure, however, in it’s 
absence cellular migration and ECM organisation is impaired (McClain et al., 1996). 
Once attached to the fibrin scaffold fibroblasts begin the production of collagen with 
fibroblast activation being the limiting step in the production of granulation tissue 
(Hakkinen et al., 1996, O'Kane and Ferguson, 1997). The provisional ECM laid down 
by the fibroblasts is predominantly composed of collagen (type III and type I), 
fibronectin and hyaluronan. The provisional ECM is laid down from the wound edges 
and base and, along with the new vasculature, (see section 1.2.1.2.2) forms what is 
known as granulation tissue. The progression of granulation is controlled by a number 
of growth factors; one of the most important is TGF-p. TGF-p modulates the activity 
of the fibroblasts within the granulation tissue, with fibroblast phenotype being 
dependent on TGF-p levels. At low levels TGF-p acts as a chemoattractant inducing 
fibroblast migration and proliferation. At higher concentrations fibroblast proliferation 
and migration is inhibited (Hughes, 2008). This feedback mechanism controls cell
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numbers within the granulation tissue, as the more fibroblasts present in the tissue the 
more TGF-p produced.
1.2.1.2.2 Neovascularisation
Angiogenesis occurs within the new connective tissue. Endothelial cells are attracted 
to the wound site by the pro-angiogenic growth factors, vascular endothelial growth 
factor (VEGF) and basic fibroblast growth factor (bFGF). This leads to the formation 
of new capillaries and their in-growth into the wound. It is the large number of blood 
capillaries that gives the granulation tissue its distinctive pink colouration. The 
infiltration of capillaries into the provisional ECM requires the interaction between 
fibroblasts and endothelial cells (Whitby et al., 1991).
1.2.1.2.3 Epithelisation
The surface of the wound is closed by re-epithelialisation with proliferating 
keratinocytes migrating over the granulation tissue as a sheet. Keratinocytes reform 
the stratified layers of the epidermis and generate a new basement membrane (Zeitz 
et al., 1978). Epithelialisation is controlled by growth factors and cell-cell 
interactions. Growth factors such as epithelial growth factor (EGF) and keratinocyte 
growth factor (KGF), as well as bFGF, stimulate keratinocyte proliferation and 
migration.
1.2.1.3 Remodelling and Scar maturation (week one onwards)
This is the longest phase of wound healing and can last for several years. The ECM 
laid down during the proliferative phase of wound healing is replaced or reorganised, 
the wound is contracted and the final scar is formed. During the remodelling phase of
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wound healing there is a decrease in the level of type III collagen and HA produced. 
At the same time the production of type I collagen and proteoglycans increases. 
During the proliferative phase of wound healing the ECM laid down by fibroblasts 
mostly consists o f collagen type III, this collagen is gradually degraded as new 
collagen type I is produced to replace it (Stamenkovic, 2003, Fini et al., 1992). 
Collagen fibres are proteolytically degraded by proteases belonging to the MMP 
family (Tomasek et al., 2002). The collagen fibres within the granulation tissue at the 
end of the proliferative phase of wound healing are disordered. As the wound 
remodelling continues the fibres become more ordered, with fresh collagen fibre 
deposition perpendicular to the wound edge. As the wound matures it begins to 
contract and fibroblasts within the wound undergo a phenotypic change into 
myofibroblasts (Mirastschijski et al., 2004). Myofibroblasts are similar to smooth 
muscle cells in that they have an actin rich cytoskeleton similar to that seen in smooth 
muscle cells and are responsible for the wound contraction (Racine-Samson et al.,
1997). Myofibroblasts attach to the matrix via cell surface receptors, which allows 
the myofibroblasts to contract the ECM, further closing the wound and partially 
restoring tissue integrity. Myofibroblasts use the integrin a  1(31 to attach to collagen 
(Levenson et al., 1965). After wound contraction the resulting scar does not contain 
any hair follicles or melanocytes. The scar tissue has a lower tensile strength 
compared to the surrounding skin, with a 20% reduction in strength even after several 
years (Falanga, 1993).
1.2.2 Chronic Wounds
Wounds do not always follow the phases described in section 1.2.1. Those wounds 
that fail to heal are classified as chronic wounds. Chronic wounds fall into three
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principal catagories: venous ulcers, pressure ulcers and diabetic foot ulcers (Menke et 
al., 2007). Though the underlying causes for chronic wounds varies, they are thought 
to have failed to resolve the inflammatory phase of the wound healing response 
(Graham et al., 2003, Moffatt et al., 2004).
Within the UK, the NHS has approximately 200,000 individual patients with chronic 
non-healing wounds (Gunnel and Hjelmgren, 2005). The annual cost to the NHS is 
estimated at between £2.3bn to £3.1 bn per year, which is 3% of the annual NHS 
budget (Budgen, 2004, Iglesias et al., 2005, Palfreyman et al., 2007, van Korlaar et 
al., 2003). As well as being expensive to treat and manage, chronic wounds reduce the 
quality o f life o f those suffering from them (Margolis et al., 2002). The prevalence of 
chronic wounds increases with age, with 3% of the population over 65 suffering from 
a chronic wound (Boulton et al., 2004). The problem of chronic wounds is set to 
increase, as by 2020 nearly 20% of the UK population will be over 65.
Diabetic foot ulcers are seen in patients whose diabetes has lead to peripheral 
neuropathy. The neuropathy inhibits the perception of pain and pressure in the feet, 
which renders the foot susceptible to minor trauma and subsequent infection. 
Peripheral neuropathy coupled with a compromised vasculature and infection can lead 
to a non-healing wound (Ho and Bogie, 2007). Pressure ulcers occur in patients with 
conditions that inhibit their mobility. They are usually secondary to another disabling 
or restrictive condition and their effect on the patients quality of life is linked with the 
primary condition. Pressure ulcers are caused by a restriction of blood flow to a 
specific region of the body caused by sustained pressure. The pressure generates a 
region of ischemia with pressure in the tissue greater than that in the blood capillaries 
preventing blood flow and oxygenation (Mekkes et al., 2003, Bello and Phillips,
1998).
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The most prevalent chronic wound, and the one this thesis will focus upon, is the 
venous leg ulcer. Between 15% and 25% of chronic wounds are linked with diabetes, 
10% to 20% linked to pressure or arterial insufficiency and 45% to 60% linked to 
venous insufficiency (Berard et al., 2002, Grey et al., 2006). Unlike diabetic foot 
ulcers, (where diabetes and peripheral neuropathy) or pressure ulcers, (where lack of 
mobility) which have underlying causes there is no universally accepted theory for the 
cause o f venous leg ulcers. The primary contributory factor in the development of a 
venous leg ulcers is chronic venous insufficiency in the lower limb leading to tissue 
ischemia and tissue damage caused by reperfusion (Mustoe, 2004). Three main 
theories for the formation of chronic venous leg ulcers are accepted. Whilst they each 
explain some of the observed pathology there is no one universally accepted theory. It 
is likely that multiple factors are involved in the formation of chronic venous leg 
ulcers, with different combinations of factors in each patient. Three factors that have 
been suggested as playing a role in most venous leg ulcers are cellular and systemic 
aging, repeated ischemia-reperfusion injury and bacterial colonization (Van de Scheur 
and Falanga, 1997, Bumand et al., 1982).
1.2.2.1 Theories explaining the formation of Chronic Wounds
1.2.2.1.1 The Fibrin Cuff Hypothesis
The fibrin cuff hypothesis suggests that the prolonged venous hypertension within the 
lower limb of patients is carried over into the capillary system within the skin. The 
increase in pressure within the capillaries leads to a stretching of the capillary walls, 
which in turn allows macromolecules to leave the capillaries and enter the tissue. 
Molecules such as fibrinogen would therefore build up around the capillaries in the 
perivascular space. Fibrinogen in the perivascular space would be converted to fibrin
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in the same way as in the haemostasis phase of wound healing. The resulting fibrin 
cuff prevents the diffusion of oxygen and nutrients into the dermis around the blood 
capillary leading to cell death and the formation of a chronic wound (Falanga and 
Eaglstein, 1993). The fibrin cuff hypothesis explains the localised tissue ischemia and 
how this may be caused by venous hypertension.
1.2.2.1.2 The ‘trap’ hypothesis
A modified version of the fibrin cuff hypothesis was put forward that linked a build­
up of perivascular macromolecules to the observed reduction in growth factors seen in 
chronic wounds. The ‘trap’ hypothesis like the fibrin cuff hypothesis suggests that 
venous hypertension could lead to the leaking of macromolecules into the perivascular 
space. In the ‘trap’ hypothesis the authors suggest that the macromolecules leaking 
into the dermis, trap growth factors and cytokines. While trapped these growth factors 
and cytokines are unable to stimulate or attract cells to the dermis (Thomas and 
Dormandy, 1988).
1.2.2.1.3 The leukocyte trapping hypothesis
Another theory for the formation of venous leg ulcers in patients with venous disease 
is the leukocyte trapping hypothesis. This hypothesis is based on observations made 
in patients with chronic venous insufficiency. Microscopic analysis of the skin of 
patients suffering from chronic venous insufficiency indicated a loss of functional 
capillary loops within the skin. Analysis of the circulation of leukocytes in patients 
with chronic venous insufficiency indicated a reduction in the leukocytes leaving the 
lower limbs compared to healthy volunteers (Coleridge Smith et al., 1988). This lead 
to the theory that the microvasculature of patients with chronic venous insufficiency
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becomes blocked by an accumulation of leukocytes. These blockages lead to localised 
tissue ischemia and cell death, in turn leading to the formation of a venous leg ulcer 
(Weyl et al., 1996, Peschen et al., 1999, Smith et al., 1999). Further evidence and a 
demonstrated mechanism for the leukocyte trapping hypothesis has been shown in the 
years since its first proposal. The expression level of adhesion molecules by 
endothelial cells was shown to increase with the progression of chronic venous 
insufficiency. Specifically the levels of Inter-Cellular Adhesion Molecule, vascular 
cell adhesion molecule and endothelial leukocyte adhesion molecule were increased 
(Weyl et al., 1996, Peschen et al., 1999, Smith et al., 1999) A subset of leukocytes 
expressing leukocyte function-associated antigen-1 and very late activated antigen-4 
were shown to adhere to vascular endothelium with increased expression of these 
adhesion molecules. This adherence was due to the affinity of the leukocyte expressed 
antigens to the endothelial expressed adhesion molecules. After adherence to the 
vascular endothelium the leukocytes move into the perivascular tissue (Stanley et al., 
1997, Mendez et al., 1998b, Vande Berg et al., 1998, Loots et al., 1999) causing 
damage to both the endothelium and the surrounding tissue. The localisation of the 
increased adhesion molecule expression and perivascular leukocyte invasion to the 
chronic wound suggests a link with this observation and the initial formation of a 
chronic wound.
1.2.2.2 Cellular and Molecular changes observed in Chronic Wounds
Fibroblasts taken from chronic wounds (CWF) have been widely studied in an attempt 
to gain an insight into the failure of chronic wounds to heal. Fibroblasts play an 
important role in the wound healing process, expressing and remodelling ECM,
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releasing growth factors and chemokines and as a source of myofibroblasts. Changes 
in fibroblast phenotype would therefore give an insight into chronic wounds.
1.2.2.2.1 Proliferation, Morphology and Senescence
The reduced proliferative life span and growth rate of CWF has been demonstrated in 
a number of studies when compared with fibroblasts from patient matched normal 
skin (NF) (Agren et al., 1999b). CWF have a reduced proliferative potential compared 
to fibroblasts taken from acute wounds (Agren et al., 1999b). It appears that it is the 
chronic wound environment rather than just a wound environment that reduces the 
proliferative potential o f the cells.
Fibroblasts normally have a bipolar morphology, however CWF have been shown to 
display an altered morphology more similar to aged cultured fibroblasts. CWF appear 
polygonal with clear actin stress fibres, they also appear to be larger than normal 
fibroblasts (Yang and Hu, 2005).
Changes in morphology and reduced proliferative potential are potentially indications 
that CWF cells are closer to cellular senescence than cells taken from patient matched 
normal skin. A marker for senescence, that was until recently widely used, is 
senescence associated p-galactosidase activity (SA P-gal). This marker for senescence 
has recently been questioned. SA P-gal activity can be induced in non senescent cells 
(Mendez et al., 1998b, Stanley and Osier, 2001a). SA P-gal activity has been detected 
in a higher proportion of CWF compared to patient matched NF (Raffetto et al., 
2001b, Lerman et al., 2003). The reduced proliferative potential and growth rate 
observed in CWF may be linked with cellular senescence. As well as reduced 
proliferation another marker for cellular senescence is a reduction in cellular 
migration. CWF have been shown to have a reduced migration rate compared to NF 
taken from the same patient (Hayflick and Moorhead, 1961). Cultured fibroblasts
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have a limited replicative capacity, after a finite number o f population they enter 
senescence (West et al., 1989, Millis et al., 1992, Wick et al., 1994). Many of the 
characteristics of chronic wound fibroblasts are similar to those of senescent cells. 
Senescent fibroblasts display altered morphological features such as cellular 
enlargement, polygonal shape and actin stress fibres throughout the cytoplasm. 
Senescent fibroblasts express higher levels of MMPs and lower levels of TIMPs than 
none senescent cells (Vasquez et al., 2004, Agren et al., 1999b, Loots et al., 1998, Lai 
et al., 2003).
1.2.2.2.2 Expression of Growth Factors and Cytokines
Growth factors and cytokines play a vital role in the coordination of the wound 
healing response. CWF have been shown to have a reduced response to various 
growth factors and cytokines compared to NF including TGF-p, EGF, bFGF, IGF and 
PDGF (Schmid et al., 1993): all known to be important in the wound healing 
response. The effect o f growth factors and cytokines on cells taken from chronic 
wounds has been shown to be altered when compared to patient matched NF. This 
may explain the failure o f chronic wounds to heal if the growth factors normally 
responsible for coordinating the healing process do not have an effect on cells within 
the wound. The levels of these signalling molecules within chronic wounds has also 
been studied and compared with acute wounds. For example TGFpi is expressed in 
acute wounds but not in chronic wounds (Lauer et al., 2000). The opposite trend is 
seen in the expression of VEGF with higher levels of mRNA detected within the cells 
of the chronic wounds compared to patient matched normal skin (Fivenson et al., 
1997, Barone et al., 1998, Trengove et al., 2000, Li et al., 1998).
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Cytokine levels have also been analysed in chronic and acute wounds, the pro- 
inflammatory cytokines IL-la, ILip, IL-6, IL10 and TNFa were shown to be 
increased in wound fluid taken from chronic wounds compared to acute wound fluid 
(Li et al., 1998, Loots et al., 1998). Therefore the high levels of pro-inflammatory 
cytokines within the chronic wounds may be responsible for their failure to resolve 
the inflammatory phase of wound healing.
The altered levels o f growth factors and cytokines observed in chronic wounds may 
directly affect other cells involved in wound healing. Chronic wounds have been 
shown to contain significantly higher numbers of macrophages and B-lymphocytes 
than acute wounds (Loots et al., 1998). This increase is not seen in all types of 
inflammatory cell as T-lymphocytes are reduced in chronic wounds compared to acute 
wounds (Mendez et al., 1998b). The alterations in inflammatory cell numbers within 
chronic wounds may also play a role in the failure of chronic wounds to resolve the 
inflammatory phase. Too many inflammatory cells would increase the levels of pro- 
inflammatory cytokines within the wound environment, prolonging the inflammatory 
phase. Too few inflammatory cells would not be able to remove dead cells and 
bacteria from the wound site, preventing the proliferative phase of wound healing 
from beginning.
1.2.2.2.3 Changes to the Extracellular Matrix
As well as having altered growth factor and cytokine levels, chronic wounds display 
alterations to ECM components and to proteases that are important for the 
remodelling of the ECM. Three key components of the ECM have been studied in 
detail within the chronic wound environment: fibronectin (Herrick et al., 1992), fibrin 
(Herrick et al., 1996) and collagen (Mendez et al., 1998c). Fibronectin gene 
expression was shown to be up-regulated in CWF compared to patient matched NF
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when cultured in vitro (Ongenae et al., 2000). In chronic wound tissue the same trend 
was observed with fibronectin mRNA up-regulated compared to acute wounds or 
normal unwounded skin (Herrick et al., 1992). Within the chronic wound there is no 
increase in fibronectin (Rao et al., 1995, Grinnell et al., 1992, Grinnell and Zhu, 
1996). Though more fibronectin mRNA is produced within chronic wound tissue the 
increased fibronectin protein produced is degraded by increased proteases within the 
chronic wound fluid. Degraded fibronectin has been identified within wound fluid 
taken from chronic wounds, but not acute wounds, confirming that it is degraded by 
proteases within the wound fluid (Grinnell and Zhu, 1996, Rao et al., 1995). Analysis 
o f wound fluid for proteases known to degrade fibronectin identified increased levels 
of elastase within chronic wound fluid (Brakman et al., 1992). Elastase is a serine 
protease that degrades fibronectin, the high levels of elastase found within chronic 
wound fluid account for the reduced levels of intact fibronectin in chronic wounds.
The fibrin cuff hypothesis explains a possible cause for the high levels of fibrin within 
chronic wounds; the leaking of fibrinogen into the perivascular space due to increased 
blood pressure. Normally fibrin can be broken down by the serine protease, plasmin, 
into fibrin degradation products. This process would break down the fibrin cuff 
preventing ischemia and tissue death. In chronic wounds an inhibitor to plasmin 
activity is present: plasminogen activator inhibitor 1 prevents the activation of 
plasmin and the breakdown of fibrin (Herrick et al., 1996).
The most abundant component of the ECM is collagen. Collagen is vital for 
successful wound healing. Collagen synthesis in CWF grown in vitro has been shown 
to be reduced compared to NF (Siddiqui et al., 1996). A reduction of collagen 
synthesis has also been seen in chronically hypoxic cells (Wysocki et al., 1993a, 
Weckroth et al., 1996, Rayment et al., 2008, Trengove et al., 1999, Saarialho-Kere,
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1998) suggesting that the hypoxic environment within the chronic wound may be 
responsible for the alteration in collagen synthesis. The effect of the wound 
environment on any collagen or other ECM component that is synthesised has also 
been considered.
MMP activity within chronic wound fluid is higher than in acute wound fluid 
(Rayment et al., 2008). Proteases able to degrade various forms of collagen have been 
identified within chronic wounds. Expression of MMP9 is increased in chronic 
wounds (Han et al., 2001), MMP9 is a protease able to digest gellatin and type IV 
collagen with the level of MMP9 appearing to be an indicator of the severity of the 
wound. The increased levels of TNFa within chronic wounds have been identified as 
a factor leading to the increased expression on MMP2 (Nwomeh et al., 1999). MMP2 
is also a gelatinase able to break down type IV collagen. Some other studies have 
identified MMP8 as the predominant collagenase within chronic wounds, with MMP1 
also detected (Vaalamo et al., 1997). MMP8 is able to digest collagen type I, II and 
III, as well as collagen I, II and III. Furthermore, MMP1 has the ability to cleave 
collagen types VII and X. Both MMP1 and 8 are found in acute wounds however they 
are in an inactive form whereas they are both active in chronic wounds. MMP 13 has 
also been identified in chronic wounds but not in acute wounds. MMP 13 is also a 
collagenase able to cleave collagen I, II and III with highest activity against collagen 
II (Trengove et al., 1999, Vaalamo et al., 1996). Potentially other proteases may also 
play a role in the chronic wound phenotype but have yet to be identified.
As well as protease levels is also important to consider the specific inhibitors of 
proteases within chronic wounds. Proteases are tightly controlled both by expression 
and by specific inhibitors. An increase in protease gene expression may have no effect 
if inhibitor gene expression increases to compensate. The expression levels of
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members o f a family of MMP inhibitors, the TIMPs have been studied in the chronic 
wound environment. In acute wounds TIMPs regulate collagenase activity, however 
in chronic wounds TIMP1 is either not expressed or its expression is severely reduced 
(Nwomeh et al., 1999). Levels of TIMP-1 protein in wound fluid have also been 
analysed and a reduction has been reported in chronic wound fluid compared to acute 
wound fluid (Vaalamo et al., 1999). The other members of the TIMP family have also 
been studied in chronic wounds, with TIMP-2,TIMP-3 and TIMP-4 all shown to be 
down regulated in chronic wounds (Frank et al., 2000, Stallmeyer et al., 1999, 
Yamasaki et al., 1998).
1.3 Models of Wound Healing
Wound healing is a complex process involving interactions between multiple cell 
types from the skin as well as inflammatory cells. The sequence of events that take 
place during wound healing is reasonably well understood, as macroscopic changes in 
cell numbers and tissue structure are easily observed. On a molecular level the wound 
healing process is less well understood. In order to better understand the wound 
healing process models of part, or all, of the wound healing process are used. Models 
of wound healing can be split into two groups in vivo models and in vitro models.
1.3.1 In vivo Models of wound healing
Many animal models for wound healing exist. At their most simple they involve 
wounding a laboratory animal and observing wound closure time. Various different 
species are used regularly for skin wounding experiments including rats, mice, rabbits 
and pigs. As well as these ‘normal’ laboratory animals, genetically modified animals
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are also used to model human diseases such as diabetes and the effect this would have 
on wound healing.
1.3.1.1 Full Thickness Excision Wounds (Mouse Model)
This model allows the investigation of haemorrhage, granulation tissue formation, 
reepithelialisation and the formation of new blood vessels (Frank et al., 2000, 
Stallmeyer et al., 1999, Yamasaki et al., 1998). Wounds are generated by the surgical 
removal o f all the layers of the skin (epidermis, dermis, subcutaneous fat and in the 
case o f the mouse the subcutaneous smooth muscle layer) from the animals back. 
Multiple wounds may be generated on each animal allowing direct comparison 
between treatments. When mice are used with this wound healing model, wounds of 
up to 5mm are generally generated with six wounds per mouse. Wounds are generated 
under anaesthetic, hair is removed from the back of the mouse, the loose skin on the 
mousse back is lifted and cut with scissors generating a wound. Wound area may be 
recorded over time giving a wound healing rate. For histological analysis animals are 
sacrificed at desired time points after wounding and the wounded skin is removed for 
analysis. This model allows for not only the rate o f wound healing to be recorded, but 
also histological analysis of the wounded skin at different time points after wounding 
(Goss and Grimes, 1975).The ability to generate multiple wounds on each animal 
increases the statistical value of this model. However, the wounds generated in this 
model of wound healing are not uniform as they are generated by hand. The depth and 
size of wounds, though similar, are not identical introducing an additional variable 
into the model.
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1.3.1.2 Punch Wounds (Rabbit/Mouse)
Punch wounds generated in the ears of rabbits have been used as a model for full 
thickness wound healing for many years. Wounds are generated using biopsy punches 
cutting through the full thickness of the ear. The wound includes damage to the 
epidermis, dermis and cartilage that make up the ear. Rabbits have the ability to 
regenerate the tissue of the ear from the margin of the punch wound inwards (Patsy K. 
Williams-Boyce, 1980, Bos et al., 2001). The wounds heal over a period of weeks and 
can be taken at different time-points for histological analysis. As the wounds are 
straight through the ear the variation in depth possible in excision wounds on the back 
of animals is not seen in this model, and as the wounds are generated using a biopsy 
punch, the size of the wounds is reproducible. Multiple punch wounds can be 
generated in each ear allowing for experimental controls. As well as its use in rabbits 
(Colwell et al., 2006, Clark et al., 1998, Heber-Katz, 1999) this model of wound 
healing has also been used in mice (Schaffer et al., 1997). Modifications to this model 
of wound healing have been proposed as a chronic wound model (1.3.3.1)
1 3 .1 3  Partial Thickness Excision Wounds
Unlike the full thickness and ear punch wounds described above, this model of wound 
healing aims to look at epidermal wound healing (Rommain et al., 1991, Nanchahal 
and Riches, 1982). Wounds are generated using a dermatome, using the same 
technique as is used to harvest skin for split thickness skin grafts. The dermatome is 
used to remove a set thickness of skin generating a partial thickness wound with the 
epidermis and some of the dermis removed. The depth of wound is somewhat 
reproducible if the dermatome is used correctly however, it is possible to generate an
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uneven wound with the dermatome leaving patches of epidermis within the wound. 
Removal of the epidermis causes initial bleeding as the blood supply to the epidermis 
is disrupted. This model of wound healing generates a larger wound by area and is 
ideal for use on larger experimental animals, such as pigs. Multiple wounds may be 
generated on each animal allowing for experimental treatments and controls on the 
same animal. As with the full thickness model, differences in wound size and depth 
are problematic in this model. The dermatome is not a precise instrument and 
different users may generate different wound depths. Any variation in wound depth 
and size would alter wound healing rates.
13.1.4 Suction Blisters
This model o f wound healing uses dry suction to separate the dermis and epidermis at 
the level o f the basement membrane. Vacuum suction is applied to the skin. The 
suction slowly separates the epidermis from the dermis, with fluid filling the 
generated inter-dermal space. The wounds generated by this technique are of a 
uniform size (the size of the suction device) and of a uniform depth (down to the 
basement membrane). This method of wound generation has been used on 
experimental animal species (Leivo et al., 2000, Levy et al., 1995) and also in human 
volunteers (Cribbs et al., 1998, Brans et al., 1994). The blister formed can be deroofed 
leaving an exposed wound. As the dermis is not damaged this is a good model of re- 
epithelisation, with reproducible wounds and the potential to generate multiple 
wounds per animal.
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13 ,1.5 Water Scald Burns
Wounds generated by scalding the skin of animals to generate blisters have been used 
in different species as a model of wound healing (Becic et al., 2003, von Bulow et al., 
2005). Blisters are generated by exposing a fixed area of skin to heated water. The 
burning process is halted by the application of ice cold water to the site of injury. A 
blister forms at the site of injury and, as in the suction blister model, the blister may 
be deroofed to expose the wound. By keeping the temperature of the water and 
exposure time constant, repeatable wounds can be formed using this technique. With 
this model it is possible to control the depth of the partial thickness wound by altering 
exposure time. This model requires a water-tight seal to be generated around the 
desired wound area. In smaller animals it is harder to generate multiple wounds on a 
single animal with this technique. To determine the required exposure time to 
generate the desired depth of wound multiple trials must be used for each new species 
or strain of experimental animal.
1.3.1.6 Thermal Burns
Another method of generating wounds with thermal damage is through the direct 
application of heat to the skin (Brans et al., 1994). Partial thickness wounds can be 
reproducibly generated by applying heat to the skin for timed periods using a metal 
template. As with the suction blister and scald wound models, a blister is formed and 
can be deroofed to expose the dermis and leave an open wound. The depth of wound 
can be controlled by increase or decrease in either the time the heated template is 
applied to the skin or in the heat of the template. As in the water scald model, a series 
of trial experiments is required to determine the optimum conditions for generating a 
wound of a specified depth. Multiple wounds may be generated in each animal and
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the size and shape of the wounds can be easily altered and is reproducible. This model 
o f wound healing has been used in multiple different species of laboratory animal and 
is especially useful in the porcine model (Liang et al., 2007). The two thermally 
generated wound models both lead to denatured proteins in the wound environment 
due to the applied heat, these denatured proteins are not found in wounds generated by 
physical trauma and their influence on wound healing should be considered.
1.3.2 In vitro Models of wound healing
Animal models of wound healing generate complex wounds involving multiple cell 
types. In some circumstances the complexity of the wounding response can make it 
impossible to accurately measure the effect of a treatment or environmental change 
and difficult to determine which cells are specifically affected. Simpler models of 
wound healing are therefore useful for looking at specific parts of the wound healing 
response. Cells cultured either alone or in multi-cellular complex cultures have been 
used to study wound healing. As it is possible to use human cells in these models 
possible differences between wound responses in different species can be reduced. It 
is also possible to use cells from different human disease states or to genetically 
modify the cells to study the effect these changes may have on the wounding 
response.
1.3.2.1 Scratch wound
One of the simplest in vitro wound models is the monolayer scratch assay, allowing 
the quantification of cellular migration. When a confluent monolayer of cells is 
wounded the cells at the edge of the wound re orientate and migrate into the space 
closing the generated wound. By imaging the wound at the beginning of cell
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migration, and at regular intervals during cell migration, it is possible to determine the 
rate of wound closure (Poujade et al., 2007). Differences in cellular migration can be 
observed using this method, keratinocytes migrate as a connected sheet (Kole et al., 
2005) whereas fibroblasts migrate individually (Goldberg et al., 2008). Scratch wound 
models can be used by themselves to study specific responses to wounding, or in 
conjunction with animal models, with the scratch wounds allowing greater control of 
the wound environment (Kitano et al., 2007, Borensztajn et al., 2008, Diaz et al., 
2008, Stevenson et al., 2008). By altering the environment, the cells or the media used 
to generate the scratch wound model it is possible to study the effect that different 
stimuli or disease states have on wound heeding (Loryman and Mansbridge, 2008). 
Scratch wounds have been used to study chronic wounds either by the addition of 
compounds known to be found in chronic wounds such as bacterial 
lipopolysaccharide (Wall et al., 2008b) or by using cells isolated from chronic wounds 
in the scratch assay (Poujade et al., 2007).
Traditionally scratch wounds are generated by hand using mechanical trauma: this can 
generate wound of varying sizes and shapes. Automated scratch wounding devices are 
available, for example the Essen Woundmaker ™ (www.essen-instruments.com) 
which is capable of generating and analysing multiple scratch wounds. Another 
alternative recently suggested to improve the reproducibility of scratch wounds 
suggested the use o f removable templates. Cells are grown within the templates, 
which when removed leaves uniform gaps between confluent strips of cells, cellular 
migration into the gaps can then be measured (Bell et al., 1979). However they are 
generated, scratch wounds are a low cost, simple and versatile model of wound 
healing.
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1.3.2.2 Fibroblast Populated Collagen Lattice Model
Wound repair within the dermis requires the replacement and remodelling of 
extracellular matrix by the dermal fibroblasts. This process can be studied in vitro 
using a fibroblast populated collagen lattice (FPCL) (Paul Ehrlich et al., 2006b, 
O'Gorman et al., 2006, Mukhopadhyay et al., 2005). Fibroblasts are introduced into a 
solution of collagen collected from rat tail tendons. The mixture of cells, media and 
collagen is cast in a petri dish and allowed to set. To generate a free-floating collagen 
lattice the lattice is detached from the sides of the dish. As the fibroblasts remodel the 
collagen lattice, the area of the FPCL is reduced. This can be measured giving a value 
for the rate o f fibroblast mediated collagen reorganisation. This wound model is more 
complex than simple monolayer scratch wounds and gives a insight into the ability of 
fibroblasts to remodel the ECM during wound healing. By altering the cells used to 
form the FPCL and the makeup of the media, the FPCL is cultured in different disease 
states and growth factors can be studied (Wall et al., 2008b, Cook et al., 2000b) 
including chronic wounds (Stark et al., 2004).
1.3.2.3 Organotypic Co-Culture Model
Single cell in vitro models do not allow any of the interactions between different cell 
types that are so important within the wound healing response. To study the 
interactions between dermal and epidermal cells without using animals, co-cultures of 
keratinocytes and fibroblasts can be used. Growing epidermal keratinocytes on a 
collagen matrix containing fibroblasts generates these epidermal equivalents. The 
keratinocytes are exposed to the air and form stratified layers as seen in the epidermis 
and are supplied with nutrients from the underlying matrix (Schneider et al., 2008, 
Kinsner et al., 2001, Wang et al., 2003, Maas-Szabowski et al., 2000, Stark et al.,
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1999). Commercially available epidermal equivalents are available 
(www.skinethic.com): modelling full thickness skin, epidermis, and epithelium from 
different part of the body. Epidermal equivalents can be modified by using cells from 
different sources (Hoeller et al., 2001) or by the addition of hair follicles to the culture 
(Genever et al., 1993, O'Leary et al., 2002). Wound healing can be studied in the 
dermal equivalents by wounding the skin model and recording the cellular responses 
(Margolis et al., 2002). Organotypic co-culture models add a level of complexity to in 
vitro wound modelling, allowing the investigation of complex cell-cell interactions. 
The organotypic models described above do not involve vasculature or the immune 
response. Organotypic models therefore offer a simplified system to study some areas 
of wound healing such as dermal epidermal signalling and cellular migration.
1.3.3 Chronic Wound Models
In order to study wounds that fail to heal and develop potential treatments for them 
models of chronic wounds have been developed. These models are adaptations of the 
wound models described previously in this chapter. In humans, chronic wounds are 
more common among patients over 65 (Boulton et al., 2004) and are associated with 
diabetes (Ho and Bogie, 2007), immobility (Mekkes et al., 2003) or vascular disease 
(Engerman and Kramer, 1982, Zhang et al., 2005). Animal models of chronic wounds 
must first artificially generate the conditions associated with chronic wound formation 
and be utilised as reproducible wound model systems
1.3.3.1 Diabetic Wound Models
It is possible to artificially generate diabetes in animal models by the surgical removal 
o f the pancreas (Howarth et al., 2008) or by chemical treatments to kill the p-cells of
34
the islets o f Langerhans (Inoue et al., 1985). The models o f induced diabetes 
demonstrate impaired wound healing compared to control animals (Inoue et al., 1985, 
Kwon et al., 2008, Lau et al., 2008, Morikawa et al., 2007, Rabelo et al., 2006, 
Velander et al., 2008). Induced diabetic animals have been used to study different 
wound treatments that may be useful in treating diabetic wounds (Chen et al., 1996). 
The surgical removal o f the pancreas to induce diabetes is a stressful operation and 
generates other symptoms along with the diabetes. The use of alloxan and 
streptozotocin to chemically induce diabetes may also have other side effects 
associated with the use of chemotherapy agents potentially limiting the value of the 
model. Genetically diabetic animals are available for use in wounding studies, with 
one of the most widely used being the db/db diabetic mouse. This mouse lacks the 
receptor for leptin normally present within the hypothalamus (Tsuboi et al., 1992). 
Genetically diabetic mice have impaired wound healing (Scott et al., 2008, Trousdale 
et al., 2008, Michaels et al., 2007) and are therefore a useful model for the study of 
diabetic wounds (Quirinia et al., 1992, Quirinia and Viidik, 1992). Wounds in 
diabetic animals (induced or genetically diabetic) demonstrate a reduced ability to 
heal however, they do eventually heal. The diabetic wound models discussed here are 
models of impaired acute wounds rather than true non healing wounds.
1.3.3.2 Ischemic wound models
Both venous leg and pressure ulcers have an underlying tissue ischemia linked with 
their formation. Chronic wound models that can generate an ischemic environment 
have therefore been developed to model the human disease state. Two methods for 
generating ischemic wounds are widely used: a back and an ear model. The ischemic 
back wound (Buemi et al., 2004) is based on a skin flap generated by an H shaped
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incision wound in the back of a rat. The generated wound shows reduced blood 
perfusion along the horizontal wound creating an ischemic environment. The vertical 
wounds do not have a reduced blood flow so can act as controls for wounding 
experiments. This is a relatively short-term wound model as the skin returns to normal 
levels of blood perfusion within 16 days. The model can be used to study the effect of 
potential treatments on chronic wound healing (Gould et al., 2005). Modifications to 
the basic skin flap ischemic wound model have also been reported, such as the 
insertion of a silicone sheet under the skin flap to reduce blood perfusion (Kloeters et 
al., 2007, Mogford et al., 2006, Mogford et al., 2004, Kamler et al., 1993, Chien, 
2007). A second model of ischemic wounds involves the generation of an ischemic 
environment in a mouse, rat or rabbit ear and the subsequent wounding of the ear (Wu 
and Mustoe, 1995). The surgical division of the rostral and central arteries of the ear 
generates an ischemic environment in one ear of the animal. This has been shown to 
generate an ischemic environment in the ear for up to 28 days (Hayflick and 
Moorhead, 1961). In this model one ear is ischemic and the other acts as a control, 
when performed in the rabbit multiple punch wounds may be generated in each ear. 
While these models do generate impaired healing they do not create wounds that fail 
to heal. They provide useful tools for studying impaired wound healing but more 
accurately model delayed acute wound healing than true chronic wounds.
1.4 Cell Lines as Models of Disease
Normal human somatic cells have a finite lifespan in culture before they enter 
replicative senescence (Masters, 2002, Gey et al., 1952). Primary cells taken from a 
patient can therefore only be used for a limited period of time before fresh patient 
samples are required. To overcome this problem cell lines have been generated for
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numerous different cell types. Initially cell lines were derived from spontaneously 
immortalised cells such as the HeLa cell line derived from a cervical tumour (Collins, 
1996). An alternative approach for cell line generation has been the use of oncogenic 
viral proteins. The introduction of viral genes such as Simian virus 40 (SV40), T 
antigen, Epstein Barr virus (EBV), Adenovirus El A and E1B, and human 
Papilomavirus (HPV) E6 and E7 can lead to the immortalisation of primary cells. The 
expansion of tumour biopsies into cell lines or the expression of viral oncogenes can 
generate useful immortalised cell lines, however, the cells are phenotypically different 
from the primary cells they were derived from. While this may be useful in the study 
of cancer biology, where the phenotypic changes in the cancer cell lines may relate to 
changes that occur in tumour formation, these cell lines are less useful for the study of 
wound healing.
Another method for generating cell lines from somatic cells is the overexpression of 
the enzyme telomerase. Telomerase is a DNA polymerase that specifically restores 
the ends o f telomeres that are damaged at cell division. Telomerase adds repeats of 
TTAGGG onto the existing telomere ends
(Harley, 1991, Harley and Villeponteau, 1995, Bodnar et al., 1998). Telomerase is 
made up of two components: a protein component human telomerase reverse 
transcriptase (hTERT) and a RNA component human telomerase RNA component 
(HTERC or hTR). Most somatic cells do not express sufficient hTERT to maintain 
their telomeres at a constant length resulting in the shortening of their telomeres at 
each cell division (Kipling, 2001). This telomere shortening in some cells leads to 
growth arrest and senescence (Nakamura et al., 1997, Meyerson et al., 1997, 
Harrington et al., 1997). The gene for hTERT was isolated and cloned in 1997 (Jiang 
et al., 1999, Morales et al., 1999), allowing for the over-expression of hTERT in
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human cells. The forced over-expression of hTERT by retroviral infection of somatic 
cells allows the generation of stable cell lines that maintain their previous phenotype 
(Bodnar et al., 1998, Yang et al., 1999, Kampinga et al., 2004). Forced over 
expression of hTERT has been used to generate immortalised cell lines in many 
different cell types. Skin fibroblasts, epithelial cells and endothelial cells have all been 
immortalised by the over expression of hTERT (Jiang et al., 1999, Morales et al.,
1999). Importantly hTERT immortalised cells do not have a tumour like phenotype: 
they remain diploid, contact inhibited, anchorage dependent and differentiated (Wyllie 
et al., 2000).
Whilst hTERT immortalised cells have generally been shown to retain their pre 
immortalised phenotype in some cases this is not true. The over expression of 
telomerase in cells taken from patients with Wemer syndrome reversed the 
accelerated aging of the cells normally seen in vitro (Thompson et al., 1993). 
However work carried out with fibroblasts isolated from chronic wounds indicates 
that the introduction of telomerase would not reverse the disease-specific phenotype 
of chronic wound fibroblasts (Stephens et al., 2003). In order to gain a better 
understanding of chronic wounds an immortalised cell line retaining a chronic wound 
specific phenotype would provide a useful tool reducing the requirement for fresh 
patient samples. Such a cell line could be used in the in vitro models of wound 
healing described previously allowing for analysis of chronic wound healing without 
the need for animal models.
Before a cell line can be used it must be characterised to ensure that the over 
expression of hTERT during the immortalisation process has not altered the 
phenotype of the cells. Another potential drawback with retroviral infection and
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insertion of hTERT is that the insertion may occur anywhere within the genome, 
potentially changing the cells by disrupting gene expression.
1.5 Reporter Constructs
To study the effect a treatment has on a model cell line some form of reporter assay is 
required. Changes in proliferation rate and cell motility may be studied using the 
models o f described previously. While microarray and QRT-PCR analysis allow 
detailed investigation of gene expression changes they require the extraction and 
purification of RNA before they may be used. To study changes in gene expression 
without the need for RNA analysis promoter regions from genes of interest may be 
used to drive the expression of reporter molecules. These reporters may then be 
detected giving a rapid readout of changes in gene expression.
1.5.1 In Vitro Reporter Assays
To quantify this type of reporter assay cell or tissue lysates which contain the reporter 
protein or culture medium when the reporter protein is secreted are directly assayed. 
In vitro assays allow a quantitative and reproducible analysis of promoter and 
enhancer elements.
1.5.1.1 Chloramphenical Acetyltransferase (CAT)
This prokaryotic enzyme catalyses the transfer of acetyl groups from acetyl-coenzyme 
A to chloramphenicol. A high signal to noise ratio can be achieved because of the 
prokaryotic origin of the enzyme, in eukaryotic cells there is minimal competition for 
the enzyme creating a very accurate reporter. CAT is stable in mammalian cells with a 
half life of 50 hr (Balu and Adams, 2003) making it ideal for transient expression 
studies but unsuited for stable expression or some enhancer studies. Initially the CAT
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assay was based on 14C labelled chloramphenicol (Hruby et al., 1990). Cell lysates 
were incubated with the isotopically labelled compound, separated by 
chromatography and visualised on film. A non radioactive quantitative method for 
detecting chloramphenciol acetylation has been developed (Gendloff et al., 1990) and 
describes a fluorescently labelled chloramphenicol derivative capable of a single 
acetylation and is available commercially (www.invitrogen.comi. An ELISA based 
assay for CAT activity was also developed (de Wet et al., 1987) allowing high 
throughput screening of samples (www.roche.com).
1.5.1.2 Firefly Luciferase
The luc gene found in the firefly Photinus pyralis was first cloned in 1987 (Bronstein 
et al., 1994) Luciferase bioluminescence requires not only the luciferase catalyst but 
also luciferin, ATP, Mg and O2 . Cell lysate are mixed with these reageants 
generating a bioluminescent flash lasting less than 1 second. This can be detected by a 
luminometer or liquid scintillation counter, with total light emission being directly 
proportional to the amount of active luciferase. A modification of the original 
protocol with the addition of coenzyme A to the reaction (Li et al., 2007)gives a 
longer bioluminescent flash allowing a longer reading time, increases sensitivity and 
imporves reproducibility between samples. Because of its short halflife luciferase is 
useful for inducible systems, allowing detection of signal above basal expression 
levels (Fowler et al., 1970).
1.5.1.3 p-Galactosidase
p-Galactosidase is a bacterial protein found in the Lac operon of Escherichia coli. p- 
Galactosidase catalyses the hydrolysis of galactosides such as lactose into
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monosaccharides. The sequence for p-Galactosidase was first published in 1970 (An 
et al., 1982). The p-Galactosidase gene can be expressed in mammalian cells with 
gene expression determined using an artificial substrate (MacGregor et al., 1987) . 
Currently 5-bromo-4-chloro-3-indolyl- beta-D-galactopyranoside (X-Gal) is routinely 
used to detect p-Galactosidase activity. p-Galactosidase can be used as a reporter of 
promoter activity in mammalian cells (Berger et al., 1988) however, X-Gal is toxic to 
the cells and the detection of p-Galactosidase expression is carried out at single 
timepoints in fixed cells.
1.5.1.4 Secreted Alkaline Phosphatase
Alkaline phosphatase is a hydrolase which removes phosphate groups from a wide 
range of molecules. The secreted form of alkaline phosphatase is a human placental 
variant o f the enzyme (Shiraiwa et al., 2007), and on secretion from the cells can be 
easily quantified. A common method for quantification of alkaline phosphatase 
activity is the hydrolysis of /?-nitophenylphopshate (4NPP), hydrolysis leads to an 
increase in absorbance at 405nm. Other substrates include 4-methylumbelliferyl 
phosphate which generates a fluorescent product upon alkaline phosphatase catalysed 
hydrolysis (Nolan et al., 1988).
1.5.2 In Vivo Reporter Assays
These reporter assays allow the detection of the reporter in live cells or tissue. The 
data obtained is less quantitiative than from in vitro reporter based systems however, 
analysis from living cells allows observation of dynamic changes in gene expression 
in real time. In vivo systems also allow for the same cells or tissue to be used in 
repeated experiments as there is no requirement for cell lysis.
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1.5.2.1 p-Galactosidase
Through modifications of the substrate used to detect p-Galactosidase activity it is 
possible to use p-Galactosidase as a reporter in living cells. Compunds such 
fluorescein di-P-galactopyranoside (Arboleda-Velasquez et al., 2008, Yamazaki et al., 
2007), which is cleaved by active p-Galactosidase into fluorescein a fluorescent 
molecule, have been used to determine gene expression over time in living cells. 
Coupled with FACS analysis this technique is still used to determine gene expression 
in living cells (Shimomura et al., 1962) however, the need to add a substrate before 
visualisation limits its use in vivo.
1.5.2.2 Fluorescent Proteins
Fluorescent proteins do not require any substrate for detection. Excitation of the 
proteins with specific wavelengths of light produces emissions of light at a shifted 
wavelength. Green fluorescent protein (GFP) from the luminescent jellyfish 
Aequorea victoria is one of the most widely used fluorescent proteins first extracted 
in the 1960s (Prendergast and Mann, 1978). The protein fluoresces in the green 
wavelength when excited with blue light (Prasher et al., 1992). The gene encoding 
GFP was succesfully cloned (Chalfie et al., 1994) and used as a reporter for gene 
expression (Heim et al., 1995). Various modifications to GFP have generating an 
enhanced (EGFP) mutant with increased fluorescence and stability (Matz et al., 1999). 
Other mutations to GFP and the discovery of new fluorescent proteins (Shaner et al., 
2005) mean that fluorescence in far red, red, orange yellow, green and blue can be 
generated as a reporter of gene expression (Wall et al., 2008b, Stephens et al., 2003, 
Agren et al., 1999a, Raffetto et al., 2001c). Currently available fluorescent proteins
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are destabilised, allowing the fluorescent proteins to be degraded within the cell 
(www.clontech.com). This destabilisation of fluorescent proteins is especially 
important if they are used as reporters of gene expression, as they can report a 
decrease in gene expression as well as an increase.
1.6 Aims of thesis
The overall aims of this thesis were to characterise hTERT immortalised chronic 
wound fibroblasts and patient matched normal fibroblasts over an extended period in 
culture. To study the phenotypes of immortalised chronic wound and patient matched 
normal fibroblasts using in vitro models of wound healing. To use Microarray 
analysis and QRT-PCR to identify disease specific genes altered between chronic 
wound and normal fibroblasts. To use promoter regions from these disease specific 
genes to generate reporter constructs and to test these constructs in both chronic 
wound and normal cells.
Specifically, it was hypothesised that:
• Fibroblasts will maintain their phenotype after hTERT immortalisation
• Chronic wound fibroblasts exhibit reduced growth rate and impaired wound 
healing in vitro
• Chronic wound fibroblasts have a distinct gene expression profile and this 
relates to the impaired wound healing in vivo
• Reporter constructs will allow the real time analysis of changes in gene 
expression allowing the study of potential treatments for Chronic wounds
• A characterised chronic wound cell line would be a real alternative to the use 
of animals in the study of impaired wound healing.
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Chapter Two 
Materials and Methods
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2.1 Cell Culture
Recruitment of patients to the study was carried out at the out-patient clinics of the 
Wound Healing Research Unit, School of Medicine, Cardiff University.Informed 
consent was obtained from all subjects and local research ethical committee approval 
was obtained from the Cardiff and Vale NHS Trust and Bro Taf Health Authority 
All cell culture carried out in this project has been conducted in sterile conditions in 
an Astec Microflow 2 cabinet. All flasks and plates were maintained in a Nuaire air- 
jacketed DH autoflow automatic CO2 incubator at 37°C/5% CO2 .
2.1.1 Fibroblast Culture
The hTERT immortalised fibroblast cell lines used in this project were generated from 
chronic wound and patient matched normal fibroblasts donated by Ivan Wall (Wound 
Biology Group, Dept. Oral Surgery Medicine and Pathology, Cardiff University). 
Fibroblasts were transfected with the hTERT containing retroviral vector pBABE- 
hTERT. Positively transfected cells were selected by the addition of lpg/ml 
puromycin to the growth medium (Fibroblast-Serum Containing Medium (F-SCM + 
Puro) consisting of Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented 
with L-glutamine (2mM), antibiotics (lOOU/mL penicillin G; lOOpg/mL streptomycin 
sulphate; 0.25pg/mL amphotericin B), puromycin lpg/ml and 10% (v/v) foetal calf 
serum (FCS) (all reagents supplied by Invitrogen, Paisley, UK). Upon reaching 80- 
90% confluence, fibroblast populations were passaged at a ratio of 1:3. The cells were 
washed twice with phosphate-buffered saline (PBS) and detached from the plastic by 
incubation with lmL 0.05% trypsin/0.53mM ethylenediaminetetraacetic acid solution 
(Invitrogen) for approximately 5 minutes at 37 C/5% CO2 . Following incubation, the 
tissue culture vessel was washed with 9mL PBS to collect trypsinised cells. The 
solution was then transferred to a 15mL centrifuge tube (Greiner Bio-one, Gloucester,
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UK) and spun at 1500rpm for 5 minutes in a Precision Durafuge 200. The supernatant 
was aspirated off and the resulting pellet was re-suspended in lmL of F-SCM. Cells 
were counted using a Neubauer haemocytometer (Sigma-Aldrich, Poole, UK) and re­
seeded as required.
2.1.2 Cryopreservation and retrieval of cells
For cryopreservation cells were re-suspended in a solution of 10% (v/v) dimethyl 
sulphoxide (DMSO) (Sigma-Aldrich) 90% (v/v) FCS, placed in cryogenic vials
o
(Gremer) and stored at -80 C in an iso-propanol freezing container. After 24 hours 
cryovials were transferred for long term storage in liquid nitrogen (at -196 C). Frozen 
cells were retrieved from storage by rapid thawing at 37°C, washed in F-SCM and 
following centrifugation (1500 rpm) for 5 minutes the cells were re-suspended in F- 
SCM and cells counted using a haemocytometer. Cells were then seeded as required.
2.1.3 Calculation of population doubling levels
To determine and compare the proliferation of different fibroblast cell lines,
cumulative population doubling levels were plotted against time. At each passage the
total number of viable cells (determined by trypan blue exclusion) were counted using
a haemocytometer and recorded. The number of cells subsequently reseeded was also
recorded. Population doubling level (PDL) of the cell population was calculated
using the following formula:
logio(total cell count obtained) -  log10(total cell count re-seeded)
P D L  = --------------------------------------------------------------------------------------------------------------------------
logio(2)
46
2.1.4 Cell Size Analysis
Cells in monolayer culture were digitally imaged 24 hours after passage using a 
Nikon Coolpix 995 digital camera (Nikon, Kingston-upon-Thames, UK) attached to 
an Olympus CK2 microscope (xlO objective lens, F-Stop 3.5) (Olympus, Southall, 
UK).Images were taken at random from various regions of the flask. Digital images 
were viewed and cell area determined using ImageJ (http://rsb.info.nih.gov/ii/). 
Average cell size was calculated from no fewer than 100 individual cells.
2.1.5 Screening for Mycoplasma contamination
Cell lines were routinely screened for the presence of Mycoplasma contamination. 
Cells were cultured overnight (lxlO 4 cells/well) under standard conditions in 24 well 
plates. Media was removed and the cells washed with lmL of Hoechst 33258 stain 
(bisbenzimide; Aventis, Bad Soden, DE) at 1 pg mL' 1 in methanol (Sigma-Aldrich).
o
Fresh stain was applied and the cells incubated for 15 minutes at 37 C/5% CO2 . 
Staining solution was removed and the cells were washed 4 times with ddFhO. 
Digital images o f stained cells were acquired using a Zeiss Axiovert 200M 
microscope (with DAPI excitation 300-390nm, emmission 410-750nm) and a 
Hamamatsu digital camera and reviewed using Adobe Photoshop 6 .
2.2 Microarray Analysis
2.2.1 RNA extraction
lxlO 6 cells were plated out into a 14cm tissue culture plate (Greiner) and left for 24 
hours to adhere. F-SCM + Puro was replaced with F-SCM + Puro containing 0.1% 
FCS and the cells serum starved for 48 hours. Cells were stimulated by the addition of 
F-SCM + Puro for 0, 1, 6  and 24 hours. After stimulation, cells were washed with 
PBS and incubated with 1.5ml TRIzol (Invitrogen) reagent (5min RT). The plates 
were scraped and 750pl of cell lysate placed into RNase free 1.5ml microcentrifuge
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tubes (Greiner). 175 pi chloroform (Sigma-Aldrich) was added to each tube and 
shaken. Chloroform/TRIzol mix was placed in 1.5ml heavy phase lock gels (Fisher 
Scientific, Loughborough, UK) and centrifuged (2min, 13000g, RT). The upper 
colourless aqueous layer was transferred to a RNase free 1.5ml microcentrifuge tube. 
RNA was precipitated by the addition of 500pl Isopropanol (Sigma-Aldrich), lp l 
glycogen (Invitrogen) (lOmin, RT) the centrifuged (lOmin, 12000g, 4°C). The 
supernatant was removed and the pellet washed with 500pl 75% Ethanol (EtOH) 
(Sigma-Aldrich) and centrifuged (5min, 7500g, 4 C). The supernatant was removed 
and the pellet air-dried and re-suspended in 10pl of DEPC H2 O.
2.2.2 Ethanol Precipitation
RNA was precipitated (overnight -20 C) by the addition of 1/10th volume NaOAc 
(Sigma-Aldrich), 2.5x volume 100% EtOH and lp l glycogen. After overnight 
precipitation, the RNA was centrifuged (20min, 12000g, 4°C) the supernatant 
removed and washed twice 500pl 80% EtOH (Sigma-Aldrich) and centrifuged
o
(lOmin, 12000g, 4C). The supernatant was removed and the pellet air-dried and re­
suspended in lOpl o f DEPC H2O. RNA samples were checked for purity (260/280 
ratio >1.6) and concentration by nanodrop spectrometer. Analysis for integrity of 
RNA samples was carried out on an Agilent 2100 bioanalyser (Agilent Technologies, 
Stockport, UK). The ratio and integrity of 18S and 28S rRNA was analysed to 
determine if the RNA has been degraded.
2.2.3 Microarray Analysis
cDNA synthesis and Microarray analysis of mRNA was carried out by Megan 
Musson, Central Biotechnology Service, Department of Pathology, Cardiff University 
using Ajfymetrix™  Genechip U133A arrays (Affymetrix UK Ltd., Maidenhead, UK). 
Raw microarray expression data was initially processed using the microarray Analysis
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Suite 5.0 (MAS5) provided by Asymetrix. The resulting data was stored in cell intensity 
(.CEL) files. Statistical analysis was carried out using Bioconductor 
(http://www.bioconductor.org) an open source R based software project for the 
analysis of genomic data. Data was also uploaded onto MADRAS Microarray Data 
Review and Annotation System (http://www.madras.uwcm.ac.uk).
2.3 Telomeric Repeat Amplification Protocol (TRAP ASSAY)
2.3.1 TRAP solutions
Unless otherwise stated all reagents used in this assay were from Sigma-Aldrich.
23.1.1 Wash Buffer per 1ml 
lOOpl 0.1M Hepes-KOH 
1.5pl IM M gCh
l.Opl KC1
1 pi 1M DTT (added before use)
DEPC water to 1 ml
2.3.1.2 Lysis Buffer per 1ml
lOOpl Tris-HCL pH8.3
1.5pl IM M gCh
lOpl 0.1MEGTA
lOOpl Glycerol
lOOpl 5% CHAPS
2pl 0.5M PMSF (added before use)
3 .5 pi 1 0 % p-mercaptoethanol (added before use)
DEPC water to 1ml
2.3.1.3 lx  Reaction Buffer per reaction
20mM Tris-HCL, pH8.3
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1.5mM MgCh 
63mM KCL 
0.005% TWEEN 
ImMEGTA
50pM dNTP’s (Promega, Southampton, UK)
0.1 mg/ml BSA (Promega)
1 pg T4 gene32 protein (Promega) (added before use)
lOOng TS primer (Invitrogen Custom Primer) (added before use) 
lOOng CX primer (Invitrogen Custom Primer) (added after first step)
2.5U Taq polymerase (Promega) (added after first step)
23.1.4 TS Primer 
5 ’ - AATCCGTCGAGC AGAGTT-3 ’
2.3.1.5 CX Primer
5 ’ -CCCTTACCCTTACCCTTACCCTAA-3 ’
2.3.2 Telomerase extraction
Cells (5xl05) were re-suspended in 1 ml wash buffer (2.3.1.1) and spun at 15,000g for
o
2 min 4C . The supernatant was removed and the cells re-suspended in lOOpl lysis 
buffer (2.3.1.2). Cells were incubated on ice for 30 min. The lysate was then
o
centrifuged at 20,000g for 30 min at 4 C and the supernatant collected and frozen on 
dry ice in lOpl aliquots.
2.3.3 TRAP assay
Reactions were set up in RNase free 0.5ml microtubes, each reaction containing 50pl 
of lx reaction mix with lpg T4 gene32 protein and lOOng TS primer added (2.3.1.3). 
Various volumes of protein extract (2.3.2) were added (lpl-5pl) to each reaction. 
Negative controls for each reaction were setup with heat denatured protein extracts.
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Protein extracts were heat denatured for 10 minutes at 85C. Reactions were
• ® oincubated for 30 minutes at 30 C, the temperature was increased to 92 C and lOOng 
CX primer, 2.5U Taq polymerase was added to each reaction. TRAP products were 
amplified by 31 cycles (92°C for 30s, 50°C for 30s and 72°C for 90s). 10 pi of 6 x 
loading dye (Promega) was added to each reaction. TRAP products were run on a 
10% polyacrylamide (19:1) 20cm gel containing 0.5x TBE, 25pl of each reaction 
were added per well and run at 300V until bromophenol blue was approximately 3cm 
from the bottom of the gel. The gel was soaked in lx  Sybr Gold (Invitrogen) for 10 
minutes and visualised on a Typhoon 9400 Variable Mode Imager (GE Healthcare, 
Little Chalfont, UK) using an excitation wavelength of 488nm and a 520 BP40 
emission filter.
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2.4 Quantitative Real Time Polymerase Chain Reaction (QRT-PCR)
2.4.1 cDNA generation
For QRT-PCR cDNA was generated from total RNA samples extracted as described 
in section 2.2. RNA concentration and integrity was quantified as described in section
2.2. For each reaction lpg mRNA was added to 0.5pg random hexamer primers 
(Promega) in a RNase free 50pl PCR tube and made up to 13 pi with DEPC treated 
ddFkO. Reactions were heated to 70°C for 5min followed by quenching on ice for 
5min. To each reaction the following reageants were added; lp l RNAsin (Promega), 
5pl MMLV 5x buffer, 5pl lOmM dNTP’s (dATP, dCTP, dGTP and dTTP) 
(Promega) and lp l M-MLV Reverse Transcriptase (Promega). Reactions were mixed 
and incubated for lOmin 25°C, 60min 42°C and 5min 95°C. Reactions were stored at - 
80°C until required.
2.4.2 GAPDH PCR
2.4.2.1 GAPDH Primers
GAPDH 1 F (5’ to 3’) CAACTACATGGTTTACATGTTCCAA 
GAPDH 1 R (5’ to 3’) TCAAGATCATCAGCAATGCCT
2.4.2.2 Confirmation of cDNA generation by Polymerase Chain Reaction
25 pi PCR reactions were setup with lOng cDNA (lp l cDNA reactions after 1:4 
dilution), 2.5pl lOx PCR buffer (Promega), 2pl 25mM MgCh, 2pl lOmM dNTP’s 
(dATP, dCTP, dGTP and dTTP) (Promega),lpl lOpM GAPDH 1 F primer, lpl lOpM 
GAPDH 1 R primer, 0.5pl Taq Polymerase (Promega) and 15pl DEPC treated 
ddH2 0 . Reactions were denatured for 2 minutes at 95°C then run for 30 cycles of 94
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°C for 20s, 55 °C for 30 s and 72 °C for 30s on a Hybaid thermal cycler (Thermo 
Electron).
2.4.2.3 Agarose Gel Electrophoresis of PCR products
A 1.5 % agarose gel containing 60 ml of TAE and 0.9 g of molecular grade agarose 
(Bioline, London, UK) was microwave-heated until the agarose was dissolved. After 
cooling to a temperature comfortable to touch, 0.6pl of ethidium bromide was added 
and the gel was poured into a 10 cm x 11.5 cm casting tray and allowed to set. The 
gel was then immersed in a tank containing 200 ml TAE and each well was loaded 
with 10 pi of PCR product containing lx blue/orange loading dye (Promega). A 100 
bp DNA ladder (Promega), also containing lx blue-orange loading dye was loaded at 
a volume of 6 pi per well and the gel was run at 75 V for 60 min.
2.4.3 Light Upon Extension Quantitative Real Time PCR
2.4.3.1 Reference Control
To allow comparison between plates a reference control was used. Stratagene QPCR 
Human Reference Total RNA (Stratagene, La Jolla, CA, USA) was supplied at s 
concentration of lpg/pl in O.lmMEDTA/RNase-ffee H2O with a A260/A280 ratio of 
1.8. cDNA controls were generated from 4 pooled cDNA reactions each containing 
5pg total RNA giving lOOpl of 200ng/pl total cDNA.
2.4.3.2 Reference Gene
A predesigned certified FAM labelled LUX primer set for GAPDH (Invitrogen) was 
chosen as the housekeeping gene for all QRT-PCR primers. Primers were designed 
against GenBank Accession number NM 002046, human GAPDH mRNA and
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amplify a region that spans the exon junction 4/5. Both labelled and unlabelled 
primers were supplied at lOpM concentration.
2.4.3.3 Primer Design
Primers pairs for each of my genes of interest were designed using the D-LUX™ 
Designer (https://orf.invitrogen.com/luxA. Genes were identified using their unique 
GenBank Accession number and the mRNA sequence inputed into the primer design 
program. Each sequence was compared by BLAST to other sequences in the Human 
database to identify unique regions for primer design. The following design 
parameters were defined, amplicon size (minimum 60bp, maximum 2 0 bp, optimum 
75bp), primer temperature (minimum 60, maximum 6 8 , optimum 64) and primer 
length (minimum 20, maximum 24, optimum 22). Primers were selected within the 
translated region where possible and with at least a 4 star quality rating.
2.4.3.4 QRT-PCR
For each 96 well plate (StarLab, Milton Keynes, UK) a standard curve of total human 
cDNA (lOOng, lOng, lng and lOOpg) was used in triplicate along with 4 GAPDH 
controls (lOng total human cDNA) to allow for comparison between plates. 25pl 
QRT-PCR reactions were setup for each sample in triplicate with one patients’ 
samples per plate. lOOng cDNA (0.5pl cDNA reaction) was made up to 5pl with 
DEPC treated H20 , to this 12.5pl Platinum qPCR SuperMix-UDG (Invitrogen) 
containing 3mM MgCl2 and ROX reference dye, 0.5pl lOpM LUX labelled primer, 
0.5|il lOpM unlabelled primer, 6.5pl DEPC treated H20 . Plates were run on an ABI 
Prism 7000 (Applied BioSystems, Foster City, USA) with the following cycling
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program; 2 min 50°C, 2 min 95°C followed by 50 cycles of 15 sec 95°C, 60 sec 60°C. 
Melting curve analysis was carried out for all reactions at 60°C.
2.4.3.5 Validation of Reference Gene
Variations in reference gene expression level were determined through analysis of ct 
values for a known concentration of cDNA. lOng of reference cDNA was used and 
reactions set up with GAPDH primers as described in section 2.4.3.4 in total 106 
reactions were run with positive results. ABI Prism 7000 SDS version 1.1 software 
was used to determine the ct value for each reaction. Data was statistically analysed in 
SPSS 14.02 and a 95% confidence interval for fold change determined.
2.4.3.6 Analysis of Expression Changes
ABI Prism 7000 SDS version 1 .1  software was used to determine standard curves for 
each gene and these curves used to determine relative gene expression for each 
sample. The mean expression for the three replicates was taken and normalised by 
dividing by the relevant GAPDH reference gene value. These values were initially 
plotted on Excel spread sheets. Statistical analysis of data was carried out in SPSS
14.02.
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2.5 Generation of Reporter Constructs
2.5.1 DNA extraction from CWF and NF
At sub-culture, cells were counted and 5xl0 5 cells were pelleted in a 1.5 ml RNase/ 
DNase free eppendorf tube (Greiner). Media was removed and cells were washed 
with PBS to remove residual culture medium. Samples were kept on ice and 300 pL 
lysis buffer (200 mM tris-HCl pH 7.5/250 mM NaCl/25 mM EDTA/0.5 % SDS in 
H2 O) along with 3 pi ribonuclease A (RNase A) was added to each pellet. 6  pL 
proteinase K ( 2 0  mg/ml) was added to each tube at room temperature before pulse 
spinning in a microcentrifuge (all reagents from Sigma-Aldrich). The solution was 
incubated overnight at 45 °C in a heat block. After incubation 300 pL 
phenol:chloroform:Iso-amyl alcohol (25:24:1; Sigma-Aldrich) was added to each 
tube and the tubes mixed on a revolving mixer for 30 min at room temperature. The 
solution was centrifuged at 13000 rpm for 5 min. The upper aqueous layer was 
carefully removed from the underlying phenol:chloroform:Iso-amyl alcohol layer and 
transferred to a new tube containing 300pl phenol:chloroform:Iso-amyl alcohol. The 
solution was mixed on a revolving mixer for 30 min at room temperature.The tubes 
were centrifuged at 13000 rpm for 5 min and the upper aqueous layer transferred to a 
new tube. DNA was precipitated by incubating with 300 pL NaOAc (3 M, pH 5.2; 
Sigma-Aldrich) and 900pl ice-cold ethanol (100 %) for 20 min at -20 °C. DNA was 
pelleted by centrifugation at 13000 rpm for 2 min, the supernatant removed and the 
pellet retained. The DNA pellet was washed with 500pl ice-cold ethanol (70 %) and 
centrifuged at 13000 rpm for 2 min. Supernatant was removed and the pellet air dried 
at room temperature for 2 h. DNA was re-suspended in 20pl DEPC treated ddH2 0  
and stored at -20°C until required.
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2.5.2 Quantification of DNA
DNA concentration was calculated using the Fluorescent DNA quantitation kit 
(BioRad) and the FLUOROStar Optima (BMG LABTECH, Aylesbury, UK). 
Samples were thawed on ice and pulse centrifuged. The DNA quantification buffer 
(TEM), consisting of 100 mM Tris, 2 M NaCl and 10 mM EDTA pH 7.4 was 
prepared 1:10 in H2O. Hoechst 33258 dye was added to the buffer at a concentration 
of 1 ng/ml. 1 pi of each DNA sample was added to 200pl of TEM buffer containing 
Hoechst stain in a 96 well fluorometric plate. A standard curve was setup in triplicate 
with calf thymus DNA at the following concentrations 2000ng, lOOOng, 500ng, 
lOOng, 50ng and 20ng. A blank control was also setup with TEM buffer containing 
Hoechst stain but no DNA. DNA was quantified using a 355nm excitation filter and a 
460 emission filter, 20 flashes per well. Sample DNA concentrations were calculated 
by comparison to the standard curve. DNA samples were then diluted to a final 
concentration of 10 ng/pl in lOmM Tris pH8 .
2.5.3 Primer Design
Primers were designed using the online primer3 software 
(http://primer 3 .sourceforge.net/) using sequence information from the Database of 
Transcriptional Start Sites (http://dbtss.hgc.ip).
2.5.4 Long Range PCR
Long range PCR was carried out using genomic DNA extracted as described in 
section 2.5.1. The proof reading polymerase Expand HiFi (Roche, Welwyn Garden 
City, UK) following the manufacturers instructions. Two reaction mixes were 
prepared, and combined just prior to thermal cycling. Mix 1; 21.75 pi d d ^ O , 1 pi
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lOmM dNTP’s (Promega), 1 pi lOmM 3’primer, 1 pi lOmM 5’ primer, lOOng 
genomic DNA. Mix 2; 19.25 pi ddH2 0 , 5 pi 10X Expand HiFi buffer (Roche), 0.75 
pi Expand HiFi polymerase (Roche). Reactions were denatured for 5 minutes at 95°C 
and then run for 35 cycles of 95 °C for 1 min, 55 °C for 30 s and 72 °C for 2 min with 
a final extension 72 °C for 7 min on a Hybaid thermal cycler (Thermo Electron). 
Products were run on a 0.8% TBE agarose gel as described previously.
2.5.5 Gel Extraction
Gel extraction was carried out using a Quiagen gel extraction kit (Quiagen, West 
Sussex, UK) following the manufactures instructions. Briefly bands were excised 
from the gel using a scalpel, weighed and three times the gel slice volume of QG 
buffer added. The gel slice was incubated with shaking at for 10 minutes. 800pl 
of gel/buffer was added to a QIAquick spin column and centrifuged for 1 min at
10.000 RPM with the flow through discarded. If any Gel/buffer solution remained it 
was added to the same column and the centrifugation repeated. 750pl PE buffer was 
added to the column, incubated at r/t for 5 min and then centrifuged for 1 min at
10.000 RPM and the flow through discarded. Remaining PE buffer was removed by a 
further centrifugation for 1 min at 13,000RPM and the column was placed in a clean 
1.5ml tube. 30pl of EB buffer was added to the column membrane, incubated for 1 
minute at r/t and centrifuged at 10,000RPM for 1 min. DNA concentration was 
determined by UV spectroscopy.
2.5.6 Ligation into Plasmids
Ligation reactions were setup either with pGEM-T recovery vector (Promega) or 
restriction digested pZsGreen reporter vector (Clontech, Saint-Germain-en-Laye,
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France). Recovered DNA from gel extracts or restriction digested PCR products were 
used as insert. Ligation reactions were setup with 5 pi 2x T4 DNA ligase buffer 
(Promega), 1 pi Vector, 1 pi T4 DNA Ligase (Promega) 3 pi insert DNA. Reactions 
were mixed by gentle pipetting up and down and incubated at 16°C overnight.
2.5.7 Transformation into competent E.coli
Subcloning Efficiency ™ DH5a™ competent E.coli (Invitrogen) were used for all 
transformations following the manufacturers recommended protocol. Briefly DH5a™ 
cells were thawed on ice and mixed gently with a pipette tip. 50pl of cells were added 
to 2 pi of ligation reaction and mixed gently. Unused cells were flash frozen on dry 
ice/EtOH. Cells and DNA were incubated on ice for 30 min after which time they 
were heatshocked at 42°C for 30 seconds. After heat shocking cells were placed on ice 
for 2 min. 950 pi of warmed SOC media (Invitrogen) was added to the cells and the 
cells/media incubated at 37°C for 1 hour at 225rpm.l00 pi of cells/media was spread 
onto agar plates with appropriate selection and incubated overnight at 37°C. Colonies 
were picked used to inoculate 5ml of LB media and grown overnight.
2.5.8 Plasmid MiniPrep
5ml of overnight bacterial culture was pelleted by centrifugation at 16,000 rpm for 5 
minutes. Pelleted bacterial cells were resuspended in 250pl buffer PI (Qiagen) and 
transferred to a fresh 1.5ml microcentrifuge tube. 250 pi of buffer P2 (Qiagen) was 
then added and mixed by inverting 4-6 times. Buffer N3 (Qiagen) was added and 
mixed by inverting 4-6 times. The lysed bacteria were centrifuged at 13,000 rpm for 
10 minutes and the resulting supernatant added to a QIAprep spin column. The 
QIAprep column was centrifuged for 60 seconds at 13,000rpm and the flow through
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discarded. The column was washed by the addition of 500 pi buffer PB (Qiagen) 
followed by centrifugation for 60 seconds at 13,000rpm and the flow through 
discarded. The column was washed by the addition of 750 pi of buffer PE (Qiagen) 
followed by centrifugation for 60 seconds at 13,000rpm and the flow through. A 
further centrifugation step of 60 seconds at 13,000rpm was used to remove left over 
PE buffer and the column was placed into a fresh 1.5ml centrifuge tube. DNA was 
eluted by the addition of 30 pi buffer EB (Qiagen), incubation for 1 minute at room 
temperature followed by centrifugation for 60 seconds at 13,000rpm. The resulting 
flowthrough was analysed for DNA concentration by absorbance at 260nm and stored 
at -20°C.
2.5.9 Restriction Digest
All restriction digests were carried out using Promeg restriction enzymes and 
preferred buffers. In the case of double digest the buffer with the highest percentage 
activity for both enzymes without star activity was used. 1 0  pi digests were setup with 
lp l DNA, lp l restriction enzyme(s), lp l lOx buffer, lp l 0.1M DTT, 6 pl ddEhO. 
Plasmid DNA from miniprep purifications or PCR product from gel extractions was 
used at a concentration no greater than 500ng/pl. Digests were incubated for 1 hour at 
37°C and visualised on an agarose gel.
2.5.10 Transfection of Adherent Fibroblasts
Fibroblasts were plated out into a 6  well tissue culture plate (Greiner) at a density of 
l x l0 5 cells per well. Cell were incubated overnight in FSCM at 37°C, 5% CO2 . After 
overnight incubation cells were between 50-80% confluent. For each well lOOpl of 
serum free DMEM (Invitrogen) plus 3 pi Gene Juice® transfection reagent (Merck
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KGaA, Darmstadt, Germany) were prepared and incubated at room temperature for 5 
minutes. For each well lpg of plasmid DNA was added to the DMEM/GeneJuice 
mixture and incubated at room temperature for 15 minutes. The 
DNA/DMEM/GeneJuice mixture was added dropwise to the cells, with the drops 
evenly distributed across the well. Cells were incubated for 24 hours at 37°C, 5% C 0 2 
before media was changed.
2.5.11 Quantification of fluorescence
Fluorescence was quantified using the FLUOROStar Optima (BMG LABTECH). 
Transfected cells were serum starved for 48 hours prior to use, FSCM was added to 
the cells and fluorescence readings taken at 0, 1, 6  and 24 hours after stimulation. 
Untransfected cells were used as a negative control and all fluorescence was 
normalised to GAPDH.
2.5.12 Confocal Microscopy.
Transfected and untransfected cells were plated at a density of 2><104 cells per well 
into each well of an 8  well chamber slides (Greiner) and maintained for 24h under 
standard culture conditions. After discarding waste media, the cells were washed 
fixed in ice cold methanol and stained with 1 mL of Hoechst 33258 stain at 1 pg mL' 1 
in methanol (Sigma-Aldrich) for 15 minutes. Stain was removed and the slides 
mounted with Fluorosave reagent (Merck). Mounted slides were visualised using a 
Leica TCS SP5 confocal microscope(Leica, Milton Keynes, UK) running the Leica 
Application Suite, Advanced Fluorescence (LASAF) software.
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CHAPTER THREE
Phenotypic Analysis 
of
Immortalised Human Chronic wound
and
Normal Fibroblasts Cell Lines
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3.1 Introduction
In order to study chronic wounds without the use of animal models a cell based 
alternative is required. Fibroblasts can be isolated and cultured from chronic wounds, 
and they have been demonstrated to be phenotypically distinct from fibroblasts taken 
from the unwounded skin of the same patient, making them a potential tool for 
understanding chronic wound cell biology (Hayflick and Moorhead, 1961, Harley, 
1991). These primary cells however have a finite replicative capacity before they 
enter senescence (Stanley and Osier, 2001b, Raffetto et al., 1999b, Mendez et al., 
1998a). Therefore the potential usefulness of primary human fibroblasts isolated from 
chronic wounds as an experimental model is severely limited by their reduced 
replicative potential (Collins, 1996).
One of the mechanisms controlling replicative senescence is the erosion of telomeres. 
Telomere erosion can be halted by the addition of hTERT to the cells. Telomerase is a 
ribonucleoprotein DNA polymerase consisting of both protein and RNA components 
(Vaziri and Benchimol, 1998). Telomerase has the ability to add 6  base pair repeats to 
the end of the telomeres restoring their length after cell division. The addition of 
hTERT to somatic diploid fibroblasts through retroviral transfection has been shown 
to increase telomere length and extend cellular replicative life span (MacKenzie et al., 
2000). The expression of hTERT allows the cells to escape telomere dependent 
senescence. After extended periods in culture hTERT infected cells may still enter a 
state of growth arrest in a telomere independent fashion (Milyavsky et al., 2003b) or 
take on a cancer like phenotype (Morales et al., 1999, Choi et al., 2001, Ouellette et 
al., 2000). Despite the possible drawbacks associated with long term growth of 
hTERT infected cell lines, the technology offers the potential to generate cell lines
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from difficult to obtain primary cells without altering their phenotype (Wyllie et al., 
2000, MacKenzie et al., 2000).
The aim of this chapter was to characterise hTERT infected chronic wound and 
patient matched normal skin fibroblasts over an extended time in culture. Before they 
can be used further it was important to confirm that the hTERT infected cells had 
escaped replicative senescence and were effectively immortalised. For the cells to be 
used as a model for chronic wounds it was also vital to confirm that the disease 
specific phenotype observed in the chronic wound derived cells was maintained, not 
only immediately after hTERT transfection but also after long term culture.
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3.2 Results
3.2.1 Long term culture of hTERT infected fibroblasts
Work carried out previously within the Wound Biology Group in Cardiff involved the 
recruitment of three patients suffering with chronic venous leg ulcers. Biopsies were 
taken from both the ulcer bed and from the ipsilateral thigh for each patient. 
Fibroblasts were isolated from the biopsies giving 6  primary cell strains (Ivan Wall 
Thesis 2006). The cell strains were labelled H, I and K identifying the 3 separate 
patients, with ‘w’ indicating wound and ‘n’ indicating normal identifying the biopsy 
site. The primary cell strains were retrovirally infected with either an empty pBABE 
plasmid conferring puromycin resistance or with a pBABE plasmid expressing human 
telomerase (hTERT). The infected cells were treated with puromycin therby selecting 
infected cells. For each cell strain two cell lines were generated; a ‘mock’ cell line 
containing the empty vector and a hTERT cell line containing the telomerase 
expressing vector. The cell lines were maintained in continuous culture with accurate 
cell counts taken at each passage. Population doubling levels (PDL) were determined 
for each cell line and plotted against time in culture (Figs 3.1-3.3). The mock and 
hTERT cell lines for each patient and for wound and normal are shown on the same 
graph allowing comparison between growth rates he average growth rate for each cell 
line over the entire extended time in culture is shown in Table 3.1.
In patient H (Fig 3.1) the mock infected normal cells (nHm) underwent 55 population 
doublings (PD) over 340 days before reaching senescence. The mock infected wound 
cells (wHm) underwent 29 PD over 231 days before reaching senescence. The hTERT 
infected normal cell line (nHh) reached 55 PD in 175 days and 128 PD in 340 days 
with no sign of a reduction in cell proliferation. The hTERT infected wound cell line 
(wHh) underwent 29 PD in 119 days, 91 PD in 340 days and showed no sign of a
65
160
140
120
100
80
60
40
20
0
4500 50 100 150 200 250 300 350 400
T im e  ( d a y s )
Figure 3.1: Relative PDL data for Patient H, mock infected cells CWF (—) and NF (—) and hTERT immortalised cell lines CWF (—)
and NF (—). Mock infected CWF complete fewer PDs than NF with both cell strains senescing before 55 population 
on doublings (senescence was determined when population doubling per week dropped below 0.5). The hTERT immortalised
cell lines exceeded the maximum PD’s seen in the mock immortalised cells completing more than 100 population 
doublings.
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Figure 3.2:
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Relative PDL data for Patient I, mock infected cells CWF (—) and NF (—) and hTERT immortalised cell lines CWF (—) 
and NF (—). Mock infected CWF complete fewer PDs than NF with both cell strains senescing before 50 population 
doublings (senescence was determined when population doubling per week dropped below 0.5). The hTERT immortalised 
cell lines exceeded the maximum PD’s seen in the mock immortalised cells completing more than 100 population 
doublings.
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Figure 3.3: Relative PDL data for Patient K, mock infected cells CWF (—) and NF (—) and hTERT immortalised cell lines CWF (—)
and NF (—). Mock infected CWF complete fewer PDs than NF with both cell strains senescing before 50 population 
doublings (senescence was determined when population doubling per week dropped below 0.5). The hTERT immortalised 
cell lines exceeded the maximum PD’s seen in the mock immortalised cells completing more than 100 population 
doublings.
Patient Type
Total Time in Culture 
(Days)
Average Growth Rate (Population 
Doubling/Week)
H Normal Skin 340 2.79
H Chronic Wound 444 1.84
I Normal Skin 354 2.70
1 Chronic Wound 384 2.70
K Normal Skin 438 2.03
K Chronic Wound 470 1.78
Table 3.1: Table showing average growth rate for each of the hTERT immortalised cell lines
reduction in cell proliferation at 116 PD and 444 days in culture. The wHh cell line 
did however undergo a brief plateau in PDL at two points in culture between days 
283-297 and between days 376-397. The PD/week dropped below 0.5 indicating 
senescence however, the wHh cell line recovered and PD/week returned to levels 
previously seen. Both the hTERT infected cell lines have escaped replicative 
senescence, undergoing more than 100 PD with no sign of a reduction in cell 
proliferation. Overall though the wHh cell line showed a reduced rate of proliferation 
compared to the nHh cell line (Table 3.1).
In patient I (Fig 3.2) the mock infected normal cells (nlm) underwent 47 population 
doublings (PD) over 205 days before reaching senescence. The mock infected wound 
cells (wlm) underwent 12 PD over 129 days before reaching senescence. The hTERT 
infected normal cell line (nlh) reached 47 PD in 149 days and 129 PD in 354 days 
with no sign of a reduction in cell proliferation. The hTERT infected wound cell line 
(wlh) underwent 12 PD in 69 days, 121 PD in 352 days and showed no sign of a 
reduction in cell proliferation at 134 PD and 384 days in culture. Compared to patient 
H the growth rates of the normal I and wound I hTERT infected cells were closer with 
no difference in average growth rates over the total time in culture (Table 3.1). At 
some points in culutre wlh did demonstrate a slightly reduced rate of proliferation 
compared to nlh with the greatest difference in proliferation rates observed between 
days 50 and 200. Both the hTERT infected cell lines escaped replicative senescence 
undergoing more than 125PD.
In patient K (Fig 3.3) the mock infected normal cells (nKm) underwent 45 population 
doublings (PD) over 266 days before reaching senescence. The mock infected wound 
cells (wKm) underwent 36 PD over 227 days before reaching senescence. The hTERT 
infected normal cell line (nKh) reached 45 PD in 192 days and 123 PD in 438 days
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with no sign of a reduction in cell proliferation. The hTERT infected wound cell line 
(wKh) underwent 36 PD in 153 days, 104 PD in 438 days and 116 PD in 470 days 
with no sign of a reduction in cell proliferation. Both the hTERT infected cell lines 
demonstrated that they had escaped replicative senescence undergoing more than 110 
PD. As in patient H there was a difference in proliferation rates between wKh and 
nKh with the wound derived cell line showing a reduced rate of cell proliferation 
(Table 3.1). Compared to the other patients the patient K hTERT cell lines showed 
generally slower rates of cell proliferation requiring a greater time in culture to reach 
100PD.
For all three patients the wound derived mock infected cells senesced at a lower PDL 
than the patient matched mock infected normal cells. For all three patients the hTERT 
immortalised normal and wound derived cells escaped replicative senescence 
undergoing significantly more PD than the mock infected cells. In patients H and I the 
hTERT infected cells maintained a difference in cell proliferation rate between the 
normal skin and wound derived cell lines with the wound cells having a reduced 
proliferation rate (Table 3.1).
3.2.2 hTERT and hTR gene expression in CWF and NF cell lines
To be active, human telomerase requires a protein and RNA component hTERT and 
hTR respectively. The expression of these components was determined by RT-PCR 
with RNA extracted from each of the hTERT infected cell lines (Fig 3.4) Gene 
expression was observed in normal and wound derived cell lines for each of the three 
patients. However the presence of hTERT and hTR RNA does not confirm the 
presence of active telomerase in the hTERT infected cell lines.
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Figure 3.4: RT-PCR for hTR, hTERT and GAPDH expression. Expression of the RNA (hTR) and the protein (hTERT) components of
to Telomerase was confirmed in all 6 immortalised cell lines by RT-PCR Products of 170bp for hTR, 150bp for hTERT and
500bp for GAPDH were seen in each patient.
3.2.3 Telomerase activity in CWF and NF cell lines
To detect the presence of active telomerase the Telomere Repeat Amplification 
Protocol (TRAP) assay was utilised. Active telomerase will add 6bp repeats to the 
primer templates within the assay solution. The presence of active telomerase within 
protein extracts will generate a characteristic ‘ladder’ of DNA fragments with 6bp 
differences between the fragments when visualised by electrophoresis. Active 
telomerase is heat sensitive, the protein and RNA components will dissociate when 
heated above 80°C removing the ability to add 6bp repeats to the primer template. 
Heat inactivation acts as a negative control helping to confirm that it is telomerase 
generating the ladder, a second potential control for the TRAP assay is the use of 
RNase to digest the hTR this was not used due to fears of RNase contamination. 
Protein extracts from hTERT infected cells were tested for active telomerase using the 
TRAP assay (Fig 3.5). Each of the hTERT infected cell lines showed active 
telomerase as demonstrated by a DNA ladder. The DNA ladder was not observed in 
samples heat treated suggesting that a heat sensitive enzyme such as telomerase was 
responsible for the ladder. Water controls were also used to demonstrate that the DNA 
ladder was due to the protein extract and not an artefact of the TRAP assay.
3.2.4 Cell Morphology of CWF and NF cell lines
Upon reaching senescence fibroblast morphology changes dramatically, they become 
enlarged and take on a polygonal appearance with stress fibres visible within the cells. 
In contrast proliferating fibroblasts have a stretched bi-polar morphology and are 
generally smaller in size. To confirm that the morphology of hTERT infected 
fibroblasts did not change over an extended time in culture bright field images were 
taken of recently passaged cells at three timepoints in culture. As the different patient
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matched wound and normal cell lines showed different growth rates, passage number 
was used to describe the time point in culture. Early time point has been defined as 
passage 23 (p23), mid time point as passage 50 (p50) and late time point as passage 
80 (p80). In Patient H the normal nHh and chronic wHh hTERT infected cell lines 
(Fig 3.6) showed no changes in morphology over the three timepoints in culture 
retaining the same bipolar fibroblast morphology seen in young primary cells. There 
were also no morphological differences between the normal skin derived cells nHh 
and the chronic wound derived cells wHh. Similarly no changes in morphology over 
time in culture were observed in patient I (Fig 3.7) or patient K (Fig 3.8) hTERT 
infected cell lines regardless of the origin of the cells. The lack of morphological 
changes in the hTERT infected cells even over extended time in culture (at p80 cells 
were in culture between 320 and 460 days), appears to show that the introduction of 
telomerase has allowed the cells to escape the changes in morphology associated with 
replicative senescence.
3.2.5 Cell Size analysis of CWF and NF cell lines
As well as morphological changes senescent cells show an increase in cell area when 
compared to non senescent cells. Previous work within the Wound Biology Group has 
demonstrated that mock infected cells increase in size as they enter senescence in the 
same way as primary cells (Thesis Ivan Wall 2006). Cell area analysis was used to 
determine if the hTERT infected cells increased in size over extended time in culture. 
Cell area was measured using the ImageJ software package. Cells were imaged 24 
hours after reseeding, the cell perimeters were traced giving area measurements for 
individual cells (Fig 3.9). Cell areas were measured for NF and CWF in each of the 
three patients at the three time points in culture described previously. Histograms of
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cell size in mm against percentage of cell population were generated for each patient 
(Figs 3.10-3.12) as well as mean cell size (Fig 3.13). The histograms generated from 
cell size data for patient H (Fig 3.10) at early (Fig 3.10a) and late (Fig 3.10c) time 
points show a shift to the right in the CWF histogram compared to the NF histogram. 
The mid time point (Fig 3.10 b) for patient H demonstrated a right shift in the NF cell 
size compared to the CWF. When the mean values for cell size are analysed (Fig 3.13) 
the mean NF cell size was significantly smaller than the CWF at early and late time 
points (ANOVA analysis p<0.05) as indicated by the histograms. Examining the cell 
sizes for patient H over time there did not appear to be an increase in cell size between 
early (passage 23) and late (passage 80) time points in culture. In the CWF the mean 
cell size appears to decrease over time in culture. The histogram showing cell size 
data for patient I at the early time point in culture (Fig 3.11) demonstrated a small 
right shift in the CWF cell sizes indicating a slight difference in cell size. At the mid 
and late time points in culture the same right shift is evident with the greatest shift 
seen in the late time point in culture. When the mean values for cell size are analysed 
(Fig 3.13) they show a significant difference between the NF and CWF at all time 
points in culture (ANOVA analysis p<0.05). As seen with patient H CWF the mean 
cell size in patient I NF and CWF appears to decrease over extended time in culture. 
The histogram for patient K at the early timepoint in culture (Fig 3.12) a spread o f all 
sizes in both NF and CWF with larger cells present in the CWF. The mid and late 
time points demonstrated a more typical cell distribution with the same right shift in 
cell size observed in the CWF compared to the NF. The mean cell size data for patient 
K (Fig 3.13) demonstrated the same significant difference in size between the NF and 
CWF with the mean cell size for CWF larger than the NF (ANOVA analysis p<0.05). 
The same decrease in cell size over extended time in culture was
79
Figure 3.9: Cell size analysis was carried out on the ImageJ software package. Cell
perimeter was traced and cell area was calculated based on scale calibration 
taken from a haemocytometer grid. Counted cells were marked and 
numbered to prevent repeated measurement. (Scale Bar lOOpm)
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Figure 3.10: Histograms showing distribution of cell area in NF (-) and CWF (-) cell lines
from patient H at (a) early, (b) mid and (c) late time point in culture.
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Figure 3.11: Histograms showing distribution of cell area in NF (-) and CWF (-) cell lines 
from patient I at (a) early, (b) mid and (c) late time point in culture.
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observed in patient K in both NF and CWF. Cell size analysis showed that the hTERT 
infected cell lines for all three patients did not increase in size over extended time in 
culture. The mean cell sizes and histograms of cell size distribution demonstrated that 
the CWF cells were larger than the NF from the same patient and that this size 
difference was maintained over extended time in culture.
3.2.6 Repopulation of a monolayer scratch wound by CWF and NF cell lines 
A simplified model for wound healing, the monolayer ‘scratch’ assay was used to 
analyse wound repopulation in the hTERT infected cell lines at early and late time 
points in culture. This simplified in vitro wounding model was used to study the 
response of NF and CWF to wounding. The repopulation of the scratch wound is 
dependent on the migratory and proliferative potential of the cells used allowing 
comparisons to be made between NF and CWF. Previously it has been observed that 
CWF have a reduced ability to repopulate the wound area compared to patient 
matched NF (Thesis Ivan Wall 2006). By comparing the early and late time points in 
culture for each of the cell lines it should be possible to determine if this phenotypic 
difference between NF and CWF cells is maintained post immortalisation and after 
an extended time in culture. Scratch wounds were analysed in two ways to determine 
if any differences in wound repopulation were apparent. Time-lapse movies were 
generated with images captures at 20 minute intervals (full movies can be found on 
the supplemental DVD); for comparison 6 time points were used to generate a 
montage for each wounding experiment. It should be noted however, that the wounds 
generated were not generally uniform with some differences in starting size altering 
the apparent rate of wound closure. The imageJ software package was used to 
determine wound area over the course of the experiment allowing for a comparison of 
wound repopulation rates over time.
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Patient H NF hTERT infected cells had successfully repopulated the scratch wound 
between 18 hour and 24 hours post wounding at both the early (Fig 3.14) and late 
(3.15) time points in culture. In comparison the CWF hTERT infected cells failed to 
completely repopulate the scratch wound by 24 hours at the early time point in culture 
(Fig 3.14) and by 30 hours at the late timepoint in culture (Fig 3.15). The normalised 
wound repopulation data (Fig 3.16) demonstrated the differences between NF and 
CWF wound repopulation rates are maintained after an extended time in culture. At 
the early time point in culture patient I NF hTERT infected cells (Fig 3.17) 
repopulate the wound area between 18 and 24 hours at the late timepoint (Fig 3.18) 
they repopulate the wound area between 24 and 30 hours. The CWF hTERT infected 
cells repopulated the wound area by 30 hours at the early timepoint (Fig 3.17) and 
after 30 hours at the late timepoint (Fig 3.18). The normalised wound area data (Fig 
3.19) demonstrated the same delayed wound repopulation by the CWF compared to 
the normal at the early and late time points in culture however, the difference between 
the NF and CWF cells appears to be less than was seen in patient H demonstrating 
some heterogeneity in patient response.
At the early time point in culture patient K NF hTERT infected cells repopulated the 
wound area between 18 and 24 hours (Fig 3.20) the CWF hTERT infected cells failed 
to repopulate the wound area within the 30 hours recorded in the montage taking 
almost 40 hours to repopulate the wound. The late time point in culture initially 
indicated a reversal of the wound repopulation phenotype with the CWF hTERT 
infected cells repopulating the wound area between 18 and 24 hours (Fig 3.21) and the 
NF hTERT infected cells repopulated the wound area between 24 and 30 hours. The 
normalised wound size data for the late time point in culture scratch wounds (Fig 3.22 
b) demonstrated that when initial wound area is taken into account the CWF appear to
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Figure 3.14: Scratch Wound montages for Patient H at Early time point in culture, a) NF b)
CWF (Scale Bar = 200pm). Movies available on supplemental DVD under
Timelapse Movies
nHh wHh
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Figure 3.15: Scratch Wound montages for Patient H at Late time point in culture, a) NF b)
CWF (Scale Bar = 200pm). Movies available on supplemental DVD under
Timelapse Movies.
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Figure 3.16: Wound Closure data for Patient H, hTERT immortalised cell lines CWF (—) and
NF (—) at Early a) and Late b) time points in culture.
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Figure 3.17: Scratch Wound montages for Patient I at Early time point in culture, a) NF b)
CWF (Scale Bar = 200pm). Movies available on supplemental DVD under
Timelapse Movies.
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Figure 3.18: Scratch Wound montages for Patient I at Late time point in culture, a) NF b)
CWF (Scale Bar = 200pm). Movies available on supplemental DVD under
Timelapse Movies.
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Figure 3.19: Wound Closure data for Patient I, hTERT immortalised cell lines CWF (—) and
NF (—) at Early a) and Late b) time points in culture.
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Figure 3.20: Scratch Wound montages for Patient K at Early time point in culture, a) NF b)
CWF (Scale Bar = 200pm). Movies available on supplemental DVD under
Timelapse Movies
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nKh
Figure 3.21: Scratch Wound montages for Patient K at Late time point in culture, a) NF b)
CWF (Scale Bar = 200pm). Movies available on supplemental DVD under
Timelapse Movies.
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Figure 3.22: Wound Closure data for Patient K, hTERT immortalised cell lines CWF (—) and
NF (—) at Early a) and Late b) time points in culture.
95
be slower at repopulating the wound area however the difference between NF and 
CWF is not as clear as at the early timepoint (Fig 3.22 a).
In summary comparing patient matched NF and CWF hTERT infected cells by 
scratch wound repopulation it is clear that the CWF demonstrate a reduced rate of 
wound repopulation. This reduced rate of repopulation is maintined after extended 
time in culture although in patient K the difference between the NF and CWF cells is 
reduced.
3.2.7 Analysis of the Cell Velocity of CWF and NF cell lines
Differences in wound repopulation rates may be due to differences in the motility of 
the cells, a simple assay for cell motility is the analysis of cellular velocity during 
wound repopulation. Cell velocity was determined using a cell tracking plugin within 
imageJ, 10 cells were tracked for each wound experiment (Fig 3.23) giving an average 
cell velocity for each cell type at each time point in culture (Fig 3.24). Average cell 
velocities for the NF hTERT infected cells were greater than for the CWF hTERT 
infected cells for all three patients at both time points in culture. The difference in cell 
velocity between NF and CWF was not statistically significant when taken together.
3.2.8 Karyotype
Cell lines in culture for extended periods of time have been reported to demonstrate 
chromosomal instability. To determine if the CWF and NF hTERT immortalised cell 
lines were chromosomally stable after extended periods in culture karyotypes for each 
cell line were determined. Cytogenetic analysis of NF and CWF hTERT infected cells 
was carried out at the West Midlands Regional Genetics Laboratory. Cells at passage 
80 were analysed for gross chromosomal abnormalities, these cells had been 
continually cultured for more than a year and therefore the most likely to have
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Figure 3.23: Scratch Wound montages showing cell tracking. 10 cells were tracked recording
position and distance travelled allowing for calculations of cell velocity..
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Cell Velocities
Bars are One Standard Error from the Mean
50H
Cell Line Passage Average Cell Velocity pm/hour
nHh P25 45.5
wHh p25 44.9
nlh p25 38.3
wlh p25 33.4
nKh p25 40.3
wKh p25 39.7
nHh p80 40.7
wHh p80 33.7
nlh p80 43.8
wlh p80 21.7
nKh p80 36.6
wKh p80 33.6
re 3.24: Cell velocities for NF ■ and CWF ■ hTERT immortalised cells at Early (p25) 
and Late (p80) for all three patients.
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chromosomal abnormalities. A karyotype was determined for each of the patient 
matched cell lines (Fig 3.25-3.27), when a mixed karyotype was observed the 
percentage of the total cells analysed with each karyotype was reported (Table 3.2). 
Patient H cell lines both showed chromosomal abnormalities. The NF hTERT infected 
cells showed two balanced translocations (Fig 3.25) these were observed in 100% of 
the cells analysed (Table 3.1). Patient H CWF hTERT infected cells had a trisomy in 
chromosome 7 (Fig 3.25) seen in 100% of the cells analysed (Table 3.1). Patient I NF 
hTERT infected cells showed no chromosomal abnormalities in any of the cells 
analysed (Fig 3.26). The CWF hTERT infected cells were a mixed population of 
trisomy 7 (Fig 3.26) and normal karyotype with 80% of the cells analysed having a 
normal karyotype (table 3.1). Patient K NF hTERT infected cells were a mixed 
population of normal karyotype and trisomy 11 derivative 19 cells (Fig 3.27) with one 
copy of chromosome 19 containing a large portion of the short arm of chromosome 7 
in place of its own long arm making these cells partially trisomic for chromosome 7. 
80% of the cells analysed had a normal karyotype (Table 3.1). The CWF hTERT 
infected cells all displayed a trisomy 7 karyotype (Table 3.1).
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Figure 3.25: Karyotypes for Patient H showing examples of translocations in the NF cell line
and trisomy 7 in the CWF cell line
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Figure 3.27: Karyotypes for Patient K showing trisomy 7 and derivative chromosome 19 in
NF and trisomy 7 in CWF.
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Patient Type Karyotype
Percentage of Cell 
Population
H Normal Skin
Two Balanced Translocations:
Short arm chromosome l<-> Long arm chromosome 12 
Long arm chromosome 7 <-> Long arm chromosome 8 100
H Chronic Wound Trisomy 7 100
I Normal Skin Normal 100
I Chronic Wound Normal 80
I Chronic Wound
Trisomy 7
20
K Normal Skin Normal 80
K Normal Skin Trisomy 11 and derivative 19 20
K Chronic Wound
Trisomy 7
100
Table 3.2: Table showing Karyotype of hTERT immortalised cell lines at p83
3.3 Discussion
The aims of this chapter were to confirm that the over expression of hTERT by 
retroviral infection permitted the CWF and NF to escape replicative senescence and 
investigate whether the phenotype of the CWF and NF remained distinct after long 
term culture. These were vital questions to answer if the cells were ultimately to be 
used as experimental models for the study of chronic wound healing and as a potential 
animal replacement system.
Patient matched CWF and NF were infected using either a retrovirus encoding the 
protein subunit of human telomerase (hTERT) or an empty retroviral vector (mock). 
Previous work within the Wound Biology Group (Thesis Ivan Wall 2006) had 
demonstrated that the mock infected NF and CWF cells both entered senescence at 
close to the same PD and non-infected primary cells. The CWF underwent fewer PD 
than the patient matched NF before entering senescence. These negative controls were 
important as they demonstrated that the retroviral ‘mock’ transfection alone was not 
sufficient for the cells to escape replicative senescence. The hTERT infected NF and 
CWF cells from each of the three patients studied all exceeded the number of PD seen 
in the primary and mock infected cells. All NF and CWF hTERT infected cells carried 
out more than 100 PD and can be considered to be successfully immortalised. The 
growth curves of the NF and CWF cell lines remained distinct after immortalisation in 
all three patients with the CWF showing a reduced rate of proliferation over the entire 
time in culture. Similar observations have been made in other hTERT immortalised 
fibroblast cell lines (Gorbunova et al., 2002, Gorbunova et al., 2003) with slower 
proliferation rates maintained after immortalisation. In patient H CWF cells showed 
two dips in their proliferation rate followed by a full recovery. hTERT immortalised 
fibroblasts have been shown to enter senescence after exposure to oxidative stress and
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cultures of hTERT immortalised fibroblasts have been shown to contain 
subpopulations of senescent cells (Gorbunova et al., 2003). It is proposed that 
overexpression of hTERT can actually lead to cellular senescence in a similar manner 
to the overexpression of oncogenic Ras, Raf, and E2F1 (Swiggers et al., 2004). It is 
possible that in patient H a subset of the cells are expressing higher levels of 
telomerase and are therefore exiting the normal cell cycle and entering senescence. 
Further work on these cells would potentially confirm this hypothesis.
In order to confirm the hTERT infected cells were actually expressing telomerase and 
that the telomerase expressed was functionally active RT-PCR and TRAP 
experiments were carried out. The presence of RNA for hTERT confirmed by RT- 
PCR indicates that the retroviral transfection has been successful. The expression of 
RNA for hTR the RNA component of active telomerase in the infected cells 
demonstrates that the cells are able to generate active telomerase. However the 
presence of hTERT and hTR RNA has been shown to be insufficient evidence of 
hTERT activity and the succeaful immortalisation of the cells (Kim and Wu, 1997). 
The TRAP assay detects active telomerase in cell lysates (Hou et al., 2001), the 
presence of active telomerase is the best marker for successful transfection and 
subsequent immortalisation. All the hTERT infected cell lines were telomerase 
positive however, the technique used was not accurate enough to detect differences in 
levels of telomerase expression. A quantitative method for analysis of telomerase 
activity has been developed (Angello et al., 1989, Cristofalo and Pignolo, 1993, 
Greenberg et al., 1977) however, the presence or absence of telomerase activity was 
considered to be sufficient information for this study.
The final confirmation that the hTERT infected cells had escaped replicative 
senescence was the analysis of cell morphology and cell size. As fibroblasts age they
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get larger (Gorbunova et al., 2003, Stephens et al., 2003, Stanley and Osier, 2001b) 
their morphology also shifts from the bipolar spindle shape associated with fibroblasts 
to a more flattened multi sided morphology. A further test for senescence associated 
with the increase in cell size and changes in morphology is the presence of SA p- 
galactosidase activity in the cells. Senescence associated p-galactosidase activity has 
been a widely used tool to quantify senescence within cell populations (Yang and Hu, 
2005). However recent work has shown that it is possible to turn p-galactosidase 
activity on and off by simply controlling the environment the cells are exposed to 
(Gorbunova et al., 2003). Although under the right conditions p-galactosidase activity 
may still be used as a marker for senescence it is not definitive and for this reason was 
not used in this Thesis. Cell morphology did not appear to change over time in 
culture. At the late time point passage 80 the hTERT infected NF and CWF cells from 
all three patients were still small bipolar and spindle shaped. Cellular morphology did 
not appear to be visibly different between the NF and CWF cell lines however, the 
CWF cells did appear larger and therefore this observation lead to the analysis of cell 
size using the imageJ software package. Detailed cell size analysis demonstrated 
maintenance or in the case of patient K reduction in cell size over extended time in 
culture. However, the average cell size for Patient K NF and CWF cells over extended 
time in culture decreased bringing the average cell size closer to the average cell size 
seen in the other patients. This may indicate the presence of two populations of cells 
in cultures of in patient K NF and CWF cells one with larger and one with smaller 
cells. The histogram showing cell size for patient K (Fig 3.12) does appear to show 
multiple peaks at all time points in culture. The multiple peaks are reduced at the late 
timepoint in culture with the largest peak shifted to the left. This may be another 
effect of variable expression of hTERT leading to cells leaving the cell cycle (Wall et
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al., 2008b). Indeed none of the hTERT infected cell lines were clonally selected and 
so they are therefore the result of expansion of a mixed population. As hTERT 
insertion into the genome is random it is possible that different levels of telomerase 
expression are linked with position of the insertion site.
Fibroblasts isolated from chronic wounds display a reduced ability to repopulate 
monolayer scratch wounds compared to patient matched normal fibroblasts (Liang et 
al., 2007). The monolayer scratch wound is a well utilised method for the study of 
wound repopulation in vitro (Raffetto et al., 2001c). Fibroblasts repopulate the scratch 
wound area through both proliferation and cellular migration mimicking their in vivo 
response to wounding. At the early time point after immortalisation CWF showed a 
reduced ability to repopulate the scratch wound compared to patient matched NF. This 
phenotype was retained at the late time point in culture across all three patients. The 
apparent reduction in the ability to repopulate a monolyer scratch wound may relate to 
the failure of chronic wounds to heal. For a wound to successfully heal fibroblasts 
must move into the wound where they are able to generate and remodel ECM. 
Without the fibroblast derived ECM re-epithelisation cannot occur and the wound will 
not heal.
Studies comparing the motility of CWT compared to NF have shown reduced motility 
in CWF (Stephens et al., 2004). To analyse cell motility cell velocity was also 
analysed, no significant differences were seen between the NF and CWT' cells 
however, the CWT' were generally slower than the patient matched NF cells. The 
observed reduced motility is not sufficient to explain the differences in wound 
repopulation rates. A possible explanation for the similarity in cell motility between 
NF and CWF but the difference in wound healing ability could be cell directionality. 
If the CWF cell movement was random rather than directed towards the wound area
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they would show a reduction in the rate of wound repopulation. This effect has been 
seen in monolayer scratch wounds when extracellular matrix proteins were 
investigated (Jiang et al., 1999, Mondello et al., 2003).
The final analysis undertaken on the hTERT infected NF and CWF was an analyis of 
their karyotype. Chromosomal abnormalities are oftem seen in hTERT immortalised 
cell lines (Mondello et al., 1999). It was considered important to analyse the 
chromosomal stability of the hTERT infected cells as the intention was to continue to 
use these cells as a model for chronic wounds. Cells were karyotyped at passage 83 
with many of the cell lines showing either a sub population or the entire population 
with chromosomal abnormalities. It has not been possible at this time to analyse the 
primary cells to determine if the abnormalities are due to the hTERT immortalisation 
or are seen in the original primary cells. The mixed nature of many of the cells 
karyotypes with a small population of the cells demonstrating an altered chromosome 
number or translocations suggests that the chromosomal alterations have been picked 
up over time in culture rather than being present at the point of transfection. All the 
CWF populations analysed showed some levels of trisomy 7, previously trisomy 7 has 
been observed in cultured cells taken from aged patients (Broberg et al., 2001). A 
further link between trisomy 7 and aging was demonstrated by the increase in trisomy 
7 with age in certain tumours (Raimund W. Kinne et al., 2003). Trisomy 7 has also 
been observed in cells taken from patients with rheumatoid arthritis (Dahlen et al., 
2001, Broberg et al., 1998) and osteoarthritis (Stanley and Osier, 2001b, Raffetto et 
al., 1999a, Mendez et al., 1998c, Fivenson et al., 1997) indicating a potential link with 
inflammation. Chronic wounds are sites of chronic inflammation and cells taken from 
them have the characteristics of aged cells (Stephens et al., 2003). The trisomy 7 seen
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in the hTERT immortalised CWF could be due to the site from which the cells were 
taken rather than as a result of the hTERT transfection.
The data presented in this chapter demonstrates that the addition of hTERT to NF and 
CWF allows them to escape replicative senescence. The infected cells underwent 
more than 100PD, the cells express active telomerase and show no change in cell size 
or morphology with increased time in culture. Previous work within the Wound 
Biology Group suggested that hTERT immortalisation would not be sufficient to 
reverse the CWF phenotype (Ouellette et al., 2000) and the data from this chapter 
agrees with this suggestion. As observed in other disease states hTERT infected cells 
maintained their phenotype after transfection (Mogford et al., 2006). The CWF 
hTERT infected cells retained the reduced ability to proliferate and repopulate scratch 
wounds that was seen in the primary cell strains (Thesis Ivan Wall 2006). The 
addition of telomerase has been suggested as a potential treatment for chronic wounds 
(Brown and Botstein, 1999) based on data from animal models of ischemic wounds. 
The data presented in this chapter suggests that telomerase is not a potential treatment 
for chronic wounds however it can be used to generate cell lines to allow further study 
of the condition. Patient matched NF and CWF from three patients have been 
successfully immortalised through the addition of hTERT to the cells. The CWF have 
maintained some of their disease specific phenotypes after immortalisation, a reduced 
proliferation rate and a reduced ability to repopulate scratch wounds was observed in 
two of the three patients. These cell lines may be used to study chronic wound healing 
as an adjunct to the use of animal models. While simple wound assays cannot 
completely replace the use of animal wound models they may be useful for the high 
throughput screening of potential wound healing agents.
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Chapter 4
Identification
of
Disease Marker Genes
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4.1 Introduction
Microarray technology has lead to a paradigm shift in experimental design, allowing 
the coordinated analysis of expression levels for thousands of genes (Southern, 1975). 
Traditionally experiments focused on a single gene or protein, identifying and 
characterising it and linking it to a biological function. With the introduction of whole 
genome and proteome projects the identification of thousands of previously unknown 
genes and proteins and their functions is now possible.
Microarray technology is based on the original techniques described by Southern in 
the mid 1970s (Schena et al., 1995) where specific nucleotide fragments could be 
detected by probing with labelled nucleotide sequences. A number of microarray 
platforms are now available with the most common variants being printed cDNA 
microarrays (Lockhart et al., 1996) and photolithographically synthesised 
oligonucleotide probe microarrays (Weinstein, 1998). Printed cDNA arrays are 
generally made using an in house robotic spotter and can be tailored to meet the 
specific needs of the researcher, they are cheaper to produce but have limited quality 
control. Oligonucleotide arrays (Affymetrix™ GeneChip®) are commercially 
available, mass produced with stringent quality control at the time of production 
making them highly reproducible. GeneChip® arrays are composed of several 
hundred thousand synthesised 25mer oligos generated by photolithography. The HG- 
U133A arrays used in this investigation contains 22,283 probe sets representing 
13,387 human genes. Each probe set is made up of between 11 and 20 complementary 
oligos specific to different regions of the same gene. To control for non-specific 
hybridisation mismatch probes are also included. These probes contain a single non­
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specific base, binding to these non-specific probes give a background hybridisation 
reading for each probe set.
The use of microarray technology in academic research has been likened to a fishing 
expedition (Brown and Botstein, 1999) with no way of knowing which genes will be 
identified if any in your experiment. However a different viewpoint is that this can be 
seen as a good starting point for more in-depth analysis of identified genes of interest 
(Pusztai, 2006). Microarrays have been used to gain an understanding of complex 
diseases (Mogford et al., 2004, Charles et al., 2008, Wall et al., 2008a) including 
chronic wounds (Smith et al., 2008). In order to gain a better understanding of the 
molecular pathways involved in wound healing microarrays have been used 
extensively. Analysis of cell derived from keloid scars, identified a number of genes 
potentially linked with the disorder (Colwell et al., 2008, Hardman and Ashcroft, 
2008). Genes involved in fibrosis were identified and offer a greater understanding of 
the underlying molecular pathways involved in the disease. As well as investigating 
disease specific changes in gene expression, microarrays have been used to study the 
effect of age on wound healing (Cooper et al., 2005, Roy et al., 2008, Theilgaard- 
Monch et al., 2004), the effect of inflammation (Swamy et al., 2004, Zhu et al., 2005) 
and the effect of different wound treatments on gene expression (Iyer et al., 1999). 
Microarray analysis of gene expression is a useful tool for the study of wound healing 
giving insight into the genes involved. Genes that have previously not been linked to 
wound healing may also be identified by microarray analysis.
In this chapter the NF and CWF at 3 time points after immortalisation were analysed 
using the serum starvation/stimulation model described by Iyer (Wall et al., 2008b) 
and compared to data obtained for the primary cell strains by Dr Ivan Wall (Iyer et al.,
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1999). Originally, attempting to use microarrays to map the temporal response of 
fibroblasts to serum stimulation cells were serum starved for 48 hours. This 
synchronised the cells in GO of the cell cycle. Addition of serum containing media 
stimulated the cells re-entry into the cell cycle. RNA was then extracted from the cells 
at numerous time points and analysed on printed cDNA microarrays. Analysis of the 
temporal gene expression profiles identified numerous genes relating to wound repair 
whose expression was controlled by serum stimulation (Chang et al., 2002). Whilst 
this is an understandably simplified model of in vivo wound healing it has been used 
to study gene expression in numerous fibroblast populations taken from varied 
anatomical sites (Cooper et al., 2004). Comparisons between gene list from serum 
starvation/re-stimulation experiments and in vivo wound models show a marked 
similarity between the early wound response in vivo and the serum stimulation model 
(Wall et al., 2008b).
The overall aims of this Thesis were to characterise hTERT immortalised CWF and 
patient matched NF over an extended period in culture and to generate disease 
reporter constructs for use in these cells. In this Chapter microarray technology was 
used to compare gene expression between NF and CWF in a simplified model of 
wounding. Gene expression was analysed over extended time in culture. The gene 
expression of immortalised cells was also compared with primary cells to investigate 
the effect immortalisation had on the cells. A set of ‘Disease Genes of Interest’ were 
to be identified that were differentially regulated between NF and CWF and may be 
used for the generation of reporter constructs. Finally over-representation analysis 
was used to identify further sets of genes that may play a role in chronic wounds.
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4.2 Results
4.2.1 Microarray Data Analysis
Gene expression profiles of CWF and patient-matched NF (patients H, I and K) from 
quiescent (0 hour) and serum stimulated (6 hour) cells were characterised using
TkjfAsymetrix GeneChip® technology. Data was previously collected from primary 
CWF and NF (Wall et al., 2008b) and this was compared to data collected from the 
hTERT-infected immortalised CWF and NF. Data was collected for the immortalised 
cell lines at three time points in culture, early (passage 23), mid (passage 50) and late 
(passage 80). RNA extracted from cells was checked for degradation using an Agilent 
2100 bioanalyzer and RNA LabChip® technology The ratio and integrity of 18S and 
28S rRNA analysed to determine if the RNA has been degraded (Fig 4.1). Although 
mRNA is not present in sufficient quantity for direct analysis, the more abundant 
ribosomal RNA can be used to give a value of RNA degradation. Any degraded RNA 
was identified by a lack of clear 26s and 18s bands on the virtual gel (Fig 4.1a) and on 
the detailed fluorescence profile (Fig 4.1c). 260/280 ratios were analysed on a 
NanoDrop® ND-1000 Spectrophotometer to detect protein or aromatic contamination 
and to accurately determine concentration and quantity of RNA. A 260/280 greater 
than 1.6 is considered acceptable, below this level protein or aromatic contamination 
maybe present which could interfere with the cDNA generation process or degrade 
the RNA. Data for RNA analysis is shown (Tables 4.1-4.3) with data points for 0, 1, 
6 and 24 hours after serum stimulation.
114
( a )
[S] 
65 -
Ladder nlh L 0... nlh L 6... wlh L ... wlhL.. . nHh L . . nHhL ... wHhL ... wHhL . . wHhM... blank blank blank
[s]
-6 5
60 - -6 0
55 -  
50 -  
45 -
-5 5
-  50
-  45
40 -  
35 -
-  40 
-3 5
30 - -3 0
25 - -2 5
20 -
L 1 2 3 4 5 6 7 8 9 10 11 12
-2 0
(b) (c)
M
: x
M
pi
x  -
25-
H<
10 -
5 -
w20 25 30 35 45 50 55 60
Figure 4.1: RNA integrity analysis carried out on the Agilent 2100 bioanalyser. RNA was
analysed for both mass and size by a combination of microfluidics, capillary 
electrophoresis and fluorescence.
(a) A typical virtual gel generated by the Agilent 2100 bioanalyser labchip 
showing ribosomal RNA (rRNA) and the time at which it is detected. The larger 
the fragment the longer it will take to migrate through the chip. A DNA ladder is 
shown allowing calibration of the chip. Lanes 1-6 and 8-9 show weak ribosomal 
RNA bands at 26s 5S rRNA, 43s 18S rRNA and 50s 28S rRNA. Lane 7 shows 
degraded RNA with no detectable 18S or 28S rRNA bands.
(b) Typical bioanalyser profile for RNA showing Fluorescence plotted against 
time with clear peaks at 43s 18S rRNA and 50s 28S rRNA the ratio of the peak 
volumes (28S: 18S) should ideally be 2.7:1 though a ratio of 2:1 is considered 
acceptable
(c) Bioanalyser profile of degraded RNA no peaks are visible for 18S or 28S 
rRNA. 115
Sample Name 18S 28S rRNA Ratio [28S /18S ]:
RNA Integrity Number 
(RIN):
260:280
ratio
Concentration
ng/pl
Quantity
M9
nHh OH E RNA 21.2 44.3 2.0841 10.0 (B.02.03) 1.93 3024.43 30.2443
nHh 1H E RNA 19.2 41.3 2.1558 10.0 (B.02.03) 1.97 2297.84 22.9784
nHh 6H E RNA 18.7 45.3 2.4186 10.0 (B.02.03) 1.94 3069.49 30.6949
nHh 24H E RNA 20 40.9 2.0452 10.0 (B.02.03) 1.8 3965.38 39.6538
wHh OH E RNA 23.8 54.2 2.2716 10.0 (B.02.03) 1.9 580.72 5.8072
wHh 1H E RNA 16.7 35.4 2.1238 9.5 (B.02.03) 1.95 721.24 7.2124
wHh 6H E RNA 21.5 37.8 1.7608 9.7 (B.02.03) 1.93 904.32 9.0432
wHh 24H E RNA 22.5 41.3 1.8352 10.0 (B.02.03) 1.96 1630.36 16.3036
nHh OH M RNA 23.6 48.3 2.0474 9.8 (B.02.03) 1.97 1446.65 14.4665
nHh 1H M RNA 21.3 41.9 1.9649 9.5 (B.02.03) 1.97 1245.15 12.4515
nHh 6H M RNA 25.1 42.2 1.6855 9.9 (B.02.03) 1.98 2017.54 20.1754
nHh 24H M RNA 24.5 47.9 1.9538 10.0 (B.02.03) 1.97 1778.53 17.7853
wHh OH M RNA 17.8 30.9 1.7405 9.4 (B.02.03) 1.95 1474.77 14.7477
wHh 1H M RNA 21 37 1.7575 9.4 (B.02.03) 1.89 484.56 4.8456
wHh 6H M RNA 21 39.2 1.8672 10.0 (B.02.03) 1.85 358.59 3.5859
wHh 24H M RNA 21.7 37.7 1.7372 10.0 (B.02.03) 1.9 638.2 6.382
nHh OH L RNA 19.8 37.7 1.9072 9.4 (B.02.03) 1.88 3459.28 34.5928
nHh 1H L RNA n/a n/a n/a n/a 2.04 2551.6 25.516
nHh 6H L RNA 19.7 37.3 1.8945 9.5 (B.02.03) 1.79 3318.78 33.1878
nHh 24H L RNA n/a n/a n/a n/a 1.48* 4344.9 43.449
wHh OH L RNA 20 32.6 1.6279 9.5 (B.02.03) 1.78 3875.8 38.758
wHh 1H L RNA n/a n/a n/a n/a 2 2847.2 28.472
wHh 6H L RNA 20.3 40.5 1.9958 9.5 (B.02.03) 1.79 3112.02 31.1202
wHh 24H L RNA n/a n/a n/a n/a 2 3178 31.78
rable 4.1: RNA analysis Patient H. RNA integrity determined by analysis on the Agilent 2100
bioanalyser is displayed as rRNA Ratio 28S/18S. RNA purity is displayed as a ratio 
of absorbance determined by NanoDrop analysis. A 260:280 ratio of greater than 1.6 
is considered acceptable. (* indicates an RNA sample with particularly high 
concentration which has masked the true 260:280 ratio).
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Sample Name 18S 28S rRNA Ratio 
[28S /18S ]:
RNA Integrity Number 
(RIN):
260:280
ratio
Concentration
ng/pl
Quantity
M9
nlh OH E RNA 20.2 37.6 1.8625 9.4 (B.02.03) 1.93 1140.83 11.4083
nlh 1H E RNA 19.3 33.2 1.7155 9.1 (B.02.03) 1.96 1083.72 10.8372
nlh 6H E RNA 21.4 37.3 1.7439 9.6 (B.02.03) 1.94 1420.37 14.2037
nlh 24H E RNA 20.9 38.7 1.8482 9.8 (B.02.03) 1.95 1826.8 18.268
wlh OH E RNA 20.4 35.2 1.7238 9.3 (B.02.03) 1.99 1578.16 15.7816
wlh 1H E RNA 20.2 32.3 1.5999 9.2 (B.02.03) 1.94 1018.13 10.1813
wlh 6H E RNA 19.5 34.1 1.7428 9.4 (B.02.03) 1.96 1613.14 16.1314
wlh 24H E RNA 26 30.9 1.19 9.6 (B.02.03) 1.96 2909.64 29.0964
nlh OH M RNA 24.8 47.8 1.9311 10.0 (B.02.03) 1.98 2782.42 27.8242
nlh 1H M RNA 24.7 43.6 1.7651 9.8 (B.02.03) 1.98 1688.86 16.8886
nlh 6H M RNA 22.6 43.4 1.9197 10.0 (B.02.03) 1.99 1651.33 16.5133
nlh 24H M RNA 27.4 48.8 1.7812 10.0 (B.02.03) 1.99 2231.45 22.3145
wlh OH M RNA 22.7 49.2 2.1659 10.0 (B.02.03) 1.98 2042.68 20.4268
wlh 1H M RNA 23.2 51.7 2.2342 10.0 (B.02.03) 1.99 2097.13 20.9713
wlh 6H M RNA 21.8 45.2 2.0777 10.0 (B.02.03) 1.97 2419.8 24.198
wlh 24H M RNA 23.1 44.3 1.9205 10.0 (B.02.03) 1.93 3314.78 33.1478
nlh OH L RNA 18.9 32.9 1.7425 9.3 (B.02.03) 1.94 2234.37 22.3437
nlh 1H L RNA n/a n/a n/a n/a 2.05 935.82 9.3582
nlh 6H L RNA 20.3 39.4 1.9393 9.3 (B.02.03) 2.02 2321.04 23.2104
nlh 24H L RNA n/a n/a n/a n/a 2.04 2068.5 20.685
wlh OH L RNA 21.1 33.4 1.5843 9.5 (B.02.03) 1.6 865.17 8.6517
wlh 1H L RNA n/a n/a n/a n/a 2.01 1390.1 13.901
wlh 6H L RNA 20.8 39.4 1.8912 9.5 (B.02.03) 1.97 1137.33 11.3733
wlh 24H L RNA n/a n/a n/a n/a 2.03 2194 21.94
Table 4.2: RNA analysis Patient I. RNA integrity determined by analysis on the Agilent 2100
bioanalyser is displayed as rRNA Ratio 28S/18S. RNA purity is displayed as a ratio 
of absorbance determined by NanoDrop analysis. A 260:280 ratio of greater than 1.6 
is considered acceptable.
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Sample Name 18S 28S rRNA Ratio [28S / 18S]:
RNA Integrity Number 
(RIN):
260.280
ratio
Concentration
ng/pl
Quantity
M9
nKh OH E RNA 22.9 46.5 2.0288 10.0 (B.02.03) 1.91 959.23 9.5923
nKh 1 HE RNA 22.5 49.9 2.2179 10.0 (B.02.03) 1.94 711.24 7.1124
nKh 6H E RNA 26.9 44.5 1.6522 10.0 (B.02.03) 1.94 934.87 9.3487
nKh 2 4 HE RNA 23.4 45 1.9248 10.0 (B.02.03) 1.92 3121.48 31.2148
wKh OH E RNA 22.2 46.9 2.1152 10.0 (B.02.03) 1.96 2405.91 24.0591
wKh 1H E RNA 21.9 45.6 2.0845 10.0 (B.02.03) 1.96 2082.93 20.8293
wKh 6H E RNA 21.2 45.3 2.1333 10.0 (B.02.03) 1.91 3186.27 31.8627
wKh 24H E RNA 21.1 43.5 2.0602 9.9 (B.02.03) 1.95 2759.5 27.595
nKh OH M RNA 20 34.1 1.7039 9.4 (B.02.03) 1.96 2679.96 26.7996
nKh 1H M RNA 19.1 34.2 1.7935 9.3 (B.02.03) 1.96 2643.06 26.4306
nKh 6H M RNA 20 37.3 1.8655 9.6 (B.02.03) 1.89 3485.43 34.8543
nKh 24H M RNA 23.6 46.6 1.9739 10.0 (B.02.03) 1.46* 4399.45 43.9945
wKh OH M RNA 23.3 41.5 1.7841 9.7 (B.02.03) 1.99 2058.51 20.5851
wKh 1H M RNA 22.7 43.2 1.9001 9.7 (B.02.03) 1.98 2099.95 20.9995
wKh 6H M RNA 23.1 45.5 1.973 9.7 (B.02.03) 1.98 2388.49 23.8849
wKh 24H M RNA 28.8 28.6 0.9933 9.2 (B.02.03) 1.98 2455.07 24.5507
nKh OH L RNA 19.5 42.3 2.16923077 9.8 (B.02.03) 1.75 4173.65 41.7365
nKh 1H L RNA 17.5 47.1 2.69142857 9.9 (B.02.03) 2.13 2034.04 20.3404
nKh 6H L RNA 19.9 40 2.01005025 10.0 (B.02.03) 1.47* 4345.91 43.4591
nKh 24H L RNA 19.2 45.4 2.36458333 10.0 (B.02.03) 1.61* 4304.51 43.0451
wKh OH L RNA 18.6 47.1 2.53225806 9.9 (B.02.03) 2.02 3314.79 33.1479
wKh 1HLRNA 19.4 40.8 2.10309278 10.0 (B.02.03) 2.09 2616.63 26.1663
wKh 6H L RNA 15.8 37.4 2.36708861 9.8 (B.02.03) 2.07 2948.2 29.482
wKh 24H L RNA 19.1 41.6 2.17801047 10.0 (B.02.03) 1.97 3604.87 36.0487
Table 4.3: RNA analysis Patient K. RNA integrity determined by analysis on the Agilent 2100
bioanalyser is displayed as rRNA Ratio 28S/18S. RNA purity is displayed as a ratio 
of absorbance determined by NanoDrop analysis. A 260:280 ratio of greater than 1.6 
is considered acceptable. (* indicates an RNA sample with particularly high 
concentration which has masked the true 260:280 ratio).
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Raw microarray expression data was initially processed using the microarray Analysis
TAASuite 5.0 (MAS5) provided by Asymetrix . MAS 5 normalises probe intensities, 
combines the different probes for each gene to give a gene expression value and 
calculates the presence/absence call and the p-values of calls. This processing allows 
different chips to be compared as the signal intensities on each chip will vary 
dramatically depending on the amount of labelled cDNA hybridised to the chip. The 
normalisation process scales the average expression intensity for each chip to a single 
constant value. However, if the scaling factor is too great the data will be rejected; 
anything greater than a 3 fold range will be rejected. The resulting data was stored in 
cell intensity (.CEL) files. Data analysis was carried out using Bioconductor 
(http://www.bioconductor.org) an open source software project for the analysis of 
genomic data by Dr Peter Giles in the Department of Pathology, Cardiff University. 
Before analysis, quality control was carried out on each of the chips, identifying not 
only aberrations in the normalisation but also identifying variation between chips 
caused by faults in the fluidics system. Quality control looks at sets of housekeeping 
genes on each chip comparing their expression levels. If theses levels and the scaling 
factor are found to be within acceptable limits the data can be used (Fig 4.2). 2 of the 
48 chips run were found to have abnormalities in the signal intensity though they did 
not fail MAS5 processing. These abnormalities are seen as areas of high signal 
intensity on the scanned chip images (Fig 4.3a) particularly obvious when compared 
to a normal chip image (Fig 4.3b) and are thought to be due to a non-critical fault in 
the scanner. The data obtained was within the limits set by Affymetrix™ however, it 
was decided that a further normalisation step would be used to reduce the effect of 
any background noise caused by these chips. All chips were therefore further
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Figure 4.2: Quality control of MAS 5.0 data generated from Affymetrix™ GeneChip®
experiments. Scaling factors should fall within a 3-fold range of each other as 
indicated in (a) for NF samples and (b) for CWF samples. The 3’:5’ ratios shown as 
blue lines all fall within the blue shaded region. Two built-in controls house keeping 
gene controls: fi-actin (A) and GAPDH (O) are also used and must fall within ± 3 for 
the data to be acceptable.
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Figure 4.3: Scanned chip images of Affymetrix™ U133A microarrays. Analysis of scanned
images identified high intensity expression in 2/48 chips used in this experiment (a) 
when compared to normal chip images (b) the high intensity of signal seen in these 
chips is easily identifiable.
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processed using rma (robust multi-array average) which generated expression values 
relative to the mean expression of all probes across the 48 chips.
4.2.2 ANOVA Analysis
ANOVA analysis was used to determine if there were any global differences between:
• CWF and NF
• Patients
• Immortalised and Primary cells
• Time points in culture
• Serum starved and serum stimulated cells
CEL file data was analysed using MAS 5.0 and left untransformed. A design matrix 
containing the 5 experimental factors chosen for analysis (patient / NF v CWF / 
immortalisation status / time point / response to serum stimulation) was generated and 
ANOVA analysis carried out using this matrix. For each factor p-values were returned 
and false discovery rate (FDR) corrected to account for the effects of multiple testing.
In order to create gene lists of a manageable size different FDR levels were chosen for
each analysis
• Patient -  0.01 (1 %)
• N/CW -  0.05 (5%)
• Immortal -  0.0001 (0.01%)
• Time Point -  0.01 (1%)
• Serum -  0.0001 (0.01%)
Heatmaps for the genes extracted for each factor were then produced, plotting both 
the whole dataset, and split to show genes moving in different directions (e.g. up in 
one plot, down in another plot). Changes in gene expression were determined in
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comparison to the average expression level of the selected dataset. Changes in gene 
expression compared to this average were indicated by intensity of colour with red 
indicating up regulation and green indicating down regulation (Fig 4.4-4.7). For easy 
access to the data all gene lists were uploaded onto the microarray data review and 
annotation system (MADRAS; www.madras.uwcm.ac.uk). On Affymetrix™ 
microarrays multiple probe sets may represent a single gene. 110 probe sets 
representing 95 were identified as being up-regulated by hTERT immortalisation (Fig 
4.4), while 206 probe sets representing 168 genes were identified as being down- 
regulated by hTERT immortalisation (Fig 4.5). A total of 263 genes were identified as 
altered by hTERT immortalisation representing 1.96% of the 13,387 genes 
represented on the microarray. When CWF and NF gene expression was compared 
144 probe sets representing 123 genes were identified as being down-regulated in 
CWF compared to NF (Fig 4.6) and 102 probe sets representing 88 genes identified as 
being up-regulated in CWF compared to NF (Fig 4.7). 211 genes were therefore 
identified as being differentially regulated between NF and CWF.
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Figure 4.4a: Genes up-regulated by hTERT immortalisation. An increase in gene expression 
compared to the average expression of all genes present is represented in red, a 
decrease in expression is represented in green with the intensity of colour indlitehting 
the level of change
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Figure 4.5c: Genes down-regulated by hTERT immortalisation. An increase in gene expression 
compared to the average expression of all genes present is represented in red, a 
decrease in expression is represented in green with the intensity of colour iqigjpating 
the level of change
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Figure 4.6a: Genes down-regulated in Chronic wounds. An increase in gene expression compared 
to the average expression of all genes present is represented in red, a decrease in 
expression is represented in green with the intensity of colour indicating the level of 
change
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Figure 4.6b: Genes down-regulated in Chronic wounds. An increase in gene expression compared 
to the average expression of all genes present is represented in red, a decrease in 
expression is represented in green with the intensity of colour indicating the level of 
change
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Figure 4.6c: Genes down-regulated in Chronic wounds. An increase in gene expression compared 
to the average expression of all genes present is represented in red, a decrease in 
expression is represented in green with the intensity of colour indicating the level of 
change
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Figure 4.7a: Genes up-regulated in Chronic wounds. An increase in gene expression compared to 
the average expression of all genes present is represented in red, a decrease in 
expression is represented in green with the intensity of colour indicating th$ jevel of 
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Figure 4.7b: Genes up-regulated in Chronic wounds. An increase in gene expression compared to 
the average expression of all genes present is represented in red, a decrease in 
expression is represented in green with the intensity of colour indicating the level of 
change 133
4.2.3 Difference of Differences Analysis
To identify genes that were differentially effected by stimulation by serum a 
‘difference of differences’ analysis was carried out. This analysis idenitified genes 
which were differentially regulated between 0 and 6 hours and differentially regulated 
between NF and CWF. This analysis was carried out independently for each patient 
and for each timepoint in culture (early, mid and late). The data was transformed 
using RMA analysis converting the data to log space. This conversion means that 
subtraction of expression levels at 0 hours from the level at 6 hours gives a figure 
equivalent to fold change.
For each probe set:
NF Patient H (nHh 6H E - nHh OH E)+(nHh 6H M - nHhOH M)+(nHh 6H L - nHh OH L)
CWF Patient H (wHh 6H E - wHh OH E)+(wHh 6H M - wHhOH M)+(wHh 6H L - wHh OH L)
This gave two new sets with the differences between 0 and 6 hours for each Patient.
Difference of differences Patient H (NF patient H -  CWF patient H)
The resultant data is then equivalent to a list of fold change values for the second set 
of differences. This process was carried out for each of the patient matched samples. 
The data was then filtered with a 2 fold change cut off (1 in log2 space) in both 
directions (2< and >2). Heat maps were generated for each of the conditions analysed 
using the untransformed data (Figs 4.8-4.19). The array data was initially analysed 
with respect to each time point in culture with all the patients pooled together. At the 
early time point in culture 17 genes were identified as being down regulate by the 
addition of serum in CWF compared to NF (Fig 4.8) and 60 genes as being up
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Figure 4.8: Difference of Differences analysis Early Time Point, genes down-regulated by
addition of serum. An increase in gene expression compared to the average 
expression of all genes present is represented in red, a decrease in expression is 
represented in green with the intensity of colour indicating the level of change
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Figure 4.9a: Difference of Differences analysis Early Time Point, genes up-regulated by 
addition of serum. An increase in gene expression compared to the average 
expression of all genes present is represented in red, a decrease in 
expression is represented in green with the intensity of colour indicating the 
level of change
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Figure 4.9b: Difference of Differences analysis Early Time Point, genes up-regulated by 
addition of serum. An increase in gene expression compared to the average 
expression of all genes present is represented in red, a decrease in 
expression is represented in green with the intensity of colour indicating the 
level of change
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Figure 4.10: Difference of Differences analysis Mid Time Point, genes down-regulated 
by addition of serum. An increase in gene expression compared to the 
average expression of all genes present is represented in red, a decrease in 
expression is represented in green with the intensity of colour indicating the 
level of change
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Figure 4.11: Difference of Differences analysis Mid Time Point, genes up-regulated by 
addition of serum. An increase in gene expression compared to the average 
expression of all genes present is represented in red, a decrease in expression 
is represented in green with the intensity of colour indicating the level of 
change 1 3 9
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Figure 4.12 Difference of Differences analysis Late Time Point, genes down-regulated 
by addition of serum. An increase in gene expression compared to the 
average expression of all genes present is represented in red, a decrease in 
expression is represented in green with the intensity of colour indicating 
the level of change
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Figure 4.13 Difference of Differences analysis Late Time Point, genes Up-regulated by 
addition of serum. An increase in gene expression compared to the average 
expression of all genes present is represented in red, a decrease in expression is 
represented in green with the intensity of colour indicating the level of change
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Figure 4.14 Difference of Differences analysis Patient H, genes Down-regulated by 
addition of serum. An increase in gene expression compared to the average 
expression of all genes present is represented in red, a decrease in expression 
is represented in green with the intensity of colour indicating the level of 
change
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Figure 4.15 Difference of Differences analysis Patient H, genes up-regulated by addition of 
serum. An increase in gene expression compared to the average expression of 
all genes present is represented in red, a decrease in expression is represented in 
green with the intensity of colour indicating the level of change
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Figure 4.16 Difference of Differences analysis Patient I, genes down-regulated by addition 
of serum. An increase in gene expression compared to the average expression of 
all genes present is represented in red, a decrease in expression is represented in 
green with the intensity of colour indicating the level of change
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Figure 4.17 Difference of Differences analysis Patient I, genes up-regulated by addition of 
serum. An increase in gene expression compared to the average expression of 
all genes present is represented in red, a decrease in expression is represented 
in green with the intensity of colour indicating the level of change
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re 4.18 Difference of Differences analysis Patient K, genes down-regulated by 
addition of serum. An increase in gene expression compared to the 
average expression of all genes present is represented in red, a decrease in 
expression is represented in green with the intensity of colour indicating 
the level of change
146
S r o f l  N 6H WOH V\r6H
FOS v fos FBJ mum* osteosarcoma viral onoogene homotog 
ZFP36 7 tnc linger protest 36. C3H type homotog (mouse)
EGftl earty growth response I
DCKT4 DNA-damage-mducOe transcript 4
JAG1 jagged 1 (Aiagille syndrome)
JUN v-jun sarooma virus 17 oncogene homotog (avian)
PIK2 poto-tike koase 2 (Drosophila)
OSR2 odd-stopped related 2 : Drosophila;
EGR2 earty growth response 2 (Kron-20 homoiog Oiosoptiilai 
BHLHB2 base hekx loop hetix domam containing class B 2 
BHLHB2 base helix loop-netix domam containing class B, 2 
EGR3 early growth response 3 
TRlBl nibbles homolog t ; Drosophila i 
DUSP1 dual specificity phosphatase '■
DUSP1 dual specificity phosphatase 1
JUN8 )un B proto oncogene
IER3 immediate earty response 3
NR4A1 nuctear receptor subfamily 4 group A member 1
DUSP2 dual specificity phosphatase 2
FOS8 FBJ muine osteosarcoma viral oncogene homolog B
NFKBIA nuclear factor of Kappa light polypeptide gene enhancer
PMLDA1 ptockstrin horrotogy- »Kc domam. family A. member 1
SIC19A2 solute earner family 19 (tfcwmne transporter) member 2
VEGF vascular endothelial growth factor
L8 ntertautan a
IL8 :nter1eukr 8
CCl ? chemokne iC-C motif) tgand 2 
IL6 mtedeulon 6 (interferon beta 2)
DUSP5 dual specificity phosphatase 5
5ERP1N82 serine (or cysteine) proteinase mhbrtor
SMAD7 SMAD. mothers against DPP homotog 7 (Drosophila)
DLX2 distal-less homeo boa 2
ID1 nhibitor of DMA bmdng 1
DKK2 dcknopf homolog 2 (Xenopus laevisi
ATP1B1 ATPase Ma*>X* transporting bets 1 polypeptide
EFN82 ephnn B2
Figure 4.19 Difference of Differences analysis Patient K, genes up-regulated by addition of serum.
An increase in gene expression compared to the average expression of all genes 
present is represented in red, a decrease in expression is represented in green with the 
intensity of colour indicating the level of change
regulated by the addition of serum in CWF compared to NF (Fig 4.9). At the mid time 
point in culture 14 genes were identified as being down regulate by the addition of 
serum in CWF compared to NF (Fig 4.10) and 28 genes as being up regulated by the 
addition of serum in CWF compared to NF (Fig 4.11). At the late time point in culture 
19 genes were identified as being down regulate by the addition of serum in CWF 
compared to NF (Fig 4.12) and 14 genes as being up regulated by the addition of 
serum in CWF compared to NF (Fig 4.13). Finally the data was analysed with respect 
to the individual patients with the different time points in culture pooled together. For 
patient H 23 genes were identified as being down regulated in CWF compared to 
patient matched NF by the addition of serum (Fig 4.14) and 39 genes were identified 
as being up regulated in CWF compared to patient matched NF (Fig 4.15). In patient I 
51 genes were identified as being down regulated in CWF compared to patient 
matched NF by the addition of serum (Fig 4.16) and 24 genes were identified as being 
up regulated in CWF compared to patient matched NF (Fig 4.17). Finally in patient K 
6 genes were identified as being down regulated in CWF compared to patient matched 
NF by the addition of serum (Fig 4.18) and 33 genes were identified as being up- 
regulated in CWF compared to patient matched NF (Fig 4.19). The difference of the 
differences analysis identified genes which were not seen in the ANOVA analysis. 
Difference of differences analysis focussed on changes in the response to serum 
between NF and CWF. Differences in the response to serum by CWF identified using 
this technique may relate to differences in wound healing potential.
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4.2.4 Over representation analysis
Gene lists generated by ANOVA analysis and from pooled Difference of Differences 
analysis were first uploaded onto MADRAS. This system allows for the graphical 
representation of gene expression levels for all experiments as well as containing 
information about genes represented on Affymetrix™ GeneChip®. Importantly 
MADRAS allows for comparisons between gene lists. This function was used to 
remove genes altered by immortalisation and genes altered between patients from 
both the ANOVA and Difference of Differences generated gene lists (Fig 4.20). 
Genes altered by the addition of hTERT to the CWF and NF cells were identified by 
ANOVA analysis (Figs 4.4 & 4.5). They represent differences between the primary 
and immortalised cells; one of the aims of this thesis was to use immortalised cells as 
a model of chronic wounds. Genes altered by immortalisation were therefore excluded 
from further analysis as they do not reflect gene expression levels in the primary cells. 
Inter-patient variability also represented a problem, genes identified as variable 
between the three patients were also excluded from further analysis. Genes identified 
as being differentially regulated between CWF and NF were initially screened for 
changes due to immortalisation and over time in culture (Fig 4.20a). Genes unchanged 
by immortalisation of time in culture were then screened against genes known to 
show inter-patient variability (Fig 4.20b). Corrected gene lists were analysed by the 
Functional Annotation Tool from the DAVID Bioinformatics Resources web site 
(http://david.abcc.ncifcrf.gov/). Briefly this tool suite provides annotation and Gene 
Ontology (GO) term enrichment analysis to highlight the most relevant GO terms 
associated with the inputted gene list. Gene Ontology (www.geneontology.org) is a 
defined method for describing a gene by molecular function, biological processes and 
the cellular location of the gene product. The DAVID software covers over 40
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Term Count % or cenes in List P value Genes
protein binding 37 37.00% 0.028766425
NUP205, MFGE8, RAC1, ACTR3B, PIK3R1, CNOT4, PTPRD, DKK1, 
IL11, HMG20A, DKK13, SNX13, FGF1, CD9, ORC5L, RABGEF1, HGF, 
EIF2AK1, DZIP3, GNAI1, MDK, ZFP161, NFIL3, TIAM1, CD58, MKRN1, 
MAGI2, PTN, ARPC1A, PDLIM5, PRRX1, DNMBP, SPON2, TSPYL2, 
DMD, SIX1, LDB2,
development 23 23.00% 0.004389058
MDK, SEMA5a, FBN2, RAC1, SPOCK, THUMPD2, IL11, SRPK2, 
DKK1, GPR65, PTN, FGF1, DPYSL3, CUTL1, PDLIM5, PRRX1, CD9, 
SPON2, TSPYL2, DMD, SIX1, IFRD1, LDB2,
extracellular space 9 9.00% 0.010360235 MDK, MFAP5, PTN, FGF1, SPOCK, SPON2, ECM1, IL11, F8,
developmental protein 8 8.00% 0.029130787 DKK13, MDK, SEMA5A, FGF1, CUTL1, PRRX1, SIX1, IFRD1,
sequence-specific DNA binding 7 7.00% 0.044487279 NFIL3, CUTL1, PRRX1, ORC5L, TSPYL2, SIX1, DKK1,
growth factor activity 6 6.00% 0.004908495 HGF, DKK1, MDK, PTN, FGF1, IL11,
extracellular matrix (sensu Metazoa) 6 6.00% 0.025645193 MFAP5, FBN2, SPOCK, SPON2, ECM1, DMD,
extracellular matrix 6 6.00% 0.026934459 MFAP5, FBN2, SPOCK, SPON2, ECM1, DMD,
protein complex assembly 6 6.00% 0.034382133 SRPK2, NAP1L3, H2AFV, CD9, LPXN, TSPYL2,
growth factor 5 5.00% 0.009505331 HGF, MDK, PTN, FGF1, IL11,
extracellular matrix 5 5.00% 0.021750277 MFAP5, FBN2, SPOCK, SPON2, ECM1,
REGULATION OF ACTIN CYTOSKELETON 5 5.00% 0.023041083 TIAM1, RAC1, FGF1, PIK3R1, ARPC1A,
blood coagulation 4 4.00% 0.026681393 HGF, CD9, IL11, F8,
coagulation 4 4.00% 0.02750818 HGF, CD9, IL11, F8,
hemostasis 4 4.00% 0.030951296 HGF, CD9, IL11, F8,
wound healing 4 4.00% 0.031845972 HGF, CD9, IL11, F8,
Cell division and chromosome partitioning 4 4.00% 0.039843129 DZIP3, 55841, CUTL1, PIK3R1,
regulation of body fluids 4 4.00% 0.041530846 HGF, CD9, IL11, F8,
heparin binding 3 3.00% 0.012005315 MDK, PTN, FGF1,
mitogen 3 3.00% 0.028131291 MDK, PTN, FGF1,
SF001949:pleiotrophin 2 2.00% 0.012269823 MDK, PTN,
L-carnitine dehydratase/bile acid-inducible protein F 2 2.00% 0.015381727 AMACR, C7orf10,
PTN/MK heparin-binding protein 2 2.00% 0.015381727 MDK, PTN,
PTN 2 2.00% 0.015599888 MDK, PTN,
domain:F5/8 type C 2 2 2.00% 0.035344181 MFGE8, F8,
domain:F5/8 type C 1 2 2.00% 0.035344181 MFGE8, F8,
transmembrane receptor protein tyrosine phosphatase 
signaling pathway
2 2.00% 0.045255371 PTN, PTPRD,
Table 4.4: Over-representation analysis of genes up-regulated in CWF compared to NF, genes altered by immortalisation and patient
differences were removed. Genes were grouped according to over-represented term and listed according to P value with a cut off
of 0.05.
ro ur vjciico
in List
P value G enes
glycoprotein 22 30.99% 0.019850983
GYPE, F10, CD83, MMP3, PLOD1, CD40, ADRA2A, SLIT3, AM BP, C3, NGFB, CYBB, CLEC3B, BAMBI, 
THBS4, MASP1, NCAM1, CSPG 4, TRPC6, MCAM, TRPV2, ST3GAL1,
glycosylation site:N-linked (GlcNAc...) 21 29.58% 0.035566759
GYPE, F10, CD83, MMP3, PLOD1, CD40, ADRA2A, SLIT3, AMBP, C3, NGFB, CYBB, BAMBI, THBS4, 
MASP1, NCAM1, C SPG 4, TRPC6, MCAM, TRPV2, ST3GAL1,
development 19 26.76% 0.002967538
R PS19, RAPGEFL1, HOXB7, FGF13, HOXB6, PLOD1, CD40, DU SP22, S100A 5, CECR1, SLIT3, NGFB, 
CLEC3B, TBX1, NCAM1, CSPG 4, NEUROD2, MCAM, PPARD,
signal 18 25.35% 0.044
GYPE, F10, CD83, MMP3, PLOD1, CD40, CECR1, SLIT3, AMBP, C3, NGFB, CLEC3B, BAMBI, THBS4, 
M ASP1, NCAM1, C SPG 4, MCAM,
disulfide bond 17 23.94% 0.023534038
F10, CD83, MMP3, CD40, CD81, ADRA2A, SLIT3, AMBP, C3, NGFB, CLEC3B, THBS4, MASP1, NCAM1, 
C SPG 4, MCAM, ST3GAL1,
direct protein sequencing 17 23.94% 0.043527695
GYPE, R PS19, F10, CD83, R PS2, MMP3, PLOD1, CD40, Sep-06, ADRA2A, C3, AMBP, CYBB, CLEC3B, 
BAMBI, CA2, MCAM,
structural m olecule activity 12 16.90% 7.62E-04 SLIT3, LOC148430, R PS19, ACTC, RPL31, EPB41L3, THBS4, CLDN11, RPS2, RPL39L, KRT7, S100A5,
extracellular region 11 15.49% 0.04030241 MAP2K2, SLIT3, AMBP, C3, CLEC3B, F10, FGF13, THBS4, MASP1, MMP3, C SPG 4,
EGF-like 6 8.45% 0.013497331 SLIT3, DKFZP586H2123, F10, THBS4, M ASP1, CD40,
EGF-like region 6 8.45% 0.014409642 SLIT3, DKFZP586H2123, F10, THBS4, MASP1, CD40,
EGF-like calcium-binding 5 7.04% 0.003270514 SLIT3, DKFZP586H2123, F10, THBS4, MASP1,
humoral immune response 5 7.04% 0.012314652 C3, CYBB, MASP1, CD83, CD40,
EGF-like, type 3 5 7.04% 0.021191091 SLIT3, DKFZP586H2123, F10, THBS4, MASP1,
structural constituent of ribosom e 5 7.04% 0.025082134 LOC 148430, R PS19, RPL31, RPS2, RPL39L,
ribosome 5 7.04% 0.026042652 LOC 148430, R PS19, RPL31, RPS2, RPL39L,
ribonucleoprotein 5 7.04% 0.027818444 R PS19, 54039, RPL31, R PS2, RPL39L,
glycosylation site:0-linked (GalNAc...) 5.63% 0.004519097 AMBP, CLEC3B, GYPE, F10,
MAPKKK ca sc a d e 5.63% 0.013625548 ADRA2A, AMBP, D U SP22, CD81,
SM 00179:EGF CA 5.63% 0.017201109 SLIT3, F10, THBS4, MASP1,
plasm a 5.63% 0.023969735 AMBP, C3, CLEC3B, F10,
humoral d efen se  m echanism  (sensu  Vertebrata) 5.63% 0.027541298 C3, CYBB, M ASP1, CD40,
serine-type endopeptidase activity 5.63% 0.029904848 C3, DKFZP586H2123, F10, MASP1,
serine-type peptidase activity 5.63% 0.038791578 C3, DKFZP586H2123, F10, MASP1,
SM 00042:CUB 3 4.23% 0.0189042 DKFZP586H2123, MASP1, PDGFD,
small ribosomal subunit 3 4.23% 0.019450491 LOC 148430, R PS19, RPS2,
cytosolic ribosom e (sen su  Eukaryota) 3 4.23% 0.024685562 R PS19, R PS2, RPL39L,
IPR000859:CUB 3 4.23% 0.0253641 DKFZP586H2123, MASP1, PDGFD,
regulation of MAPK activity 3 4.23% 0.035179861 ADRA2A, D USP22, CD81,
serine proteinase 3 4.23% 0.042107423 C3, F10, M ASP1,
glycosylation site:0-linked (XyL.) (chondroitin sulfate) 2 2.82% 0.023385439 AMBP, C SPG 4,
B asic m echanism  of action of PPARa 2 2.82% 0.032184646 RXRA, PPARD,
sialoglycoprotein 2 2.82% 0.03274671 GYPE, NCAM1,
alpha-crystallin-related small heat shock protein 2 2.82% 0.034537155 H SPB3, H SPB7,
Alpha crystallin 2 2.82% 0.046240368 H SPB3, HSPB7,
beta-hydroxyaspartic acid 2 2.82% 0.048722306 F10, THBS4,
Table 4.5: Over-representation analysis of genes down-regulated in CWF compared to NF, genes altered by immortalisation and patient
differences were removed. Genes are grouped according to overrepresented term and listed according to P value with a cut off of
0.05.
Term Count
% of Genes 
In List
P value Genes
nuclear protein 31 36.05% 4.83E-04 JUNB, TFAP2C, MEOX2, FOS, SMAD7, JUN, VDR, FOSB, EGR1, SOX18, PHLDA1, PLAGL1, PLAGL1, TGIF, ATF4, DUSP5, EGR3, DGKI, 
BHLHB2, BHLHB2, ID1, FOXD1, OSR2, DUSP2, EGR2, TBX3, ZFP36, NR4A1, LOC389168, ZBTB38, TRIB3, DLX2, ZNF281,
dna-binding 22 25.58% 2.05E-05
ATF4, JUNB, TFAP2C, MEOX2, EGR3, BHLHB2, BHLHB2, FOXD1, FOS, EGR2, TBX3, ZFP36, JUN, NR4A1, VDR, FOSB, EGR1, SOX18, 
ZBTB38, DLX2, PLAGL1, PLAGL1, ZNF281, TGIF,
transcription regulation 21 24.42% 6.09E-05
ATF4, JUNB, TFAP2C, MEOX2, EGR3, BHLHB2, BHLHB2, FOXD1, SMAD7, EGR2, TBX3, JUN, NR4A1, VDR, EGR1, SOX18, ZBTB38, 
TRIB3, DLX2, PLAGL1, PLAGL1, ZNF281, TGIF,
transcription 19 22.09% 6.95E-04
ATF4, JUNB, TFAP2C, EGR3, BHLHB2, BHLHB2, FOXD1, SMAD7, EGR2, TBX3, JUN, NR4A1, VDR, EGR1, SOX18, ZBTB38, TRIB3, 
PLAGL1, PLAGL1, ZNF281, TGIF,
MAPK SIGNALING PATHWAY 11 12.79% 6.71 E-05 ATF4, DUSP5, IL1B, IL1B, JUN, NR4A1, KRAS, DUSP1, DUSP1, DUSP6, DUSP6, DUSP6, MKNK2, FOS, DUSP2,
DNA binding 11 12.79% 7.56E-05 ATF4, JUNB, MEOX2, ZFP36, NR4A1, VDR, EGR3, EGR1, SOX18, DLX2, FOS,
developmental protein 9 10.47% 0.00653687 TBX3, MEOX2, EREG, EFNB2, EFNB2, ID1, VEGF, VEGF, DKK2, DLX2, JAG1,
phosphoprotein 9 10.47% 0.01062178 IGF1R, IL6, NFKBIA, ENPP1, DUSP5, DUSP1, DUSP1, LOC389168, NEF3, DUSP2,
CANCER 9 10.47% 0.02209049 IL6, IL1B, IL1B, GAS1, VDR, KRAS, IL8, IL8, IL24, VEGF, VEGF, IL8, IL8,
CYTOKINE-CYTOKINE RECEPTOR INTERACTION 8 9.30% 0.00564969 IL6, CCL2, IL1B, IL1B, IL8, IL8, IL24, VEGF, VEGF, IL8, IL8, IL11,
:TOLL-LIKE RECEPTOR SIGNALING PATHWAY 7 8.14% 1.69E-04 IL6, NFKBIA, IL1B, IL1B, JUN, IL8, IL8, IL8, IL8, FOS,
cytokine 7 8.14% 5.41 E-04 IL6, CCL2, IL1B, IL1B, GDF15, IL8, IL8, IL24, IL11,
activator 7 8.14% 0.02176692 EGR2, ATF4, TFAP2C, EGR1, ZBTB38, SOX18, PLAGL1, PLAGL1,
growth factor 6 6.98% 0.00106309 IL6, GDF15, EREG, HBEGF, VEGF, VEGF, IL11,
Basic-leucine zipper (bZIP) transcription factor 5 5.81% 2.64E-04 ATF4, JUNB, JUN, FOSB, FOS,
LUPUS 5 5.81% 2.65E-04 IL6, IL1B, IL1B, VDR, IL8, IL8, IL8, IL8,
BRLZ 5 5.81% 6.18E-04 ATF4, JUNB, JUN, FOSB, FOS,
EPITHELIAL CELL SIGNALING IN HELICOBACTER 
PYLORI INFECTION
5 5.81% 7.91 E-04 NFKBIA, JUN, IL8, IL8, HBEGF, IL8, IL8,
NFkB activation by Nontypeable Hemophilus influenzae 5 5.81% 0.0016108 NFKBIA, IL1B, IL1B, DUSP1, DUSP1, IL8, IL8, IL8, IL8,
INFECTION 5 5.81% 0.01328811 IL6, IL1B, IL1B, VDR, IL8, IL8, IL8, IL8,
zinc finger 5 5.81% 0.01792951 NR4A1, VDR, EGR3, EGR1, ZNF281,
nucleus 5 5.81% 0.03438949 MEOX2, NR4A1, LOC389168, DLX2, DUSP2,
proto-oncogene 5 5.81% 0.0497628 JUN, KRAS, LOC389168, BTG1, BTG1, FOS,
dual specificity protein phosphatase (MAP kinase 
phosphatase)
4 4.65% 1.40E-05 DUSP5, DUSP1, DUSP1, DUSP6, DUSP6, DUSP6, DUSP2,
MAP kinase phosphatase 4.65% 2.34E-05 DUSP5, DUSP1, DUSP1, DUSP6, DUSP6, DUSP6, DUSP2,
Rhodanese-like 4.65% 3.01 E-04 DUSP5, DUSP1, DUSP1, DUSP6, DUSP6, DUSP6, DUSP2,
RHOD 4.65% 5.34E-04 DUSP5, DUSP1, DUSP1, DUSP6, DUSP6, DUSP6, DUSP2,
Dual specificity protein phosphatase 4.65% 6.67E-04 DUSP5, DUSP1, DUSP1, DUSP6, DUSP6, DUSP6, DUSP2,
DSPc 4.65% 7.24E-04 DUSP5, DUSP1, DUSP1, DUSP6, DUSP6, DUSP6, DUSP2,
bZIP transcription factor, bZIP_1 4.65% 8.32E-04 ATF4, JUNB, JUN, FOS,
Genomic reformatting Brain Ischemia 4.65% 0.0017469 JUNB, IL6, JUN, EGR1,
Cadmium induces DNA synthesis and proliferation in 
macrophages
4.65% 0.00306722 NFKBIA, JUN, KRAS, FOS,
Regulation of hematopoiesis by cytokines 4.65% 0.0037228 IL6, IL8, IL8, IL8, IL8, IL11,
IGF-1 Signaling Pathway 4.65% 0.00617828 IGF1R, JUN, KRAS, FOS,
IL 6 signaling pathway 4.65% 0.00716817 IL6, JUN, KRAS, FOS,
h- Table 4.6: Over-representation analysis of genes up-regulated in NF compared to CWF across all patients. Genes were identified by
difference of the difference analysis. Genes altered by immortalisation and patient differences were removed. Genes were grouped
according to over-represented term and listed according to P value with a cut off of 0.01.
III 1.191
signal 28 35.44% 2.28E-04
PCDHGA12, PODXL, PCDHGA12, IGFBP5, CXCL1, PCDHGA12, TNFAIP6, TNFAIP6, 
CXCL3, COL6A1, CXCL5, CCL3L3, TIMP3, PCDHGA12, PCDHGA12, CXCL12, DKK2, 
PCDHGA12, , JAG1, JAG1, ICAM1, IL7R, BMP2, CCL3L3, CXCL10, CXCL2, INHBA, 
CXCL11.CXCL11, HBEGF,
direct protein sequencing 21 26.58% 0.02269497
G1P2, VIL2, VIL2, VIL2, IGFBP5, MX1, CXCL1, CCL3L3, COPA, CXCL10, TNFAIP6, 
TNFAIP6, CXCL3, COL6A1, CXCL2, CXCL5, CCL3L3, TIMP3, CXCL11, CXCL11, 
FABP3, HBEGF, PLSCR1, PLSCR1, , ICAM1,
interferon induction 16 20.25% 3.54E-24 IFITM1, IFITM1, G1P2, MX1, DDX58, CXCL10, IFIT2, IFIT5, OAS2, OAS1, OAS1, IFIT1, 
IFI44, GBP1, GBP1, IFI16, IFI16, OASL, OASL, MX2, IFIT3,
CYTOKINE-CYTOKINE RECEPTOR INTERACTION 12 15.19% 5.54E-07 TNFSF10, CXCL2, CCL3L3, CXCL5, IL7R, INHBA, CXCL11, CXCL11, BMP2, CXCL12, 
CXCL1, CXCL10, CXCL3,
cytokine 11 13.92% 6.39E-08
TNFSF10, CXCL2, CCL3L3, CXCL5, CXCL11, CXCL11, BMP2, CXCL12, CXCL1, 
CCL3L3, CXCL10, CXCL3,
Small chemokine, interleukin-8-like 9 11.39% 1.41E-10 CXCL2, CCL3L3, CXCL5, CXCL11, CXCL11, CXCL12, CXCL1, CCL3L3, CXCL10, 
CXCL3,
SM00199:SCY 9 11.39% 5.58E-10 CXCL2, CCL3L3, CXCL5, CXCL11, CXCL11, CXCL12, CXCL1, CCL3L3, CXCL10, 
CXCL3,
cell adhesion 9 11.39% 0.00129348
COL6A1, PCDHGA12, PCDHGA12, PCDHGA12, PCDHGA12, PCDHGA12, 
PCDHGA12, TNFAIP6, TNFAIP6, ICAM1,
calcium 9 11.39% 0.032281709 PCDHGA12, PCDHGA12, PCDHGA12, PCDHGA12, PCDHGA12, PCDHGA12, CALB2, 
PLSCR1, PLSCR1, JAG1, JAG1,
sensory transduction 8 10.13% 5.86E-04 CXCL2, CCL3L3, TIMP3, CXCL11, CXCL11, CXCL12, CCL3L3, CXCL10, CXCL3,
Small chemokine, C-X-C 7 8.86% 2.50E-10 CXCL2, CXCL5, CXCL11, CXCL11, CXCL12, CXCL1, CXCL10, CXCL3,
chemotaxis 7 8.86% 1.83E-06 CXCL2, CCL3L3, CXCL11, CXCL11, CXCL12, CCL3L3, CXCL10, CXCL3,
beta-thromboglobulin 6 7.59% 1.72E-08 CXCL2, CXCL5, CXCL12, CXCL1, CXCL10, CXCL3,
Cadherin-like 6 7.59% 1.66E-05 PCDHGA12, PCDHGA12, PCDHGA12, PCDHGA12, PCDHGA12, PCDHGA12,
inflammatory response 6 7.59% 3.14E-05 CXCL2, CCL3L3, CXCL11, CXCL11, CXCL1, CXCL10, CXCL3,
Cadherin 6 7.59% 3.46E-04 PCDHGA12, PCDHGA12, PCDHGA12, PCDHGA12, PCDHGA12, PCDHGA12,
SM00112:CA 6 7.59% 8.48E-04 PCDHGA12, PCDHGA12, PCDHGA12, PCDHGA12, PCDHGA12, PCDHGA12,
Small chemokine, C-X-C/lnterleukin 8 5 6.33% 1.92E-06 CXCL2, CXCL5, CXCL12, CXCL1, CXCL3,
antiviral defense 5 6.33% 4.79E-05 IFIH1, MX1, DDX58, MX2, PLSCR1, PLSCR1,
growth factor 5 6.33% 0.007575534 INHBA, BMP2, CXCL12, CXCL1, HBEGF,
Tetratricopeptide-like helical 5 6.33% 0.016352099 IFIT1, SAMD9, IFIT5, IFIT2, IFIT3,
interferon-induced 56K protein 4 5.06% 2.43E-06 IFIT1, IFIT5, IFIT2, IFIT3,
Tetratricopeptide TPR_2 4 5.06% 0.002507113 IFIT1, IFIT5, IFIT2, IFIT3,
Chemokine_families 4 5.06% 0.009279094 CCL3L3, CXCL11, CXCL11, CXCL12, CXCL10,
tpr repeat 4 5.06% 0.022129383 IFIT1, IFIT5, IFIT2, IFIT3,
TGF-BETA SIGNALING PATHWAY 4 5.06% 0.022317208 INHBA, BMP2, ID1, ID3,
Tetratricopeptide TPR_1 4 5.06% 0.022879146 IFIT1, IFIT5, IFIT2, IFIT3,
2-5-oligoadenylate synthetase 3 3.80% 2.35E-04 OAS1, OAS1, OAS2, OASL, OASL,
:2-5 oligoadenylate synthetase, ubiquitin-like region 3 3.80% 3.91 E-04 OAS1, OAS1, OAS2, OASL, OASL,
PAP/25A core 3 3.80% 0.002505496 OAS1, OAS1, OAS2, OASL, OASL,
Caspase Recruitment 3 3.80% 0.008417984 IFIH1, RIPK2, DDX58,
DNA replication, recombination, and repair 3 3.80% 0.047002226 IFIT1, IFIH1, DDX58,
dynamin-related protein VPS1 2 2.53% 0.025877093 MX1, MX2,
Antiural defense 2 2.53% 0.027019297 G1P2, IRF7,
Dynamin GTPase effector 2 2.53% 0.037405996 MX1, MX2,
transcription repressor Id-2 2 2.53% 0.042764316 ID1, ID3,
UJ
Table 4.7: Over-representation analysis of genes down-regulated in NF compared to CWF across all patients. Genes were identified by
difference of the difference analysis. Genes altered by immortalisation and patient differences were removed. Genes were grouped
according to over-represented term and listed according to P value with a cut off of 0.05.
Teem Count P value Genesin List
nuclear protein 34 35.42% 7.18E-05
JUNB, CDKN1B, MEOX2, ID2, TPR, NR2F2, RKHD1, RUNX1T1, FOS, JUN, FOSB, EGR1, 
SOX18, PIK3C2A, ATF3, DACT1, SYNCRIP, PLAGL1, UPF3A, ARL7, MYBL1, DUSP5, 
EGR3, TCF7L2, KLF4, DUSP2, NFIL3, EGR2, TBX3, REV3L, ID4, NR4A1, LOC389168, 
ZBTB38,
dna-binding 21 21.88% 1.26E-04 JUNB, MYBL1, MEOX2, EGR3, TCF7L2, KLF4, NR2F2, FOS, RUNX1T1, NFIL3, EGR2, 
TBX3, REV3L, JUN, NR4A1, FOSB, EGR1, SOX18, ZBTB38, ATF3, PLAGL1,
transcription regulation 18 18.75% 0.00252764
JUNB, MYBL1, MEOX2, EGR3, TCF7L2, KLF4, NR2F2, RUNX1T1, NFIL3, EGR2, TBX3, 
JUN, NR4A1, EGR1, SOX18, ZBTB38, ATF3, PLAGL1,
transcription 16 16.67% 0.01638153
JUNB, MYBL1, EGR3, TCF7L2, KLF4, NR2F2, RUNX1T1, EGR2, TBX3, JUN, NR4A1, 
EGR1, SOX18, ZBTB38, ATF3, PLAGL1,
zinc-finger 13 13.54% 0.03779863 EGR3, TRIM2, KLF4, NR2F2, RKHD1, RUNX1T1, EGR2, TANK, REV3L, NR4A1, EGR1, 
EGR1, ZBTB38, PLAGL1,
DNA binding 9 9.38% 0.00228779 JUNB, MYBL1, MEOX2, NR4A1, EGR3, EGR1, EGR1, SOX18, NR2F2, FOS,
MAPK SIGNALING PATHWAY 8 8.33% 0.00368293 DUSP5, IL1B, JUN, NR4A1, DUSP1, DUSP6, DUSP6, FOS, DUSP2,
activator 8 8.33% 0.0074968 EGR2, MYBL1, TCF7L2, EGR1, EGR1, ZBTB38, SOX18, KLF4, PLAGL1, PLAGL1, 
PLAGL1,
Basic-leucine zipper (bZIP) transcription factor 6 6.25% 2.33E-05 NFIL3, JUNB, JUN, FOSB, ATF3, FOS,
BRLZ 6 6.25% 4.54E-05 NFIL3, JUNB, JUN, FOSB, ATF3, FOS,
proto-oncogene 6 6.25% 0.01456013 JUN, LOC389168, TPR, BTG1, BTG1, FOS, RUNX1T1,
CYTOKINE-CYTOKINE RECEPTOR INTERACTION 6 6.25% 0.04293483 CCL2, IL1B, IL8, IL8, IL24, IL8, IL8, IL11,
TOLL-LIKE RECEPTOR SIGNALING PATHWAY 5 5.21% 0.00628661 IL1B, JUN, IL8, IL8, IL8, IL8, FOS,
cytokine 5 5.21% 0.0218373 CCL2, IL1B, IL8, IL8, IL24, IL11,
nucleus 5 5.21% 0.03894905 MYBL1, MEOX2, NR4A1, LOC389168, DUSP2,
dual specificity protein phosphatase (MAP kinase 
phosphatase)
4 4.17% 2.25E-05 DUSP5, DUSP1, DUSP6, DUSP6, DUSP2,
MAP kinase phosphatase 4.17% 3.15E-05 DUSP5, DUSP1, DUSP6, DUSP6, DUSP2,
Basic leucine zipper 4.17% 2.02E-04 NFIL3, FOSB, ATF3, FOS,
Rhodanese-like 4.17% 4.03E-04 DUSP5, DUSP1, DUSP6, DUSP6, DUSP2,
RHOD 4.17% 5.63E-04 DUSP5, DUSP1, DUSP6, DUSP6, DUSP2,
DSPc 4.17% 7.64E-04 DUSP5, DUSP1, DUSP6, DUSP6, DUSP2,
Dual specificity protein phosphatase 4.17% 8.90E-04 DUSP5, DUSP1, DUSP6, DUSP6, DUSP2,
inflammatory response 4.17% 0.00658322 CCL2, IL1B, IL8, IL8, CHST2,
NFkB activation by Nontypeable Hemophilus influenzae 4.17% 0.00866786 IL1B, DUSP1, IL8, IL8, IL8, IL8,
transcription factor 4.17% 0.01555411 JUNB, EGR3, ID2, NR2F2,
Tyrosine specific protein phosphatase and dual specificity 
protein phosphatase
4 4.17% 0.02115542 DUSP5, DUSP1, DUSP6, DUSP6, DUSP2,
fos transforming protein 3 3.12% 7.62E-04 FOSB, ATF3, FOS,
TSP-1 Induced Apoptosis in Microvascular Endothelial Cell 3 3.12% 0.0055225 JUN, THBS1, FOS,
Regulation of MAP Kinase Pathways Through Dual Specificity 
Phosphatases
3 3.12% 0.00927263 DUSP1, DUSP6, DUSP6, DUSP2,
inflammation 3 3.12% 0.01143063 CCL2, IL1B, IL8, IL8,
bZIP transcription factor, bZIP_1 3 3.12% 0.01793706 JUNB, JUN, FOS,
114.Genomic_reformatting_Brain_lschemia 3 3.12% 0.02855055 JUNB, JUN, EGR1, EGR1,
Regulation of hematopoiesis by cytokines 3 3.12% 0.02875015 IL8, IL8, IL8, IL8, IL11,
LUPUS 3 3.12% 0.03759547 IL1B, IL8, IL8, IL8, IL8,
IGF-1 Signaling Pathway 3 3.12% 0.03972245 JUN, 204686_at, FOS,
Pertussis toxin-insensitive CCR5 Signaling in Macrophage 3 3.12% 0.04368458 CCL2, JUN, FOS,
Insulin Signaling Pathway 3 3.12% 0.04368458 JUN, IRS-1, FOS.
Transcription factor Jun 2 2.08% 0.02917256 JUNB, JUN,
£  Table 4.8: Over-representation analysis of genes up-regulated in NF compared to CWF across all time points in culture. Genes were
identified by difference of the difference analysis. Genes altered by immortalisation and patient differences were removed. Genes
were grouped according to over-represented term and listed according to P value with a cut off of 0.03.
Term Count
% of Genes 
in List
P value Genes
signal 19 43.18% 1.77E-04
PTGS2, PODXL, IGFBP5, CXCL6, SERPINB2, ASPN, CXCL1, CCL3L3, MMP3, TGFA, CXCL10, CCL5, CCL5, MFAP5, 
MFAP5, CCL3L3, CXCL5, CXCL11, CXCL12, FST. FST, DKK2,
direct protein sequencing 15 34.09% 0.006598163 IGFBP5, CXCL6, SERPINB2, ASPN, MX1, CXCL1, MMP3, CCL3L3, CXCL10, CCL5, CCL5, Sep-11, CCL3L3, CXCL5, 
CXCL11, FST,
cytokine 10 22.73% 3.50E-09 TNFSF10, CXCL6, CXCL5, CCL3L3, CXCL11, CXCL11, CXCL12, CXCL1, CCL3L3, CXCL10, CCL5,
CYTOKINE-CYTOKINE 
RECEPTOR INTERACTION
9 20.45% 9.68E-06 TNFSF10, CXCL6, CXCL5, CCL3L3, CXCL11, CXCL11, CXCL12, CXCL1, CXCL10, CCL5,
SCY 9 20.45% 3.01 E-12 CXCL6, CXCL5, CCL3L3, CXCL11, CXCL11, CXCL12, CXCL1, CCL3L3, CXCL10, CCL5, CCL5,
:Small chemokine, interleukin-8- 
like
9 20.45% 1.34E-12 CXCL6, CXCL5, CCL3L3, CXCL11, CXCL11, CXCL12, CXCL1, CCL3L3, CXCL10, CCL5,
interferon induction 8 18.18% 4.96E-11 OASl, IFIT1, MX1, OASL, MX2, CXCL10, IFIT2, IFIT3,
sensory transduction 7 15.91% 1.32E-04 CXCL6, CCL3L3, CXCL11, CXCL11, CXCL12, CCL3L3, CXCL10, CCL5, CCL5,
chemotaxis 7 15.91% 5.04E-08 CXCL6, CCL3L3, CXCL11, CXCL11, CXCL12, CCL3L3, CXCL10, CCL5, CCL5,
Chemokine families 6 13.64% 2.34E-05 CXCL6, CCL3L3, CXCL11, CXCL11, CXCL12, CXCL10, CCL5, CCL5,
Small chemokine, C-X-C 6 13.64% 1.47E-09 CXCL6, CXCL5, CXCL11, CXCL11, CXCL12, CXCL1, CXCL10,
inflammatory response 5 11.36% 4.85E-05 CCL3L3, CXCL11, CXCL11, CXCL1, CXCL10, CCL5, CCL5,
Tetratricopeptide-like helical 4 9.09% 0.018346279 IFIT1, SRP72, SRP72, IFIT2, IFIT3,
TOLL-LIKE RECEPTOR 
SIGNALING PATHWAY
4 9.09% 0.010600023 CCL3L3, CXCL11, CXCL11, CXCL10, CCL5, CCL5,
TPR 4 9.09% 0.005235576 IFIT1, SRP72, SRP72, IFIT2, IFIT3,
Tetratricopeptide region 4 9.09% 0.005227872 IFIT1, SRP72, SRP72, IFIT2, IFIT3,
Tetratricopeptide TPR_1 4 9.09% 0.005078947 IFIT1, SRP72, SRP72, IFIT2, IFIT3,
tpr repeat 4 9.09% 0.004405128 IFIT1, SRP72, SRP72, IFIT2, IFIT3,
Small chemokine, C-X- 
C/lnterleukin 8
4 9.09% 1.98E-05 CXCL6, CXCL5, CXCL12, CXCL1,
SF002522:beta-thromboglobulin 4 9.09% 1.86E-05 CXCL5, CXCL12, CXCL1, CXCL10,
transcription factor 3 6.82% 0.031733059 ID1, KLF10, ID3,
Tetratricopeptide TPR_2 3 6.82% 0.0106462 IFIT1, IFIT2, IFIT3,
antiviral defense 3 6.82% 0.005672997 IFIH1, MX1, MX2,
Chemokines in EAE 3 6.82% 0.003321686 CCL3L3, CXCL10, CCL5, CCL5,
GProt-
coupled_Rec_T_Cell_medJnflam
m
3 6.82% 0.003321686 CCL3L3, CXCL10, CCL5, CCL5,
Small chemokine, C-C 3 6.82% 0.003123246 CCL3L3, CCL3L3, CCL5, CCL5,
macrophage inflammatory protein 3 6.82% 8.76E-04 CCL3L3, CCL3L3, CCL5, CCL5,
interferon-induced 56K protein 3 6.82% 1.48E-04 IFIT1, IFIT2, IFIT3,
Dynamin 2 4.55% 0.046364914 MX1, MX2,
PAP/2 5A core 2 4.55% 0.042874181 OAS1, OASL,
DYNc 2 4.55% 0.030917256 MX1.MX2,
GED 2 4.55% 0.026557629 MX1, MX2,
transcription repressor Id-2 2 4.55% 0.025214085 ID1t, ID3,
Dynamin central region 2 4.55% 0.021666336 MX1, MX2,
Dynamin GTPase effector 2 4.55% 0.021666336 MX1, MX2,
& Table 4.9: Over-representation analysis of genes down-regulated in NF compared to CWF across all time points in culture. Genes were
identified by difference of the difference analysis. Genes altered by immortalisation and patient differences were removed. Genes
were grouped according to over-represented term and listed according to P value with a cut off of 0.02.
annotation categories these include; GO terms, protein-protein interactions, protein 
functional domains, disease associations, bio-pathways, sequence general features, 
homologies, gene functional summaries and gene tissue expressions. Genes are 
grouped and given an EASE score, which is a modified Fisher Exact p-value. The 
Fisher Exact is adopted to measure the gene-enrichment compared to the human 
genome background (30,000 gene total). Groups of genes with a p-value of <0.05 
were selected for genes up regulated in CWF compared to NF (Table 4.4) and genes 
down regulated in CWF compared to NF (Table 4.5). Genes identified by difference 
of differences analysis as having altered responses to serum stimulation were also 
analysed. They were sub grouped into differences of differences observed when each 
patients data was analysed separately (Tables 4.6-4.7) and when each time points data 
was analysed separately (Tables 4.8-4.9). The over representation analysis included 
all the GO terms. This included GO terms such as ‘protein binding’ which was 
identified as the most relevant group of genes up regulated in CWF compared to NF 
(Table 4.4). The inclusion of potentially irrelevant data in the generated gene lists is a 
drawback to over representation analysis using this type of software.
4.2.5 Identification of Genes of Interest
Microarray analysis was carried out to identify potential disease marker genes which 
could then be used for the generation of chronic wound reporter constructs. For this 
project it was decided that a clear difference in gene expression between CWF and NF 
was required for a potential reporter gene. Therefore a list of Genes of Interest 
differentially regulated between NF and CWF was generated, including serum 
independent and serum stimulated genes (Table 4.10). This list was assembled from 
genes identified by ANOVA analysis and Difference of Differences analysis which
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were not altered by immortalisation or between patients. Gene lists were manually 
sorted using MADRAS. Genes demonstrating stability across all three patients and 
ideally greater than 2 fold alterations in gene expression between NF and CWF were 
selected. Over representation analysis was carried out independently of the selection 
of genes of interest however the genes selected (Table 4.10) were also present in one 
or more important pathway or functional group as determined by DAVID over 
representation analysis. The selected genes are potential disease marker genes.
4.2.6 Pathway Architect Relevance Networks
The list of Genes of Interest (Table 4.10) was entered into Pathway Architect a 
pathway discovery tool. Pathway Architect uses natural language processing to search 
PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) abstracts from this data it constructs 
pathways involving the genes entered. The pathways generated are interaction 
networks demonstrating direct interactions, shortest path, putative targets and putative 
regulators. Pathway Architect will also suggest genes that though not originally 
entered have have high relevance and known interactions with the genes under 
analysis. Pathway Architect was used to generate relevance networks showing known 
interactions between the genes of interest (Fig 4.21). While this information is based 
solely on text mining the PubMed database and is not based on experimental 
interactions it did suggest that this list of genes shared some common factors.
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Figure 4.20: Venn diagrams showing gene lists from anova analysis. Genes were 
selected that were not altered by time in culture, by the process of 
immortalisation but were differentially expressed between NF and CWF a) 
These genes (ringed in red) were then controlled for inter patient variability 
b). This gave a final gene list of 199 genes (ringed in black). 1 ^
Gene Symbol Gene name
ACTC Actin, Alpha, Cardiac Muscle Down in CWF
MMP3
Matrix MetaUoproteinase 3 (stromelysin 1, 
Progelatinase) Down in CWF
ID1 Inhibitor O f DNA Binding 1, Dominant 
Negative Helix-loop-helix Protein Down in CWF(serum response)
CXCL1
Chemokine (C-X-C Motif) Ligand 1 
(melanoma Growth Stimulating Activity, Alpha)
Down in CWF(serum response)
CXCL12
Chemokine (C-X-C Motif) Ligand 12 (stromal 
Cell-derived Factor 1) Down in CWF(serum response)
CXCL3 Chemokine (C-X-C Motif) Ligand 3 Down in CWF(serum response)
CXCL5 Chemokine (C-X-C Motif) Ligand 5 Down in CWF(serum response)
IGSF4 Immunoglobulin Superfemily, Member 4 Up in CWF
CD9 CD9 Antigen (p24) Up in CWF
IL11 Interleukin 11 Up in CWF (serum response)
THUMPD2 THUMP Domain Containing 2 Up in CWF (serum response)
TM4SF1 Transmembrane 4 L Six Family Member 1 Up in CWF (serum response)
GALNAC4S-6ST B Cell RAG Associated Protein Up in CWF (serum response)
Table 4.10: Genes of interest. Genes selected from lists generated by microarray analysis
of CWF and patient matched NF. Genes are grouped into 4 sets; genes up- 
regulated in CWF compared to NF, genes up-regulated in CWF compared to 
NF in response to serum, genes down-regulated in CWF compared to NF and 
genes down-regulated in CWF compared to NF in response to serum
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o  Figure 4.21: Pathway Architect representation of all known interaction between genes of interest identified by Microarray analysis.
Lines shown in the diagram represent pubmed citations, the shorter the line the greater that number of citations. Genes not
originally entered into Pathway Architect have no blue ring.
4.3 Discussion
Throughout this Chapter the gene expression profiles of CWF and NF from 3 
different patients at 4 time points in culture have been analysed and compared. Data 
obtained from primary fibroblasts (Iyer et al., 1999) was compared to data generated 
from hTERT immortalised cell lines. This global gene analysis gives an insight into 
differences between CWF and NF allowing genes potentially responsible for the non­
healing phenotype to be identified for further analysis.
The experimental design for this Chapter is based on the serum starvation, serum 
stimulation model used by Iyer et al (Iyer et al., 1999). Here serum starvation is used 
to place the fibroblasts into a state of quiescence, this synchronises the cells in GO of 
the cell cycle. Under normal physiological conditions skin fibroblasts are not exposed 
to serum and do not proliferate; serum starvation mimics that quiescent state. Serum 
stimulation triggers a proliferative response from the fibroblasts, this is thought to 
mirror the dermal fibroblast response to wounding (Lindvall et al., 2003). As the cells 
in this experiment were synchronised in GO prior to serum stimulation the cells early 
responses to serum will also be synchronised.Upon stimulation with serum the 
synchronised cells will enter the cell cycle together, changes in gene expression due to 
serum stimulation will be observed in the majority of the cells at the same time. If the 
cells were not synchronised their response to serum stimulation may have been 
staggered reducing the observed alterations in gene expression.
161
4.3.1 Analysis of changes due to immortalisation
Initial analysis was carried out comparing gene expression in primary cells with the 
hTERT immortalised cell lines. These comparisons were made between each primary 
cell strain and the matching immortalised cell line irrespective of the patient or cell 
type. In Chapter 3 it was demonstrated that hTERT immortalisation had allowed the 
cells to escape replicative senescence and form cell lines, demonstrated by their 
continued proliferation. Phenotypic studies demonstrated that the immortalised NF 
and CWF retained differences in proliferation rates and wound healing responses 
typical of primary cells. As discussed in Chapter 3 this retention of phenotype after 
immortalisation makes the NF and patient matched CWF cell lines a potential tool for 
the study of chronic wounds. Previous studies on hTERT immortalised fibroblast cell 
lines disagree as to the effect hTERT has on the cellular phenotype. Lindvall et al 
(2003) describe significant differences in gene expression in their hTERT 
immortalised cells including DNA repair genes and growth factors (Wang et al., 
2000). Wang et al (2000) showed hTERT immortalisation activated the oncogene c- 
MYC (Farwell et al., 2000, Noble et al., 2004), the repression of p i6 and 
chromosomal aberration after hTERT immortalisation as well as repression of pi 4 has 
been reported in some cell lines (Pirzio et al., 2004). Other studies however, 
contradict these findings. Pirzio et al (2004) showed low frequencies of chromosomal 
aberrations in hTERT immortalised fibroblasts suggesting a role in genome stability 
for telomerase (Milyavsky et al., 2003a). Milyavsky et al (2003) showed an up- 
regulation of pi 6 in their hTERT immortalised cells and the retention of chromosome 
stability and the ability to enter GO (Lindvall et al., 2003). However, Milyavsky et al 
(2003) did demonstrate effects of hTERT immortalisation described in other papers 
after prolonged culture of the cells. They examined their cell lines at 500 PDLs after
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telomerase immortalisation and demonstrated overexpression of c-MYC and Bmi-1 
oncogenes and loss of p i4 expression in later time points. In this Thesis gene 
expression analysis of the immortalised cell lines compared to the primary cell strains 
identified 263 genes altered significantly by immortalisation totalling only 1.96% of 
the genes analysed. None of the gene expression alterations described previously were 
seen in any of the patient matched NF or CWF cell lines. In other studies the 
oncogenes RAB36 and MAFB and the protooncogene B MET were all down 
regulated in immortalized cells. Over representation analysis of genes up regulated by 
immortalisation identified pathways relating to the cell cycle and glycolysis as well as 
genes linked with protein sequencing. These findings correlate with the increased 
proliferative ability of the immortalised cells. The hTERT immortalisations lead to 
more decreases in gene expression when compared to the primary cells than increases. 
However, fewer pathways were identified by overrepresentation analysis in the down 
regulated genes. Alterations to pathways associated with GAP junction signaling, 
genes linked with control of the cell cycle and growth factor binding were identified. 
The alteration in growth factor and cell cycle genes mirrors Lindvall et al (2003) 
findings (Wysocki, 1996, Fivenson et al., 1997, Barone et al., 1998, Schmid et al., 
1993). In this Thesis the number of genes altered by immortalisation was small and 
few known pathways appear to have been effected. Therefore genotypically as well as 
phenotypically the hTERT immortalised cell lines appear to be a good model of the 
primary cell strains from which they were generated.
4.3.2 Analysis of Inter-patient variability
The three different patient matched samples demonstrated differences in phenotype in 
Chapter 3, with differences in proliferation rate, rate of wound repopulation and cell
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size observed between the different patients. Taken separately each of the patient 
matched samples demonstrated the same differences between NF and CWF however, 
when taken together the inter-patient differences are often greater then those seen 
between the NF and CWF cell lines. Genotypic analysis also identified differences 
between the patient matched cells with 633 genes showing statistically significant 
differences across the three patients. Analysis of these genes identified no 
significantly altered pathways or GO terms. Despite the differences between the 
patients it was possible to identify genes altered between CWF and NF across all 
patients independent of the serum response with 246 genes identified. Though this 
gene list is relatively small the alterations in gene expression are relevant as they have 
been seen in all three patients before and after immortalisation irrespective of the time 
point in culture.
4.3.3 Gene expression and CWF phenotype
Chronic wounds are characterised by their failure to escape the inflammatory phase of 
wound heeding. Chronic wounds have been shown to demonstrate alterations in levels 
of cytokines in the wound environment, the reduction of growth factors in the wound 
environment and aberrant extracellular matrix deposition (Agren et al., 1999a, Cook 
et al., 2000b, Raffetto et al., 2001a, Stephens et al., 2003, Wall et al., 2008b). 
Fibroblasts from chronic wounds display reduced proliferative ability, reduced 
mobility and altered extracellular matrix reorganisation (Sheterline, 1993, May et al., 
1999). Over representation analysis of the gene lists generated by microarray 
comparison between NF and CWF has identified a number of groups of genes up- or 
down-regulated in CWF relating to these observed phenotypes.
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4.3.3.1 Cell Migration
Cell migration requires the controlled polymerisation of actin molecules into 
filaments within laminapodia (Huang et al., 2006) and this process is controlled 
through a series of growth factor controlled signalling pathways. Genes involved in 
the regulation of the actin cytoskeleton were identified as being up regulated in CWF 
as well as growth factors known to influence actin filament formation (Table 4.4). 
CWF demonstrated a reduced ability to repopulate a scratch wound in Chapter 3 
suggesting that CWF have a reduced migratory ability. Chronic wounds fail to resolve 
the inflammatory phase of wound healing, this may be due to the inability of 
fibroblasts to migrate into the wound.Hepatocyte growth factor (HGF) identified as a 
growth factor up-regulated in CWF regulates cell growth and motility through a 
tyrosine kinase signalling cascade. HGF binds to the c-MET receptor (which is also 
upregulated in CWF). The signalling cascade feeds into Ras/Rac pathway which in 
turn controls the Arp2/3 complex responsible for the formation of actin filament 
growth. The upregualation of RAC, HGF, ARPC1A and MET should increase the 
ability of the CWF to migrate. However the tetraspanin CD9 a cell surface signal 
transduction protein has been linked to regulation of the actin cytoskeleton (Bowler 
and Davies, 1999). Huang et al demonstrated that overexpression of CD9 reduced the 
motility of cells by affecting the formation of actin filaments. Huang et al identified 
WAVE2 and WASF2 both part of the Ras/Rac pathway as being regulated by CD9 
(Fig 4.22). WASF2 forms a multiprotein complex that links the MET receptor and 
actin. The multiprotein complex serves to tranduce signals that involve changes in cell 
shape and motility. Over expression of CD9 and its subsequent effect on the 
formation of actin filaments could explain the upregulation of other cytoskeleton 
related genes. This upregulation may be an attempt
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Figure 4.22: Pathways responsible for Actin filament formation, a) HGF signals 
through the MET receptor instigating a tyrosine kinase signalling 
cascade. This cascade activates the Ras/Rac pathway (b) however 
CD9 negatively regulates the Ras/Rac pathway through Wave 2 
(Huang et al 2006) reducing actin filament formation. Images 
modified from biocarta (www.biocarta.com) (a) and KEGG 
(www.genome.jp/kegg) (b). 166
to compensate for the CD9 controlled reduction in cell motility. The overexpression 
of CD9 may explain the reduced motility observed in CWF compared to NF and the 
reduced ability to repopulate scratch wounds.
4.3.3.2 Inflammation
Chronic wounds are characterised by their high incidence of bacterial infection, with 
bacterial infection thought to be among the contributing factors to the non-healing 
nature of chronic wounds (Scanzello et al., 2008, Sabroe et al., 2008). Toll like 
receptors (TLR) play a vital role in the innate immune response to bacterial infection, 
linking the bodies innate and adaptive immune systems (Cole et al., 1998). TLRs 
found on the surface of cells within the wound space recognise different ligands, each 
specific to a family of pathogens. A signalling cascade leads to the translocation of 
NF-kB into the nucleus and the expression of pro inflammatory cytokines.
CWF demonstrate up regulation of a number genes relating to pro-inflammatory 
proteins linked to the TLR signalling pathway. The pro inflammatory cytokines IL6, 
IL1B and IL8 were all identified as being up regulated in CWF compared to NF. 
These pro inflammatory cytokines are linked with signalling through the TLR (Fig 
4.23). CWF have been removed from the wound environment and cultured in sterile 
tissue culture facilities. However, the CWF still demonstrate up regulation of TLR 
signalling pathway controlled pro-inflammatory cytokines. This may relate to the 
failure of chronic wounds to escape the inflammatory phase of wound healing. The 
innate immune response to bacteria controlled by TLRs should shut down when 
bacteria are no longer present, if this is not the case as seen in CWF isolated from the 
wound site then the inflammatory phase of wound healing will not be resolved.
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Figure 4.23: Toll like Receptor Signalling Pathway. Toll-like receptors (TLR) play a pivotal role in the regulation of 
innate immune responses; linking the innate and adaptive immune responses. Altered gene expression 
levels seen in CWF appear to be linked with the TLR pathway and could play a role in the continued 
inflammation observed in chronic wounds. Pathway taken from KEGG (www.genome.jp/kegg)
As well as an upregulation of pro inflammatory cytokines linked with the TLR CWF 
also demonstrated down-regulation of genes linked with TLR controlled immune 
responses. Chemokines responsible for the recruitment of inflammatory cells to the 
site of wounding were down in CWF in response to serum compared to the NF patient 
matched controls. The chemokines CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, 
CXCL10, CXCL11 and CXCL12 were all identified as being down regulated in CWF 
compared to NF. Of these CXCL10 and CXCL11 are known to be controlled by TLR 
pathways and are responsible for the chemotactic attraction of active T-Cells 
(Angiolillo et al., 1995) and monocytes (Bleul et al., 1996a, Bleul et al., 1996b) to the 
wound space. The chemokine CXCL12 or stromal derived growth factor is a 
chemotractant for neutrophils, monocytes and lymphocytes (Li et al., 2002) and is 
down in CWF in response to serum. Also down in CWF compared to NF CXCL1 is 
thought to control the influx of neutrophils into the site of injury via MMP7-mediated 
shedding (Wolpe et al., 1989). CXCL2 or Macrophage inflammatory protein 2 is 
normally expressed and secreted by macrophages and monocytes however, this Thesis 
shows that it is expressed by NF in response to serum and not in CWF. CXCL2 acts 
as a chemotactant for polymorphonuclear leukocytes (Nieuwenhuis et al., 2002). In 
animal models a reduction in CXCL2 secretion was linked with reduced neutrophil 
influx into sites of infection and a failure to clear bacterial infections (Bowler and 
Davies, 1999). The down regulation of CXCL2 in CWF may relate to the high 
infection rate in chronic wounds (Chang et al., 1994, Corbett et al., 1994). Another 
chemokine identified as being downr regulated in CWF compared to NF was CXCL5 
also known as epithelial cell-derived neutrophil-activating peptide. CXCL5 is an 
inflammatory chemokine which is down in CWF in response to serum. Normally 
CXCL5 is produced along with IL18 in response to stimulation with ILlp or TNFa.
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CXCL5 is responsible for the activation of neutrophils and their recruitment to the site 
of injury (Rovai et al., 1997, Wuyts et al., 1997). CXCL6 or granulocyte chemotactic 
protein 2 is a potent inflammatory mediator attracting neutrophilic granulocytes to the 
wound site, signalling through receptors CXCR1 and CXCR2 (Cole et al., 1998, Luo 
et al., 1998) Another chemokine down regulated in CWF was CXCL11 a chemokine 
known to induced a chemotactic response in activated T cells and monocytes and to 
be induced by IFNG (Hembruff et al., 2005, Mimmack et al., 2004).
Chemokines are clearly important in the normal wound healing response by the timely 
recruitment of inflammatory cells to the wound site. The observed down regulation of 
chemokines in CWF would relate to a failure to attract neutrophils, monocytes and 
lymphocytes to chronic wounds. In this model, serum stimulation was intended to 
mimic the change in cellular environment seen in wounding of the skin. The 
chemokines identified were all regulated by serum stimulation in NF. CWF display an 
impaired response to the pro-inflammatory cytokines found in serum. In-vivo a failure 
to produce the chemokines required for inflammatory cell recruitment could lead to 
the prolonged inflammation and bacterial colonisation seen in chronic wounds.
4.3.4 Potential CWF Disease Marker Genes
Genes from the pathways identified as well as genes that did not fall into any specific 
pathway but whose altered expression levels between NF and CWF were of interest 
were selected (Table 4.10). The genes selected include genes up in CWF compared to 
NF and genes down in CWF compared to NF independent of serum stimulation. The 
list also included genes up regulated in CWF compared to NF by the addition of 
serum and genes down regulated in CWF compared to NF in response to serum 
stimulation. These genes were identified despite the large inter-patient variability
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which further validates them as genes important to the chronic wound phenotype. 
When analysed for known interactions by Pathway Architect multiple PubMed 
citations were found linking the genes of interest to each other. As well as these 
interactions a number of other genes were identified as relevant to the CWF disease 
marker genes. TNF, TGF-pl and IFN-y were all identified as interacting with the 
identified CWF disease marker genes (Fig 4.21).
This Chapter has presented data obtained by microarray analysis of primary and 
hTERT immortalised fibroblasts taken from chronic wounds and their patient matched 
normal controls. Analysis using over-representation and interactive networking has 
identified individual genes and whole pathways that are potentially interesting with 
respect to the chronic wound phenotype. One of the aims of this thesis was to validate 
hTERT immortalised CWF and NF cell lines as potential models for use in studying 
chronic wounds. Gene expression changes between NF and CWF were maintained 
after immortalisation. These changes relate to the observed chronic wound phenotype 
and may be important in the future design of chronic wound treatments. Importantly 
the data has shown the requirement for patient matched controls within these 
experiments as inter-patient variability accounted for the largest lists of identified 
gene alterations. A second aim of this thesis was to identify potential disease marker 
genes for use as reporter genes. A number of potentially interesting genes were 
identified (Table 4.10). These genes demonstrated significant changes in gene 
expression between NF and CWF as identified by ANOVA or difference of 
differences analysis. To confirm that the gene changes observed in the genes of 
interest selected are ‘real’ and to allow further time points in the serum response to be
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analysed the genes of interest need next to be validated using quantitative realtime 
PCR.
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Chapter Five
Confirmation
of
Disease Reporter Genes
by
Quantitative Real-Time PCR
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5.1 Introduction
Microarray analysis is a invaluable tool for investigating genome wide alterations in 
gene expression levels as the technology allows all genes present on the array to be 
analysed at the same time. Though Affymetrix™ gene chip technology allows for 
many levels of quality control it is generally considered necessary to validate 
observed expression changes by another method (Bermejo-Rodriguez et al., 2006, 
Sato et al., 2003). Two methods of validation are widely used: western blot analysis 
and quantitative real time PCR (QRT-PCR). These methods are often used in 
conjunction with one another (Langmann et al., 2005, Finn et al., 2007, Iyer et al., 
1999). Western blotting allows for the quantitative analysis of protein concentration 
which confirms that gene expression changes observed in microarray analysis are 
actually having an effect at the protein levels. As the aim of this project was to 
specifically identify genes differently expressed between NF and CWF and generate 
promoter based reporter constructs for the disease marker genes identified, the 
alterations in gene transcription, not translation are of paramount concern. Thus an 
assay that investigates at the gene expression levels in more detail is more appropriate 
to validate the array data for this project.
Quantification of PCR reactions requires data collection at the exponential phase of 
PCR amplification, where the amount of PCR product present is doubled after each 
cycle. For end point PCR, this requires running reactions for varying numbers of 
cycles to identify the exponential phase for each reaction. Rather than altering cycle 
numbers to identify the exponential phase, QRT-PCR uses fluorescent dyes to take 
accurate readings for each sample at each cycle. This allows identification of the 
exponential and linear phases of the PCR reaction based on alterations in fluorescence 
levels.
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There are three different methods for generating a fluorescent signal used by QRT- 
PCR systems, all taking advantage of the specific chemistries of fluorescent 
molecules: Forster Resonance Energy Transfer (FRET) used in TaqMan and Scorpion 
probes, SYBR Green dye and Light Upon Extension (LUX).
TaqMan (Applied BioSystems) utilises FRET, with a fluorescent reporter molecule 
attached to the 5’ and quencher moiety attached to the 3’ ends of the same 
oligonucleotide probe. The release of the reporter and quencher molecules is 
dependant on the 5'- nuclease activity of DNA polymerase used for PCR. The probe is 
designed to hybridise to the region between the forward and reverse primers. When 
the probe is free in solution the proximity of the quencher molecule to the fluorophore 
prevents any fluorescent signal through FRET. When PCR amplification takes place 
the 5’-nuclease activity of the polymerase digests the probe decoupling the 
fluorophore from the quencher and releasing it into solution increasing fluorescence. 
Fluorescence will therefore increase with each cycle as more probe is cleaved. 
TaqMan probes are able to be multiplexed as different fluorophores can be attached to 
each probe. However each target mRNA requires a new TaqMan probe which are 
expensive to synthesise. TaqMan based QRT-PCR has been used to validate 
microarray analysis (Hembruff et al., 2005).
SYBR Green based qRT-PCR allows the detection and quantification of PCR 
products through the fluorescence of the SYBR green dye. SYBR green is a DNA 
binding dye which when bound to DNA fluoresces upon excitation with 485nm light. 
As PCR product accumulates after repeated cycles the level of fluorescence increases. 
Unlike TaqMan based QRT-PCR any double-stranded DNA will cause an increase in 
fluorescence: this includes primer dimers and non-specific products. This can lead to 
an overestimation of the target cDNA concentration. SYBR green QRT-PCR is
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inexpensive and with well designed primers SYBR green has been found to be as 
accurate as TaqMan (Mimmack et al., 2004). SYBR green will work with any primers 
without the need to design new probes which makes it an ideal choice for looking at 
multiple genes (Lowe et al., 2003, Chen et al., 2004, Nazarenko et al., 2002a, 
Nazarenko et al., 2002b, Rekhviashvili et al., 2007, Nordgren et al., 2007, Antal et al., 
2007, Rekhviashvili et al., 2006). However, it is not possible to multiplex with SYBR 
green.
The system used in this Thesis was the Light Upon Extension system (LUX). LUX 
QRT-PCR is based on one normal and one labelled primer. The labelled primer has a 
fluorescent molecule attached to the 3’ end within a hairpin structure. The hairpin 
configuration quenches the fluorophore removing the need for a separate quenching 
moiety. When free in solution the LUX primers have very low fluorescence. When 
incorporated into double stranded DNA the fluorophore is unquenched and thereby 
fluorescence increases (Nazarenko et al. 2002a; Nazarenko et al. 2002b). After each 
cycle the number of LUX primers incorporated into double stranded PCR product 
increases allowing the quantification of starting cDNA. LUX probes can be made 
with a range of fluorophores attached allowing multiplex QRT-PCR and as no 
quencher moieties are required the cost of each LUX primer is significantly less than 
a TaqMan probe. Any product which incorporates the primers will lead to an increase 
in fluorescence so good primer design is essential as is confirmation of primer 
specificity. The LUX system has been used for a number of different applications 
including viral identification (Ikeyama et al., 1993) and offers a cost effective QRT- 
PCR option.
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The aims of this chapter were to analyse gene expression for disease reporter genes of 
interest identified by microarray analysis (Chapter 4), to confirm changes in gene 
expression identified by microarray and to gain a better understanding of the time 
course of gene expression. Gene expression analysis was carried out using QRT-PCR 
on cDNA generated from total RNA extracted from both CWF and NF at various 
experimental timepoints. For genes of interest to be taken forward for use in reporter 
constructs detailed expression data was required.
177
5.2 Results
5.2.2 Generation of cDNA
RNA was extracted from serum starved and serum stimulated NF and CWF (n=3) at 
OH (serum starved) 1H, 6H and 24H after stimulation with 10%(w/v) FCS. The RNA 
was quantified and checked for quality as described in Chapter 4 with final RNA 
concentration, RNA quality and RNA integrity listed in Tables 4.1-3. For cDNA 
generation 1 pg of RNA was taken for each time point/cell type/patient giving a total 
of 72 samples. To confirm successful cDNA generation non-quantitative PCR was 
carried out using primers for GAPDH designed to generate a product spanning an 
intron/exon boundary. A positive band would indicate successful cDNA synthesis. 
Agarose gel electrophoresis (Fig 5.1) demonstrates good amplification and single 
bands generated from Patients H, I and K for all timepoints. Variation in cDNA 
concentration was controlled for by reference to GAPDH in QRT-PCR reactions. To 
allow a reproducible standard curve to be generated for each of the genes of interest 
and for standards to allow comparison between plates Total Human RNA (Stratagene) 
was used. Microarray analysis data provided by Stratagene made it possible to 
confirm that transcripts from each of the genes under investigation were present in the 
pooled RNA. Total Human cDNA was generated as described previously with 
identical random hexamer primers and under the same conditions that were used for 
generating cDNA from each of the experimental RNA samples. To obtain sufficient 
cDNA to generate standard curves, 5pg of RNA was used per cDNA reaction, with 4 
reactions carried out. To confirm successful cDNA generation non-quantitative PCR 
was carried out using primers specific for GAPDH. Agarose gel analysis of the 
products (Fig 5.1) demonstrated positive bands for each of the 4 cDNA generation 
reactions. The 4 reactions were pooled and used to generate a dilution series.
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Figure 5.1: Confirmation of cDNA by PCR. The presence of GAPDH was confirmed by
PCR with a band of approximately 300bp observed in each cDNA react
5.2.3 Design of LUX PCR primers
LUX primers were designed using the D-LUX™ designer available through the 
Invitrogen website (www.invitrogen.com). The primer design software requires the 
unique Entrez Ref Seq accession number for each gene under investigation. Entrez 
ID’s were identified through PubMed (www.ncbi.nlm.nih.gov/entrez). The D-LUX™ 
designer identifies the location of known single nucleotide polymorphisms (SNPs) 
and determines exon/intron location. This allows any primers to be located across 
intron/exon boundaries thereby facilitating detection of genomic DNA contamination 
in any cDNA sample analysed. The locations of known SNPs are important because 
they reduce the efficiency of primer binding. It was possible to select regions of the 
gene to include or exclude from the primer design process. This includes selecting 
which region of the RNA the primers are designed against. In this experiment primers 
were designed against the open reading frame (ORF) of the gene where possible, with 
the 3’ or 5’ un-translated regions being used only if unique primers could not be 
found in the ORF. To confirm that any primers designed were specific to the gene 
under investigation a BLAST search was carried out against a species specific 
database selecting primers against unique regions of the gene. Finally the 
amplification parameters of the primers were selected including amplicon size, Tm 
and primer length. The optimum values were for an amplicon between 60 and 200 
bases (optimum of 75) with a Tm between 60°C and 68°C (optimum 64°C) and primer 
length between 20 and 24 bases (optimum 22 bases). Potential primers were scored 
according to the closeness of fit with the selected parameters with 5 star primers 
fitting most of the parameters exactly. All primers designed for this experiment were 
4 or 5 star primers. Pairs of primers were selected with one primer labelled with the 
fluorescent molecule FAM (carboxyfluorescein) and the other primer unlabelled. The
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exception to this was the primer pair for MMP3 where the fluorophore selected was 
JOE.
A housekeeping gene was selected from pre-designed LUX primers available from 
Invitrogen. GAPDH with a FAM label was selected. Athough the sequence of the 
primers was not available the primer pair was known to amplify the coding region 
spanning exon 4/5 of GAPDH.
5.2.4 Confirmation of primers
Each primer pair designed for this experiment was novel and had not been tested prior 
to this experiment therefore, each pair was tested to ensure that a single product was 
produced and that the product was of the size indicated by the D-LUX™ designer. 
Reactions were carried out using an ABI Prism 7000 following the Invitrogen 
recommended protocol for this machine with total human cDNA. Successful 
amplification was detected for each primer pair by the ABI Prism through an increase 
in fluorescence. The products from each amplification were run on a 1.5% agarose gel 
(Fig 5.2). Each primer pair successfully generated a single product of the expected 
size.
5.2.5 Standard Curves
Due to the number of genes under investigation and the number of patient samples it 
was not possible to run all reactions on the same plate. To determine expression levels 
for each of the genes under investigation and to allow comparisons between plates a 
standard curve of reference cDNA was used on each plate. Comparison with the 
standard curve (Fig 5.3) gave expression levels for each sample. A separate plate was
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Figure 5.2: Confirmation of primers by PCR with cDNA generated from total human RNA 
supplied by Stratagene. Composite gels demonstrated the specificity of all LUX 
primers, only one band was observed from each primer pair with a DNA 
fragment of the appropriate size.
run for the housekeeping gene GAPDH. To allow comparisons between plates, 
GAPDH primers were used with lOng of reference cDNA in triplicate on each plate.
5.2.6 Validation of Reference Gene
The reference gene GAPDH was used to normalise expression levels for each sample 
and to normalise variation between plates. Any variation between plates would 
require further normalisation of the data. Analysis of ct values for all lOng reference 
cDNA with GAPDH (Fig 5.4a) shows the median level of expression at a ct of 18.3 
with 75% of the values within 0.58 of the median (Fig 5.4b). Despite some outlying 
points (Fig 5.4c) the majority of the reference gene ct values lie within let of each 
other.
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5.2.7 Alpha Cardiac Actin, ACTC
The relative gene expression levels for Actin, Alpha, Cardiac Muscle (ACTC) are 
shown separately for each patient. Patient H (Fig 5.5), patient I (Fig 5.6) and patient K 
(Fig 5.7) with each time point in culture separately represented as Early (a) Mid (b) 
and Late (c). To aid comparison between the QRT-PCR data and that obtained 
through microarray analysis, a MADRAS generated figure for microarray determined 
gene expression is also show (d). For patient H the level of relative gene expression 
at all time points after serum stimulation and at all points in culture (Fig 5.5a-c) are 
lower in CWF compared to NF. This was also observed in the microarray data (Fig 
5.5d). As microarray analysis investigated only two time points after serum 
stimulation (0 and 6 hours) the apparent increase of gene expression reported at 24 
hours was not observed. The same trend was observed in patient I with lower relative 
expression levels in CWF than NF observed at all time points in culture (early, mid 
and late) and at all points after serum stimulation (1,6 and 24 hours). Two of the three 
time points in culture for patient K Early (Fig 5.7a) and Late (Fig 5.7c) demonstrated 
the same trend as observed at all points in culture for patients H and I with reduced 
relative expression in CWF compared to NF observed at all points after serum 
stimulation 0-24 hours. The mid point in culture (Fig 5.7b) demonstrated a reversal of 
the trend. This was also observed in the microarray data (Fig 5.7d). Though the data 
in Fig 5.7b contradicts the trend observed in all other points in culture regardless of 
patient of origin it does confirm what was observed in the microarray data
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Figure 5.5: Graphs showing relative gene expression levels for ACTC in Patient H at Early (a) Mid (b) and Late (c) time points in
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and
6  hours after stimulation is shown for comparison (d)
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5.2.8 CD9
The relative gene expression levels for p24/CD9 are shown separately for each 
patient. Patient H (Fig 5.8), patient I (Fig 5.9) and patient K (Fig 5.10) with each time 
point in culture separately represented as Early (a) Mid (b) and Late (c) as well as 
relevant microarray data (d). For patient H (Fig 5.8) and I (Fig 5.9) at all three time 
points in culture and at all time points after serum stimulation relative expression 
levels of CD9 were higher in CWF compared to NF. These observations confirm 
what was demonstrated by the microarray analysis (Fig 5.8d and Fig 5.9d). Patient K 
(Fig 5.10) demonstrated little pattern in the relative gene expression levels. At the 
Early time point in culture (Fig 5.10 a) at 6 hours and 24 hours after serum 
stimulation CWF relative expression levels were greater than NF as observed in 
patients H and I. However at 0 and 1 hour after serum stimulation the pattern was 
reversed with NF relative expression levels being greater than CWF. At the mid time 
point in culture (Fig 5.10b) there was no difference between CWF and NF. At the late 
time point in culture (Fig 5.10c) 0 hours after serum stimulation relative gene 
expression in NF was greater than CWF. At all other time points after serum 
stimulation CWF relative expression was greater than NF as observed in patients H 
and I.
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Figure 5.9: Graphs showing relative gene expression levels for CD9 in Patient I at Early (a) Mid (b) and Late (c) time point in culture
in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and 6  hours
after stimulation is shown for comparison (d)
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5.2.9 Chemokine (C-X-C motif) ligand 1, CXCL1
The relative gene expression levels for CXCL1 are shown separately for each patient. 
Patient H (Fig 5.11), patient I (Fig 5.12) and patient K (Fig 5.13) with each time point 
in culture separately represented as Early (a) Mid (b) and Late (c) as well as relevant 
microarray data (d). At the early time point (a) all three patients demonstrated a lower 
level of gene expression in the CWF sample relative to the NF with an increase in 
expression upon addition of serum. This pattern was maintained in Patient K at mid 
(Fig 5.13b) and late (Fig 5.13c) points in culture. In patient K there was an increase in 
relative levels of expression across the 3 points in culture, this correlates with what 
was observed in the microarray data (Fig 5.13d). In patient H the mid (Fig 5.1 lb) and 
late (Fig 5.1 lc) points in culture do not maintain the same pattern, in fact the observed 
pattern was reversed with a higher relative expression observed in CWF than NF. This 
reversal was also observed in patient I at mid (Fig 5.12b) and late (Fig 5.12c) points in 
culture. Microarray data for Patient H (Fig 5.1 Id) and I (Fig 5.12d) does show a 
reversal of expression levels at the late but not the mid point in culture.
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Figure 5.12: Graphs showing relative gene expression levels for CXCL1 in Patient I at Early (a) Mid (b) and Late (c) time point in
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and
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5.2.10 Chemokine (C-X-C motif) ligand 12, CXCL12
The relative gene expression levels for CXCL12 are shown separately for each 
patient. Patient H (Fig 5.14), patient I (Fig 5.15) and patient K (Fig 5.16) with each 
time point in culture separately represented as Early (a) Mid (b) and Late (c) as well 
as relevant microarray data (d). Microarray analysis (Fig 5.14d-5.16d) identified 
CXCL12 as a serum response gene down in CWF compared to NF, in patient H this 
pattern was observed at 6 hours and 24 hours post stimulation in the early point in 
culture (Fig 5.14a) . It was also observed at 6 hours post stimulation in the mid point 
in culture (Fig 5.14b) but not at 24 hours. It was not observed at any point post 
stimulation at the late timepoint in culture (Fig 5.14c). In patient I all of the early 
point in culture (Fig 5.15a) show reduced expression in CWF compared to NF. This 
was also observed at 24 hours post stimulation at the mid point in culture (Fig 5.15b) 
but not observed at the late point in culture (Fig 5.15c). Patient K matches the 
microarray data most closely, with CWF showing reduced expression compared to the 
NF. The exceptions to this pattern are the 24 hour post serum stimulation at Early (Fig 
5.16a) and mid (Fig 5.15b) points in culture.
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Figure 5.14: Graphs showing relative gene expression levels for CXCL12 in Patient H at Early (a) Mid (b) and Late (c) time point in
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and
6  hours after stimulation is shown for comparison (d)
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Figure 5.15: Graphs showing relative gene expression levels for CXCL12 in Patient I at Early (a) Mid (b) and Late (c) time point in
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and
6  hours after stimulation is shown for comparison (d)
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Figure 5.16: Graphs showing relative gene expression levels for CXCL12 in Patient K at Early (a) Mid (b) and Late (c) time point in
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and
6  hours after stimulation is shown for comparison (d)
5.2.11 GALNAC4S-6ST B Cell RAG Associated Protein, GALNAC4S
The relative gene expression levels for GALNAC4S are shown separately for each 
patient. Patient H (Fig 5.17), patient I (Fig 5.18) and patient K (Fig 5.19) with each 
time point in culture separately represented as Early (a) Mid (b) and Late (c) as well 
as relevant microarray data (d). GALNAC4S was observed to be up in CWF 
compared to NF as well as being a serum response gene by microarray analysis. This 
pattern was observed in patient H (Fig 5.17) with an increase in expression across the 
time points post serum stimulation peaking at 6 hours and reducing at 24 hours post 
stimulation. The same pattern of serum stimulation was observed in CWF and NF but 
with increased expression levels in CWF (Fig 5.17). The serum response at the late 
time point (Fig 5.17c) was less evident as the expression level at 0 hours was higher 
than at 1 hour post stimulation. Patient I demonstrated a serum response at the early 
point in culture (Fig 5.18a) with higher expression in CWF at 0, 1 and 24 hours after 
serum stimulation. The mid time point (Fig 5.18b) does not appear to have a serum 
response with CWF having higher relative expression at 1 hour post serum 
stimulation only. At the late point in culture (Fig 5.18c) CWF have higher relative 
expression than NF at 0 and 24 hours post serum stimulation. In patient K the pattern 
observed in patient H was also observed at the early (Fig 5.19a) and late (Fig 5.19c). 
At the mid point in culture (Fig 5.19b) the serum response was observed in the NF 
however the CWF expression was absent and the trend was reversed.
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Figure 5.17: Graphs showing relative gene expression levels for GALNAC4S in Patient H at Early (a) Mid (b) and Late (c) time point in
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and
6  hours after stimulation is shown for comparison (d)
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Figure 5.18: Graphs showing relative gene expression levels for GALNAC4S in Patient I at Early (a) Mid (b) and Late (c) time point in
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and
6  hours after stimulation is shown for comparison (d)
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Figure 5.19: Graphs showing relative gene expression levels for GALNAC4S in Patient K at Early (a) Mid (b) and Late (c) time point in
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and
6  hours after stimulation is shown for comparison (d)
5.2.12 Inhibitor of DNA binding 1, ID1
The relative gene expression levels for ID1 are shown separately for each patient. 
Patient H (Fig 5.20), patient I (Fig 5.21) and patient K (Fig 5.22) with each time point 
in culture separately represented as Early (a) Mid (b) and Late (c) as well as relevant 
microarray data (d). ID1 was identified as a serum response gene that was down in 
CWF in response to serum by microarray analysis compared to patient matched NF. 
In patient H the serum response can be observed with an increase of expression after 1 
hour of serum stimulation (Fig 5.20). However only two time points show NF with 
greater expression levels than CWF; 1 hour after stimulation at the early time point 
(Fig 5.20a) and 6 hours post stimulation at the late time point (Fig 5.20c). The QRT- 
PCR data does not match the observed microarray data (Fig 5.20d). In patient I the 
serum response was also observed at all time points in culture (Fig 5.21) with NF 
demonstrated greater expression than CWF with after serum stimulation at the early 
(Fig 5.21a), mid (Fig 5.21b) and at 1 and 6 hours in the late time point in culture (Fig 
5.21c). In patient K (Fig 5.22) the serum response was observed at the early point in 
culture (Fig 5.22 a), NF demonstrated greater levels of relative expression than CWF. 
The serum response at the mid point in culture (Fig 5.22b) appears reduced in NF 
compared to CWF, with CWF having greater relative expression than NF at 1,6, and 
24 hours post serum stimulation. At the late point in culture (Fig 5.22c) NF gene 
expression was greater than CWF only at 0 and 1 hours after serum stimulation. At 
other time points CWF expression was greater than NF.
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Figure 5.20: Graphs showing relative gene expression levels for ID1 in
in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum
after stimulation is shown for comparison (d)
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Figure 5.21: Graphs showing relative gene expression levels for ID1 in Patient I at Early (a) Mid (b) and Late (c) time point in culture in
NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and 6  hours
after stimulation is shown for comparison (d)
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§  Figure 5.22: Graphs showing relative gene expression levels for ID1 in Patient K at Early (a) Mid (b) and Late (c) time point in culture
in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and 6  hours
after stimulation is shown for comparison (d)
5.2.13 Immunoglobulin Superfamily, Member 4, IGSF4
The relative gene expression levels for IGSF4 are shown separately for each patient. 
Patient H (Fig 5.23), patient I (Fig 5.24) and patient K (Fig 5.25) with each time point 
in culture separately represented as Early (a) Mid (b) and Late (c) as well as relevant 
microarray data (d). Patient H (Fig 5.23) at all points in culture (a-c) demonstrated 
an increased relative expression in CWF compared to NF at all points after serum 
stimulation. Furthermore, there was a reduction in expression levels over time in 
culture which was also observed in the microarray data (Fig 5.23d). Patient I 
demonstrated the same trend (Fig 5.24) with higher expression in CWF than the 
patient matched NF with a reduction of expression from early to late points in culture 
(Fig 5.24a-c) as observed in the microarray data (Fig 5.24d). The same trend was 
observed in Patient K at the early (Fig 5.25a) and late (Fig 5.25c) points in culture 
with CWF having higher relative levels of expression as well as the late time point in 
culture (Fig 5.25c) having lower expression levels than the early time point (Fig 
5.25c). The mid point in culture (Fig 5.25b) demonstrated a mixed trend with NF 
higher than CWF at 0, 6 and 24 hours after stimulation.
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Figure 5.23: Graphs showing relative gene expression levels for IGSF4 in Patient H at Early (a) Mid (b) and Late (c) time point in
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and
6  hours after stimulation is shown for comparison (d)
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Figure 5.24: Graphs showing relative gene expression levels for IGSF4 in Patient I at Early (a) Mid (b) and Late (c) time point in culture
in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and 6  hours
after stimulation is shown for comparison (d)
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Figure 5.25. Graphs showing relative gene expression levels for IGSF4 in Patient K at Early (a) Mid (b) and Late (c) time point in
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and
6  hours after stimulation is shown for comparison (d)
5.2.14 Interleukin 11, IL11
The relative gene expression levels for IL11 are shown separately for each patient. 
Patient H (Fig 5.26), patient I (Fig 5.27) and patient K (Fig 5.28) with each time point 
in culture separately represented as Early (a) Mid (b) and Late (c) as well as relevant 
microarray data (d). Microarray analysis of IL11 gene expression identified it as a 
serum response gene with increased expression in CWF compared to NF. The serum 
response was observed in all the patients and time points in culture with highest 
expression at 6 hours post stimulation and gene expression back to the 0 hour level by 
24 hours. In patient H (Fig 5.26) at all time points in culture gene expression levels in 
CWF were greater at 6 hours than NF. In patient I the mid (Fig 5.27b) and late (Fig 
5.27c) points in culture demonstrated the same trend with higher expression levels in 
CWF however, the early point in culture (Fig 5.27a) showed higher relative 
expression in NF at 6 hours compared to CWF. In patient K the early (Fig 5.28a) and 
mid (Fig 5.28b) time points in culture demonstrated increased relative expression in 
CWF compared to NF at 6 hours post stimulation. At the late time point in culture 
(Fig 5.28c) gene expression in NF was very close to CWF, although slightly higher. 
The reduction in difference between the 6 hour gene expression level between CWF 
and NF was observed in the microarray data for patient K (Fig 5.28d)
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Figure 5.26: Graphs showing relative gene expression levels for IL11 in Patient H at Early (a) Mid (b) and Late (c) time point in culture
in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and 6  hours
after stimulation is shown for comparison (d)
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Figure 5.27: Graphs showing relative gene expression levels for IL11 in Patient I at Early (a) Mid (b) and Late (c) time point in culture
in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and 6  hours
after stimulation is shown for comparison (d)
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Figure 5.28: Graphs showing relative gene expression levels for IL11 in Patient K at Early (a) Mid (b) and Late (c) time point in culture
in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and 6  hours
after stimulation is shown for comparison (d)
5.2.15 Matrix Metallopeptidase 3, MMP3
The relative gene expression levels for MMP3 are shown separately for each patient. 
Patient H (Fig 5.29), patient I (Fig 5.30) and patient K (Fig 5.31) with each time point 
in culture separately represented as Early (a) Mid (b) and Late (c) as well as relevant 
microarray data (d). Expression of MMP3 was identified as being down in CWF 
compared to NF by microarray analysis irrespective of serum stimulation. Analysis of 
QRT-PCR data for patient H shows that at the early time point (Fig 5.29a) CWF 
expression of MMP3 was lower than NF. This was also observed at the 0 hour time 
point at the mid point in culture (Fig 5.29b) and at the 6 hour and 24 hour post serum 
stimulation time points in the late point in culture (Fig 5.29c). At all other post 
stimulation time points CWF demonstrated greater expression than NF. The 
microarray data for patient H (Fig 5.29d) shows that this pattern of expression was 
observed with high levels of expression in the NF primary cell strains reducing over 
extended periods in culture after immortalisation. In patient I (Fig 5.30) at all time 
points in culture and all points after serum stimulation NF had greater gene expression 
levels compared to CWF. The level of gene expression decreased over extended 
periods in culture from a relative expression level of 400 at the early time point (Fig 
5.30a) to 5 at the late time point (Fig 5.30c). This reduction of expression was 
observed in the microarray data (Fig 5.30d). Patient K showed higher levels of gene 
expression in NF compared to CWF at all time points post serum stimulation in the 
early time point in culture (Fig 5.31a) as well as at 6 and 24 hours post stimulation at 
the late point in culture (Fig 5.31c). At all other points, expression of MMP3 was 
greater in CWF compared to NF. This pattern of gene expression was observed in the 
microarray data for patient K (Fig 5.3Id), as was the observed reduction of gene 
expression levels from early to late time points in culture.
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Figure 5.29: Graphs showing relative gene expression levels for MMP3 in Patient H at Early (a) Mid (b) and Late (c) time point in
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and
6  hours after stimulation is shown for comparison (d)
Figure 5.30: Graphs showing relative gene expression levels for MMP3 in Patient I at Early (a) Mid (b) and Late (c) time point in culture
in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and 6  hours
after stimulation is shown for comparison (d)
wl
h 
24H
 
M
(«)
a is o° ? j
(C)
K)K>
10 00
(A)
Jj 2.SO
( d )
IO
2500
Xo
S
K
2
X Xvo £vo Xtj-
<N
53
<N
„  „  jg j  s
© g o
c o c 2 £ £ c c 2 c
Figure 5.31: Graphs showing relative gene expression levels for MMP3 in Patient K at Early (a) Mid (b) and Late (c)
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time
6  hours after stimulation is shown for comparison (d)
X w s  J
5  $  $  $
* 5  £  5
time point in 
point at 0 and
5.2.16 THUMP domain containing 2, THUMPD2
The relative gene expression levels for THUMPD2 are shown separately for each 
patient. Patient H (Fig 5.32), patient I (Fig 5.33) and patient K (Fig 5.34) with each 
time point in culture separately represented as Early (a) Mid (b) and Late (c) as well 
as relevant microarray data (d). Microarray analysis of gene expression levels for 
THUMPD2 demonstrated that it was up in CWF in response to serum. A serum 
response was observed in patient H in both the CWF and NF at all time points in 
culture (Fig 5.32) with a greater response in CWF compared to the NF. Even when 
serum starved at 0 hours the CWF had greater relative expression than the NF. In 
patient I CWF demonstrated greater expression than NF at all time points except 0 
hours at the mid point in culture (Fig 5.33b). A serum response was observed in NF 
and CWF with a greater level of stimulation in the CWF. The same expression pattern 
was observed in patient K (Fig 5.34) with CWF expression higher than NF at all time 
points (except 24 hours post serum stimulation) at the early point in culture (Fig 
5.34a).
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Figure 5.32: Graphs showing relative gene expression levels for THUMPD2 in Patient H at Early (a) Mid (b) and Late (c) time point in
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and
6  hours after stimulation is shown for comparison (d)
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Figure 5.33: Graphs showing relative gene expression levels for THUMPD2 in Patient I at Early (a) Mid (b) and Late (c) time point in
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and
6  hours after stimulation is shown for comparison (d)
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Figure 5.34: Graphs showing relative gene expression levels for THUMPD2 in Patient K at Early (a) Mid (b) and Late (c) time point in
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and
6  hours after stimulation is shown for comparison (d)
5.2.17 Transmembrane 4 L Six Family Member 1, TM4SF1
The relative gene expression levels for TM4SF1 are shown separately for each 
patient. Patient H (Fig 5.35), patient I (Fig 5.36) and patient K (Fig 5.37) with each 
time point in culture separately represented as Early (a) Mid (b) and Late (c) as well 
as relevant microarray data (d). TM4SF1 was identified as a serum response gene by 
microarray analysis however, it was identified as being up in NF in response to serum 
in one patient and up in CWF in response to serum in the other two patients. 
Microarray analysis of gene expression in patient H (Fig 5.35d) showed an up 
regulation of TM4SF1 with serum after 6 hours in NF but not in the patient matched 
CWF. The QRT-PCR data showed the same up regulation of gene expression in NF 
after 6 hours at the mid (Fig 5.35b) and late (Fig 5.35c) time points in culture and 
after 24 hours at the early time point in culture (Fig 5.35a). In patient I TM4SF1 was 
identified as a serum response gene but up in CWF in response to serum (Fig 5.36d). 
QRT-PCR identified the same serum response at the early time point in culture (Fig 
5.36a) however in the mid (Fig 5.36b) and late (Fig 5.36c) time points in culture the 
serum response was not observed until 24 hours after stimulation. Microarray analysis 
demonstrated a mixed pattern in patient K with TM4SF1 up-regulated in CWF at one 
time point in culture in response to serum and up in NF at another time point in 
culture (Fig 5.37d). This mixed pattern was observed in the QRT-PCR data. At the 
early point in culture (Fig 5.37a) CWF expression was greater than NF at 0, 1 and 6 
hours after serum stimulation. At the mid point in culture (Fig 5.37b) NF expression 
was greater than CWF at 0, 1 and 6 hours after serum stimulation. At the late point in 
culture (Fig 5.37c) NF expression was greater than CWF at all time points. For patient 
K the QRT-PCR data confirmed the changes in expression observed by microarray, 
with no clear pattern discemable.
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Figure 5.35: Graphs showing relative gene expression levels for TM4SF1 in Patient H at Early (a) Mid (b) and Late (c) time point in
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and
6  hours after stimulation is shown for comparison (d)
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Figure 5.36: Graphs showing relative gene expression levels for TM4SF1 in Patient I at Early (a) Mid (b) and Late (c) time point in
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and
6  hours after stimulation is shown for comparison (d)
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Figure 5.37: Graphs showing relative gene expression levels for TM4SF1 in Patient K at Early (a) Mid (b) and Late (c) time point in
culture in NF (■) and CWF (■) at 0, 1,6 and 24 hours after serum stimulation. Microarray data for each time point at 0 and
6 hours after stimulation is shown for comparison (d)
5.2.18 Trends observed in Microarray and qRT-PCR analysis
The QRT-PCR data did not match exactly to the microarray data obtained in the 
previous chapter. There were however, similar trends observed in the QRT-PCR data 
that were also observed in the array data (Table 5.1). Some of the trends were patient 
specific with little clear agreement between the QRT-PCR and microarray data when 
all three patients were pooled; genes such as ID1 and TM4SF1 showed clear trends in 
patient I but were less obvious in the other two patients. Overall the QRT-PCR data 
demonstrated some agreement with the microarray data previously obtained with the 
general trend across all three time points in culture agreeing with the array data. The 
gene expression changes observed in the selected disease marker genes were also 
observed in the QRT-PCR data.
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Gene Name Microarray Data qRT-PCR
ACTC Down in CWF Down in CWF
CD9 Up in CWF Up in CWF
CXCL1 Down in CWF (serum response) Down in CWF (serum response)
CXCL12 Down in CWF (serum response) Down in CWF (serum response)
GALNAC4S Up in CWF (serum response) Up in CWF (serum response)
ID1 Down in CWF (serum response) Patient dependant, down in CWF 
(serum response)
IGSF4 Up in CWF Up in CWF
IL11 Up in CWF (serum response) Up in CWF (serum response)
MMP3 Down in CWF Down in CWF
THUMPD2 Up in CWF (serum response) Up in CWF (serum response)
TM4SF1 Up in CWF (serum response) Patient dependant
^Table 5.1: Table showing gene expression trends identified by microarray analysis and qRT-PCR with percentage agreement between the two
techniques.
5.3 Discussion
In this Chapter the gene expression profiles for a set of genes identified by microarray 
analysis as being differentially regulated between CWF and NF (Chapter 4) were 
further analysed by qRT-PCR. This was done firstly to validate the microarray 
analysis carried out and secondly to generate a more detailed serum stimulation 
profile for each gene of interest. If the gene expression changes observed by 
microarray analysis can be validated then the potential role these genes play in 
chronic wounds can be explored.
Variations were observed between the three patients with respect to gene expression 
for each gene under investigation. During the microarray analysis the patients were 
analysed separately, allowing the identification of gene expression changes between 
CWF and NF unique to that patient. The patients were also pooled giving an overall 
view of the changes in gene expression levels between CWF and NF. In a similar way 
the different time points in culture did not always show the same trends in gene 
expression often with a reduction of gene expression over extended periods in culture, 
although without an obvious change in the pattern of expression. The reduction of 
gene expression was not uniform across all genes identified. MMP3 in patient I 
showed dramatic reductions in relative expression levels over time in culture but other 
genes did not. No references to this phenomenon have been identified through 
literature searches.
The genes studied in this chapter were not selected specifically for their known links 
to wound healing or chronic wounds. They were selected through manual curation of 
microarray derived gene lists, developed MADRAS thus allowing the expression 
levels for each gene to be observed. The genes selected were chosen because of the 
large changes of expression between NF and CWF and the maintenance of these
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expression changes over time in culture as well as between patients. The large 
changes in expression level for the genes selected suggest a potential use as part of a 
reporter assay. Interactions between the genes selected have been identified (Fig 
4.21) as well as interactions with known wound healing genes such as TNFa. Most of 
the genes selected have been previously characterised and potential links with wound 
healing and the chronic wound phenotype are discussed below.
5.3.1 Genes validated as being up in CWF by QRT-PCR
Two genes were identified as having an increased expression in CWF compared to the 
patient matched NF independent of serum stimulation. These genes were always over­
expressed in CWF.
CD9 is also known as: BA2, BTCC-1, DRAP-27, GIG2, MIC3, MRP-1, P24 and 
TSPAN29. CD9 is a member of the transmembrane-4 superfamily of cell surface 
molecules and is thought to be involved in cell migration and adhesion. CD9 
expression is higher in CWF compared to NF. CD9 has been over-expressed in a 
range of cell types with all of the cells showed suppressed cell motility (Miyake et al., 
1995). In melanoma BL6 cells CD9 expression suppresses metastatic potential (Zheng 
et al., 2005). CD9 expression in OS3-R5 cells caused suppression of the liver 
metastasis (Huang et al., 2006) this effect was thought to be due to inhibition of cell 
proliferation and motility. CD9 overexpression effects cell motility, a possible 
mechanism for this is via the Wnt-independent signal pathway (Watabe et al., 2003). 
CD9 regulates the actin cytoskeleton through a down-regualation of WAVE2. In 
relation to thisCWF cells have been shown to have a reduced proliferation rate 
compared to patient matched NF as well as reduced motility (Chapter 3). This
233
reduction in proliferation and migration could be partially caused by the increased 
expression of CD9 observed in the CWF.
IGSF4 Immunoglobulin Superfamily, Member 4 is also known as BL2, 
DKFZp686F 1789, IGSF4A, NECL2, ST17, SYNCAM, TSLC1 and sTSLC-1. Many 
roles for IGSF4 have been identified (Biederer et al., 2002). IGSF4 was identified as a 
cell adhesion molecule found at the synapse and thought to be brain specific (Ito and 
Oonuma, 2006). IGSF4 was shown to be the adhesion molecule involved in mast cell 
interactions with nerve cells, IGSF4 was shown to bind homophilically with both 
mast cells and neurons expression the protein (Trabucchi et al., 1988, Martin and 
Leibovich, 2005). Mast cells play an important role in wound healing possibly 
contributing to the early response to wounding and play a role in the inflammatory 
reaction as well as angiogenesis (Kuramochi et al., 2001, Masuda et al., 2005). IGSF4 
has been identified as a tumor suppressor gene in non small cell lung cancer with high 
levels of IGSF4 expression leading to tumor suppression (Laurent K. Verkoczy, 
1998). IGSF4 may therefore play a number of roles within the chronic wound 
environment, its over-expression may be responsible for the inhibition of cell 
proliferation as observed in tumor cells. Over-expression of IGSF4 may also maintain 
the mast cell population in the wound longer than normal adding to the prolonged 
inflammatory phase.
5.3.2 Genes validated as being up in CWF (Serum response) by QRT-PCR
Four genes were identified as having an increased response to serum stimulation in 
CWF compared to patient matched NF. In the model for wound healing used in this 
experiment these genes were over-expressed altering the CWF wounding response.
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GALNAC4S-6ST B Cell RAG Associated Protein is also known as BRAG, N- 
Acetylgalactosamine 4-Sulfate 6-O-Sulfotransferase, DKFZp781H1369, KIAA0598 
and MGC34346. GALNAC4S-6ST is a membrane-integrated glycoprotein expressed 
in B cells (Ohtake et al., 2001). GALNAC4S-6ST has been shown to have 
sulfotransferase activity (Ito and Habuchi, 2000) GALNAC and to transfer sulfate to 
chondroitin sulfate A and dermatan sulfate (Paul et al., 1990). The sulfation of 
chondroitin sulfate alters the biological function of the glycosaminoglycan. No role 
for GALNAC in the skin has been identified however, glycosaminoglycans are 
important in the ECM of the skin and GALNAC may play a role in the modification 
of the ECM generated by the dermal fibroblasts. The increases expression of 
GALNAC in CWF in response to serum may lead to modifications of the ECM not 
observed in normal skin.
IL11 is a member of the gpl30 family of cytokines characterized by containing 
transmembrane signalling receptor IL6ST (gpl30). IL11 has been shown to play a 
role in the development of B cells, specifically the development of immunoglobulin- 
producing B cells (Schinkel et al., 2005). IL11 has been identified as being up- 
regulated after trauma in patients (Du et al., 1997) and has been shown to have a 
protective effect in animal models of ischemic bowel necrosis (Du et al., 1994) and 
after combination radiation/chemotherapy (Takeuchi et al., 2002). IL11 has also been 
identified as having a role in bone formation, enhancing the effect of bone 
morphogenetic protein (Ameglio et al., 1997). Under normal conditions IL11 appears 
to have a positive effect on bone and on wound healing. Aberrant expression of IL11 
has been observed in psoriatic lesions of the skin and after total hip replacement 
surgery (Ameglio et al., 1997). In the psoriatic lesions of the skin IL11 was found to 
be present at significantly higher levels than non lesion skin (Xu et al., 1998) possibly
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playing a role in the disease. In total hip replacements a significantly higher number 
IL11 expressing cells were found compared to control tissue. IL11 expression was 
hypothesized to play a role in periprosthetic osteolysis the loss of bone in the vicinity 
of the implant (Marchler-Bauer et al., 2007). IL11 over-expression has been observed 
at sites of inflammation, in the skin and bone. The increased expression of IL11 
observed in CWF may play a role in the extended inflammatory phase observed in 
chronic wounds.
THUMPD2 is also known C2orf8 and MGC2454. THUMPD2 is named after the 
THUMP domain which it contains. The THUMP domain is predicted to be a RNA- 
binding domain with a structure similar to the C-terminal domain of translation 
initiation factor 3 and ribosomal protein S8. No actual function has been determined 
for THUMPD2 however, the THUMP domain is thought to aid in the modification of 
RNA through delivery of RNA modifying enzymes (Zhang et al., 2001). THUMPD2 
was identified as a methyltransferase gene linked to hereditary gingival fibromatosis 
with (Farrer-Brown et al., 1972, Bozzo et al., 1994, Araujo et al., 2003). Gingival 
fibromatosis can be characterized by gingival enlargement, because of an increase in 
the amount of connective tissue. The enlargement is due to fibrosis with densely 
arranged collagen bundles poorly vascularised connective tissue and a increase in the 
fibroblast population. In some cases mucosal ulceration and inflammation have been 
observed (Maecker et al., 1997). If gingival fibrosis is caused by aberrant expression 
of THUMPD2 as suggested by Zhand et al then the increased expression observed in 
CWF could be having an effect on the ECM deposition in chronic wounds. 
Transmembrane 4 L Six Family Member 1 is also known as TM4SF1, H-L6, L6, 
M3 SI and TAAL6. TM4SF1 is a member of the transmembrane 4 superfamily, also 
known as the tetraspanin family. This family of proteins are cell surface proteins
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known to play a role in the regulation of cell development, activation, growth and 
motility (Marken et al., 1992). The TM4SF1 protein is a cell surface antigen and is 
highly expressed in different carcinomas including lung, breast, colonic and ovarian 
carcinomas (Kao et al., 2003). Over-expression of TM4SF1 in lung carcinoma cells 
increases their invasiveness (Storim et al., 2001). In human epidermal keratinocytes 
TM4SF1 is expressed after proteolytic detachment of the cells. The expression of 
TM4SF1 is increased after wounding in an in vitro keratinocyte wound model. 
Inhibition of TM4SF1 by antibodies reduces cell motility (Wysocki et al., 1993b). 
The increased expression of TM4SF1 has been linked to carcinoma invasiveness as 
well as keratinocyte motility and wound responses. The increased expression of 
TM4SF1 in CWF observed in a number of patients could be linked with the increased 
levels of MMPs observed in chronic wounds (Halbersztadt et al., 2006, Deryugina 
and Quigley, 2006). Increased MMP level is linked to invasiveness in carcinomas 
(Mogensen et al., 1999). TM4SF1 may play a role in generating the altered wound 
environment observed in chronic wounds and leading to the delay in the generation of 
extracellular matrix.
5.3.3 Genes validated as being down in CWF by QRT-PCR
Two of the genes studied in this chapter were observed to have a reduced expression 
in CWF, this was independent of serum stimulation suggesting that the genes are 
permanently down-regulated in CWF.
ACTC is a member of the actin family of proteins, actins are a major constituent of 
the microfilaments of the cytoskeleton of eukaryotic cells. Alpha actins are normally 
observed in muscle tissues, in these tissues they are a major constituent of the 
contractile apparatus. Defects in ACTC have been linked with familial hypertrophic
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cardiomyopathy (Hinz et al., 2003). Another isoform of apha actin, alpha smooth 
muscle actin is known to be important in wound healing, (Chaponnier and Gabbiani, 
2004, Hinz et al., 2001) specifically in myofibroblast contraction. ACTC does not 
show the same contractile ability as alpha smooth muscle actin (Cooper et al., 2004) 
however, ACTC was identified as an inflammation independent ‘activation’ gene 
activated by wounding in mouse skin (Chin et al., 1985, Wilhelm et al., 1987). While 
this mouse wounding experiment suggests a role for ACTC in wound healing it does 
not describe how ACTC is involved. ACTC gene expression was down-regulated in 
CWF compared to patient matched NF, as chronic wounds have impaired wound 
healing this may be further evidence for the importance of ACTC in the wound 
healing response.
MMP3 is also known as, Stromelysin 1, SL-1, STMY, STMY1, STR1 and 
TRANSIN. MMP3 is a proteoglycanase expressed in human fibroblasts, it is closely 
related to collagenase (MMP1) and is able to act on a number of different substrates. 
MMP3 is able to degrade proteoglycan, fibronectin, laminin, and type IV collagen 
(Madlener, 1998). MMP3 is normally expressed in acute wounds within 24 hours of 
wounding (Li et al., 2004). Studies of wound healing in the intestinal mucosa in a 
MMP3 KO mouse showed that tissue remodeling and wound healing were possible 
without the presence of MMP3. The mice did however, exhibit a delayed clearance of 
bacteria from the wound site (Bullard et al., 1999a). Skin wounds in MMP3 KO mice 
showed a failure of wound contraction in excisional wounds as well as delayed 
healing compared to wild type controls (Bullard et al., 1999b). Collagen gel 
reorganisation in MMP3 KO fibroblasts is significantly reduced compared to wild 
type controls (Saarialho-Kere et al., 1994). MMP3 expression was observed in 
keratinocytes at the edge of chronic wounds as well as in the dermis immediately
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beneath and to the sides of the wound (Iyer et al., 1999). Initially the reduced 
expression of MMP3 in CWF reported in this Chapter does not agree with the 
observed MMP3 expression in the dermis of chronic wounds. However, the paper 
describing the expression of MMP3 in the dermis of chronic wounds does not 
quantify the levels of expression. The paper does not demonstrate that MMP3 is not 
expressed in the dermis of acute wounds. The QRT-PCR data shown in this Chapter 
and the microarray data shown in Chapter 4 demonstrate expression of MMP3 in both 
NF and CWF cells. The level of expression in CWF is however, reduced in 
comparison to patient matched NF. The MMP3 KO mouse model suggests that if 
CWF fibroblasts have reduced MMP3 expression as indicated by this data they would 
demonstrate a reduced ability to remodel and contract the wound. The data presented 
in this Chapter suggests that the role of MMP3 in chronic wound healing may warrant 
further investigation.
5.3.4 Genes validated as being down in CWF (serum response) by QRT-PCR
Three of the genes investigated in this Chapter were serum response genes whose 
induction by serum stimulation was decreased in CWF. The serum response in this 
experiment attempts to model wounding of the skin (Devalaraja et al., 2000). These 
genes potentially represent a loss of function in the CWF in response to wounding. 
CXCL1 is also known as: GROl, GROa, MGS A, MGS A alpha, MGSA-a, NAP-3 and 
SCYB1. CXCL1 is a member of the CXC family of chemokines. CXCL1 signals 
through the receptor CXCR2, this receptor has been knocked out in mice (Nanney et 
al., 1995) and wounding experiments carried out. Delayed wound healing was 
observed in the KO mice compared to controls with delayed epithelialisation and 
decreased neovascularisation. Analysis of the wounds for inflammatory cells
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identified defective neutrophil recruitment in the KO mice as well as an altered 
temporal pattern of monocyte recruitment. CXCL1 expression has been observed in 
human bum wounds with a potential role as an important cytokine involved in the 
inflammatory and proliferative phases of cutaneous wound repair. (Engelhardt et al., 
1998). In cutaneous wound healing the expression of CXCL1 is directly linked to 
neutrophil infiltration (Smith et al., 2005). CXCL1 also has a role in monocyte 
recruitment (Bleul et al., 1996b) mediating monocyte arrest, one of the earliest steps in 
monocyte recruitment. CXCL1 plays an important role in the recruitment of 
inflammatory cells to the wound area in normal wound healing. The reduced 
expression of CXCL1 observed in CWF compared to NF in this Chapter may play a 
role in the failure of chronic wounds to escape the inflammatory phase of wound 
healing.
CXCL12 is also known as: PBSF, SCYB12, SDF-la, SDF-lb, SDF1, SDF1A, 
SDF1B, TLSF-a, TLSF-b and TPAR1. CXCL12 is a small cytokine, a member of the 
intercrine family of cytokines. These cytokines are known to activate leukocytes after 
induction by pro-inflammatory stimuli. CXCL12 has chemotactic properties, acting 
on lymphocytes and monocytes but not neutrophils (Florin et al., 2005). In the skin 
CXCL12 from skin fibroblasts has been shown to promote keratinocyte proliferation 
(Norton, 2000). In this chapter CXCL12 gene expression was shown to be down in 
CWF compared to patient matched NF. CXCL12 is able to recruit lymphocytes and 
monocytes to the wound site and promote keratinocyte proliferation; the reduced 
expression in CWF could explain the failure of chronic wounds to escape the 
inflammatory phase of wound healing and their failure to reepithelialise.
ID1 is a member of the ID family of helix-loop-helix motif containing protein known 
to regulate tissue-specific transcription through the binding of basic helix-loop-helix
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containing transcription factors. ID proteins have roles in cell cycle progression, cell 
proliferation and are thought to have a role in tumour growth and metastasis (Hara et 
al., 1994). ID1 is expressed transiently in human fibroblasts with expression highest G 
phase of the cell cycle, quiescent cells do not express ID1. Upon serum stimulation 
early passage fibroblast show an induction of ID1 expression, this induction of 
expression is reduced in senescent cells (Nickoloff et al., 2000). ID1 has the ability to 
delay senescence in keratinocytes (Alani et al., 2001). The observed inhibition of 
senescence has been shown to be through direct repression of the tumor-suppressor 
protein p l6Ink4a (Ding et al., 2006). In bladder cancer ID1 was shown to be up- 
regulated, ID1 was suggested as a therapeutic target as a reduction of expression 
appeared to inhibit the invasive phenotype (Volpert et al., 2002). ID1 null mice have 
been generated, they have defects in angiogenesis (Thompson et al., 1993). ID1 
expression has been shown to be lower in senescent cells in response to serum 
stimulation. The expression of ID1 expression is lower in CWF in response to serum 
than patient matched NF, this may indicate that CWF even after immortalisation have 
characteristics of senescent cells. The impaired angiogenesis observed in ID1 null 
mice could also be important, since angiogenesis is a crucial step in wound healing.
In conclusion, this Chapter has attempted to show the data obtained from a qRT-PCR 
study of gene expression in CWF compared with patient-matched NF. This data has 
validated the changes in gene expression observed by microarray analysis. 
Importantly the data has added to the microarray data obtained previously with the 
extra data points giving a more complete picture of gene expression changes between 
CWF and NF. Further study of this reduced set of disease marker genes has identified 
potential roles for the genes within the chronic wound. Trends in gene expression
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have been validated for each of the genes identified by microarray analysis. Therefore 
all the genes validated in this chapter will be taken on for the generation of reporter 
constructs. From the 3 patients studied Patient I showed the most consistent 
maintenance of gene expression profile across the different time points in culture. 
Cells from patient I will therefore be used in the generation of reporter cell lines.
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Chapter Six
Generation and Testing
of
Chronic Wound 
Reporter Constructs
6.1 Introduction
To measure changes in gene expression in real time it is possible to link cis-acting 
sequences from genes of interest to the coding sequence of a reporter gene. A reporter 
gene can be defined as any gene whose transcribed protein may be detected. There are 
a number of different commonly used reporter genes some of which are described 
below. There are two main categories of reporter constructs giving different levels of 
information about the expression of the gene under examination. Transcriptional 
reporters are made from the promoter region of the gene under investigation driving 
the expression of the reporter gene. The promoter region normally consists of 
approximately 2Kb of DNA upstream of the transcriptional start site, this region 
contains enough gene specific regulatory sequences to give a reliable expression 
pattern for the gene of interest. Translational reporters are gene fusions between the 
reporter and the gene of interest. A translational reporter should contain the entire 
genomic locus of the gene of interest, this includes 5’upstream regions, introns, exons 
and 3’ untranslated regions. The reporter is inserted anywhere in the open reading 
frame where it will not disrupt the function of the protein.
To make a good reporter, the protein should not be normally present in the host, or 
easily distinguishable from host proteins. The detection of the reporter should be both 
rapid and sensitive so small short lived changes in gene expression can be detected. 
Ideally the assay for detecting the reporter should cover a wide range of reporter 
levels so both small and large changes can be detected with the same system. Most 
importantly the presence and expression of the reporter gene must not alter the 
phenotype of the host. Reporter constructs fall into two groups; in vitro assays such 
as CAT (de Wet et al., 1987), Luciferase (Fowler et al., 1970), p-Galactosidase 
(Berger et al., 1988) and Secreted Alkaline Phosphatase (Nolan et al., 1988) and in
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vivo assays such as P-Galactosidase (Shimomura et al., 1962) and fluorescent proteins 
(Arhondakis et al., 2008). In vitro reporter assays require the detection of the reporter 
in cell / tissue lysates or culture medium when the reporter protein is secreted. In 
vitro assays are quantitative and reproducible but are not able to give results in real 
time. In vivo Reporter Assays allow the detection of the reporter in live cells or tissue 
usually through fluorescence. In vivo Reporter Assays are less quantitative than in 
vitro reporter based systems however, analysis from living cells allows observation of 
dynamic changes in gene expression in real time. As well as giving real time data on 
gene expression in vivo systems allow for the same cells or tissue to be used in 
repeated experiments as there is no requirement for cell lysis.
For this Chapter the aim was to generate reporter cell lines using both NF and CWF 
able to quantifiably determine real time changes in gene expression over extended 
time in culture. For this to work the cells must not be lysed as this would only give a 
fixed timepoint reading of gene expression. A fluorescence based reporter was chosen 
as this should allow the quantification of gene expression in living cells.
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6.2 Results
6.2.1 Identification of Promoter regions
Promoter regions for each of the genes of interest were identified by bioinformations 
at the Babraham Institute using the Database of Transcriptional Start Sites (DBTSS 
http://dbtss.hgc.ipA). The DBTSS is a comprehensive database containing sequence 
information for most of the genes identified in the human genome, this data includes 
transcriptional start sites (TSS) and the regions upstream of the TSS. Information 
about known promoter regions identified experimentally is available as well as 
hypothetical transcription factor binding sites and enhancer regions. A region of 2Kb 
upstream of the TSS for each gene was identified as the most likely promoter region. 
Full sequences can be found in Appendix 1.
6.2.2 Design of promoter amplification primers
For each gene of interest a segment that extended from 2450bp upstream to 300bp 
downstream of the TSS was identified from the DBTSS and added to the primer3 
primer design software (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3 www results.cgiV The selected region was masked for human 
repeats and a region (between 500bp and 2000bp upstream of the TSS) was delimited 
within which primers were not selected as this contained the desired promoter region. 
The product range was set to 2000-23OObp and a primer length of between 28 and 30. 
The Tm was set to 66-70 with a maximum difference of 1 degree. Primers were 
identified for each gene of interest (Table 6.1).
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Gene Name Primer start position Product Length Sequence
ACTC Left primer 457 2237 AATCAACCTGATTCTTTAAAAGGCAGAGC
ACTC Right primer -1780 2237 CCC AGGACAAAACAAGTT AGAACCAAAT C
CD9 Left primer 452 2153 GCCTT CATT CATTCTT CT CT CACCT G AAC
CD9 Right primer -1701 2153 GTTAAAT C C G AAC AG C AG GT ATTT G ATG C
CXCL1 Left primer 440 2288 T CAGGAAGAT GT G AAAAGAGAAAT AATT GA
CXCL1 Right primer -1848 2288 CCT AGGGAAG AAGAGACT CACT GACT G
CXCL12 Left primer 473 2261 CAGCGGCCAGGCCTGAATCCCTGGTT
CXCL12 Right primer -1791 2261 T AAGCGAGCT GCCT CC ACCCCC ACT GT GT
GALNAC4S-6ST Left primer 448 2144 GTAT AAAT ACCTTT GGAAAGTCCCT GGTG
GALNAC4S-6ST Right primer -1969 2144 ACCT AACTT GT ACCT GAGAAGCCT GAGT C
ID1 Left primer 298 2252 GTCGT GT GGAGCCT C AGTTT CCTTT GT AT
ID1 Right primer -1954 2252 GATT CTT GGCG ACT GGCT G AAAC AGAAT
IGSF4 Left primer 304 2492 AGGATT CTTGCC AT AT AGG ACCT GCCTTT
IGSF4 Right primer -2188 2492 CT C AGCCCT GAGTTTCCT CTCCAC ACT
IL11 Left primer 111 2494 GAGAGAGAGCT CTT ACCT GAGGCGAT G
IL11 Right primer -2383 2494 AACC AACTT ACAGTT CAT GT CCCCACAG
MMP3 Left primer 389 2298 AAAAT AGAGT AGCAGAGGC AGGTACAAGG
MMP3 Right primer -1909 2298 AAGACACACAGAATGGTTT CAGCTT ACT C
THUMPD2 Left primer 342 2219 AAACAAG AGTAGCCCCGACCTT GCT GACC
THUMPD2 Right primer -1877 2219 CACCTCTCGCATTACGAACGGCTCCAG
TM4SF1 Left primer 1 1868 GTAGTTTAAGCATCACTTTCCCCCATTT
TM4SF1 Right primer -1868 1868 CTTCT CTTT GTCTT CAGCT C AGT GAT ACC
j GAPDH Left primer 391 2347 ACT CGT GTT CCCTAAT CCCAT CT CCAAAG
J GAPDH Right primer -1956 2347 GGAGGGAGAGAACAGTGAGCGCCTAGT
Table 6.1: Table showing primer sequences, primer position relative to the transcriptional start site of each gene and the product size.
6.2.3 Amplification of Promoter regions
Genomic DNA from Patient I CWF was used a template for PCR amplification of the 
promoter regions of each gene of interest, with lOOng used in each reaction. 
Polymerase Expand HiFi was chosen for its proof reading ability as well as the single 
A overhang left at the 3’ end of the product removing the need for a second A-tailing 
reaction. Products were visualized on a 0.8% Agarose BE gel with the Invitrogen 
1Kb ladder used for sizing (Fig 6.1). Bands of approximately 2400bp (see Table 6.1 
for sizes) were observed for ACTC, CXCL12, ID1, THUMPD2, GAPDH, 
GALNAC4S and TM4SF1 (Fig 6.1). Single bands were not seen in these reactions as 
the amplification from genomic DNA required sub optimum annealing temperatures 
and long extension times. Despite repeated attempts and alteration to the PCR 
conditions strong bands of the correct size were not observed for CD9, CXCL1, 
IGSF4, IL11 and MMP3 (Fig 6.1) and so these genes were not taken forward for 
further analysis. Bands of the correct size were excised from the gel and recovered 
using a gel extraction kit eluting in ddF^O.
6.2.4 Recovery into pGEM-T
The amplified promoter regions were recovered into pGEM-T allowing amplification 
and analysis of the fragments. The pGEM-T vector is shipped linearised after 
restriction digestion with EcoR V, the linearisation leaves a single 3’ thymine 
overhang preventing re-circularisation of the plasmid (Fig 6.2a). The enzyme used to 
amplify the promoter regions was a proofreading polymerase but unlike most 
proofreading polymerases it leaves a single 3’ adenine overhang at each end of the 
product (Fig 6.2c). The PCR product and linearised pGEM-T vector were incubated 
together with a DNA ligase and the complementary 3’ overhanging bases allowed
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Figure 6.1: Long range PCR amplification of 11 genes of interest and GAPDH from genomic
DNA isolated from Patient I CWF.
249
pGEM®-T
Vector
PCR Product
Xmnl 1994
Seal
1 8 7 5 X
Nael
2692
f1 ori
Apal 
Aatll 
Sphl 
BstZI 
Ncol 
Sac 1
lacZ
Insert
ori
lacZ
Recovered DNA
Spel
Notl
BstZI
Pstl
Sail
Ndel
Sac I
BstXI
Nsil
T 3P6
Figure 6.2: Schematic representation of the recovery of PCR products into pGEM-t plasmid, a)
pGEM-T plasmid restriction digested gives a single 3’ T overhangs preventing re- 
circularisation of the plasmid, the lacZ gene is disrupted by the digest, b) PCR 
product has single 3’ A overhangs at each end. c)T4 DNA Ligase is used to ligate the 
PCR product and the digested plasmid generating a complete plasmid, insertion of the 
PCR product disrupts the lacZ gene. (Images adapted from www.promega^^gm/tbs/)
successful ligation of the amplified promoter region into the vector generating a new 
plasmid. The orientation of insertion is random. Each of the ligation mixtures was 
transformed into chemically competent E.coli DH5a by heat shock and the bacteria 
plated onto selective agar containing p-galctosidase as well as ampicillin. The vector 
pGEM-T contains an ampicillin resistance cassette, only transformed E. coli 
containing the vector will be able to grow on the ampicillin selection plate. Insertion 
of DNA into the plasmid allowing it to recircularise and in so doing disrupts the LacZ 
gene which spans the site of insertion. Any plasmid without an insert will give blue 
colonies when transformed into bacteria and grown on P-galctosidase containing agar 
plates, any colonies containing an insert will be white.
6.2.5 Restriction maps of pGEM-T-Promoter plasmids
Each transformation produced over 100 white colonies indicating the presence of an 
insert. A method for screening the colonies prior to sequencing was therefore 
required. For each promoter region amplified and recovered into pGEM-T a 
restriction map was generated using VectorNTI as well as for the empty pGEM-T 
vector (Fig 6.3). The restriction maps allowed the identification of restriction sites 
only present in the desired DNA insert and not present in pGEM-T.
6.2.6 Screening transformed colonies by Restriction Digest
Initial screening was carried out on 9-10 colonies from each transformation, all 
colonies were negative for LacZ activity and were therefore white. Colonies were 
selected and grown overnight in LB media containing ampicillin. Plasmid preps were 
carried out and plasmid DNA analysed by UV spectroscophy to determine DNA 
concentration. Restriction digests were carried out on each colony with specific
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Figure 6.3: Restriction maps for pGEM-T (a) and all succesfully amplified promoter
regions (b). Restriction sites for ApaLI, Aval, BamHI, Clal, EcoRI, Hindlll, 
Ncol, PstI, Sacl, Smal and Xmal are shown. Generated in Vector NTI 
(Invitrogen)
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restriction enzymes for each insert. A virtual restriction digest was run for each insert 
using VectorNTI with the potential insert in both possible orientations (Fig 6.4a). 
Comparison between the actual restriction gel (Fig 6.4b) and the virtual digest 
allowed the identification of successful inserts and the direction of the inserted 
promoter DNA.
6.2.7 Sequencing pGEM-T promoter plasmids
To confirm the identity and orientation of the recovered DNA the plasmids confirmed 
to contain inserts by restriction digest (Fig 6.4) were sequenced. Sequencing was 
carried out by Cogenics Lark Inc (http://www.cogenics.com) a commercial 
sequencing company using T7 and SP6 sequencing primers (Fig 6.5a). Sequence data 
of up to 1Kb was obtained for each plasmid. To confirm sequence identity and 
orientation, Vector NTI (www.invitrogen.com) was used to align the T7 and SP6 
sequences with the known sequence of the promoter (Fig 6.5b). GALNAC has been 
used as an example as it was the only recovered promoter sequence that was present 
in both orientations. Sequencing was carried out for each of the plasmids generated 
by blunt end ligation into pGEM-T. At least one clone was found to contain a 
complete promoter sequence for the following genes; ACTC, CXCL12, GALNAC4S, 
GAPDH, ID1, THUMPD2 and TM4SF1. For each of the plasmids a plasmid map 
was generated using VectorNTI (Fig 6.5c), the maps included any restriction sites.
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Figure 6.5: Confirmation of insert identity by sequencing a) Sequence analysis using T7 ■
and SP6  ■ primers allows sequencing of the recovered DNA. b) sequences were 
aligned with the known promoter sequence and contigs generated using Vector 
NTI. The two different orientations of GALNAC promoter are shown here, c) 
Plasmid maps for each sequenced plasmid were generated using Vector NTI.
6.2.8 Generation of the final reporter constructs
The recovered promoter regions included transcription start sites for the original genes 
of interest. If the promoters were inserted with these intact the reporter protein would 
not be produced. For the reporter construct to work the promoter sequence must be 
upstream from the reporter proteins own transcription start site with no other 
transcription start sites present. The recovery vector pGEM-T did not have the correct 
restriction sites in all cases for digestion and ligation into the destination vector. To 
overcome these problems primers were designed specificaly to each recovered 
promoter region but including a non-complementary sequence at the 5’ end (Fig 6.6 
a). The non-complementary sequence contained restriction sites (Table 6.2). The 
restriction sites were ones not found within the promoter region and that would allow 
ligation into the multiple cloning site (MCS) of the destination vector.
PCR was carried out using these primers and the products seperated on an agarose gel 
to identify the fragment of the correct size (Fig 6.6b). The corresponding fragment 
was excised and purified. Restriction enzymes were used to digest the destination 
plasmid pZsGreen as well as the purified PCR products and DNA ligase used to ligate 
the fragment together. Each of the ligation mixtures was transformed into chemically 
competent E.coli DH5a by heat shock and the bacteria plated onto selective agar 
containing Kanamycin to select for positive transformations. Colonies were selected 
and overnight cultures grown. Purified plasmids were generated from 5ml of 
overnight culture. As before restriction digests were used to screen selected colonies 
(Fig 6.6c). Completed reporter constructs were succesfiilly generated for ID1, 
TM4SF1 and GAPDH.
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Gene Name Restriction Enzyme Seq
ACTC 3' SP6 primer/ Sacl ATTTAGGTGACACTATAG
ACTC 5’ Kpnl CTAGccatggGCC I IGGCTGAATGC
CXCL12 3' EcoRI GAT CgaattcAGGCCT GAATCCCT GGTT CG
CXCL12 5' BamHI CT AGggatccGCAAT GCGGCT GAC
ID1 3’ Xhol GAT CctcgagGTCGT GT GG AGCCT CAG
ID1 5' BamHI CTAGggatccACGTGG AAT G AGAGTGC
THUMPD2 3' Xhol GAT CctcgagCAAGAGT AGCCCCGACCTT G
THUMPD2 5’ BamHI CT AGggatccACCCGCAGT GCAG AAGAAT C
TM4SF1 3' EcoRI GATCgaattcATAGATCAGCAGACAGGAG
TM4SF1 5' BamHI CTAGggatccATT AGAT GAAAGT GT GC
GAPDH 3' EcoRI GATCgaattcGAAG I ICAGATCATG
GAPDH 5' Kpnl CT AGccatggCGT CTT C ACCT GGCGACGC
Table 6.2: Table showing primer sequences for introduction of restriction sites and the restriction site to be included in the product. Restriction
sites are shown in red, linker DNA in blue. ACTC 3’ primer is for the SP6 sequencing primer as the Sacl restriction site lies between 
the SP6 primer and the promoter region.
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Figure 6.6: a) Primers designed to amplify promoter regions have non-complementary 
sequences at the tail encoding restriction sites, b) PCR amplification of promoter 
regions from pGEM-T recovery vector introducing restriction sites at either end. 
Successful products were seen for TM4SF1, GAPDH, ID1 and THUMPD2 
(ringed). c)Restriction digests to screen potential vectors for the correct size inserts 
identified positive colonies for TM4SF1, ID1 and GAPDH.
6.2.9 Transfection and Testing of completed constructs
In order to test expression of the constructs in human fibroblasts each of the three 
completed^ reporter constructs were transfected into patient I CWF and NF 
immortalised cell lines described in Chapter 3. Transient transfections were carried 
out using GeneJuice™ with 0.4pg of purified plasmid used per well in a six well 
plate. Cells were fixed and counterstained with Hoescht nuclear stain and imaged 
using a Leica SP5 confocal laser scanning microscope. Images were captured for 
DAPI and ZsGreen fluorescence and the images merged using LAS AF software (Fig 
6.7). Green fluorescence was observed in NF and CWF for each of the three plamids 
tested. As no selection was used not all cells present were expressing ZsGreen 
however, the promoters for each of the genes of interest were able to drive gene 
expression in both NF and CWF cell lines. Transfection controls were carried out (Fig 
6.7g-h) with reagent added to the cells without DNA. None of the transfection 
controls were positive for ZsGreen fluorescence.
ID1 and TM4SF1 both demonstrated an increase in expression after serum stimulation 
in patient I, with differences in the level of expression between NF and CWF 
(demonstrated by microarray in Chapter 4 and QRT-PCR in Chapter 5). To determine 
if the promoters contained within the constructs still behaved in the same way and 
therefore represent true reporters a serum starvation/stimulation experiment was 
undetaken. NF and CWF cells transfected with either a construct containing the 
promoter for ID1, TM4SF1 or GAPDH or with reagent alone were serum starved for 
48 hours. Serum containing medium was then added and fluorescence/reporter levels 
recorded at 0, 6 and 24 hours after serum stimulation utilising a FluoStar plate reader. 
Background levels of fluorescence were recorded from the transfection control cells 
and used as blank readings. To control for changes in global gene expression the
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Figure 6.7: Confocal images o f  patient I NF and CW F transiently transfected with reporter constructs; reporter 
expression is seen in green with hoechst stained nuclei shown in blue . Images a and b show expression of 
GAPDH promoter linked ZsGreen expression. Images c and d show ID1 promoter linked ZsGreen 
expression. Images e and f  show TM4SF1 promoter linked ZsGreen expression. Images g an d Ji show 
untransfected cells (scale bar = 250pm).
readings for ID1 and TM4SF1 were divided by the GAPDH readings. GAPDH has 
been previously used as a housekeeping gene in both microarray and QRT-PCR 
experiments. In the fibroblasts used no changes in GAPDH gene expression were seen 
in response to serum stimulation. Changes in fluorescence were compared to changes 
in gene expression level determined by QRT-PCR (Chapter 5). Expression levels of 
ID1 increased upon serum stimulation in both NF and CWF (Demonstrated by QRT- 
PCR) but this increase was lower in CWF than NF (Fig 6.8a). The same pattern was 
seen with the reporter construct (Fig 6.8b). Serum stimulation led to an increase in 
fluorescence in both NF and CWF but the fluorescence levels observed in NF were 
greater than in CWF. The changes in fluorescence observed in cells transfected with 
the ID1 reporter construct mimicked the changes in ID1 gene expression determined 
by QRT-PCR.
Expression levels of TM4SF1 were shown to increase with serum stimulation by 
QRT-PCR (Fig 6.8c) with higher levels of expression in CWF in patient I. The 
TM4SF1 reporter construct demonstrated an increase in fluorescence for both NF and 
CWF after serum stimulation with higher levels of fluorescence observed in CWF 
(Fig 6.8d). As with ID1 cells transfected with the TM4SF1 reporter construct 
demonstrated changes in fluorescence mimicking the changes in TM4SF1 gene 
expression observed by QRT-PCR.
Whilst these initial experiments testing the promoter based reporter constructs were 
limited, the data suggests that the amplified promoter regions are sufficient for 
reporter gene expression and therefore generation of fluorescence in a disease specific 
way. Importantly changes in this fluorescence upon serum stimulation match the 
known changes in gene expression for the two genes of interest.
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Figure 6.8: Graphs showing relative expression of genes of interest in response to serum, a) 
ID1 expression determined by qRT-PCR (Chapter 5). b) ID1 expression determined 
by reporter fluorescence, c) TM4SF1 expression determined by qRT-PCT (Chapter 
5). d) TM4SF1 expression determined by reporter fluorescence.
6.3 Discussion
Gene expression analysis (Chapters 4 & 5) identified Patient I as having the greatest 
change in expression between quiescent and stimulated states for ID1 and TM4SF1. 
This cell line was therefore selected and used at an early time point in culture (p23), 
with all gene expression data taken from this early time point. The initial construction 
of the reporter constructs required the amplification of large regions of DNA upstream 
of the genes of interest. The primers designed were specific to the upstream region of 
each gene however the long range PCR gave multiple bands when analysed. The 
observed bands were smaller than the desired fragment, a possible explanation for 
these fragments would be that the repetitive G/C rich nature of promoter regions has 
lead to hairpins in the amplified DNA truncating the product. The truncated products 
would still be recognised by both 3’ and 5’ primers and would be subsequently 
amplified. As the promoter regions of the selected genes of interest were not well 
characterised it was not possible to design primers closer to the transcriptional start 
site which may have made amplification of the upstream regions easier. G/C rich 
regions flanking genes are important in the control of gene expression (Remington, 
2006) so eliminating these regions from the amplified upstream regions may have 
reduced the efficiency of the promoter. A number of proof reading PCR enzymes are 
available that are specifically designed to amplify these regions and future studies 
may use a battery of different enzymes to attempt amplification of difficult upstream 
regions. The recovery of the amplified promoter regions into pGEM-T recovery 
vector added an extra step into the production of the reporter constructs. However the 
use of a recovery vector simplified the initial ligation and further amplification of the 
promoter regions. The recovery vector required only that the PCR products contained 
a single nucleotide overhang for successful insertion making ligation easier. With the
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amplified region contained within a plasmid further PCR was not required to amplify 
the region as the plasmid could be transformed into E. coli. After transformation with 
the plasmid the competent E. coli would replicate the plasmid allowing large 
quantities of the amplified promoter regions to be generated. The chosen plasmid 
pGEM-T allowed screening of the bacteria for the presence of the plasmid in three 
ways. The antibiotic resistance cassette incorporated into the plasmid allowed 
selection of any bacteria containing a pGEM-T plamid. The lacZ gene into which any 
recovered DNA was incorporated allowed blue/white screening of colonies using 
XGal identifying plasmids with added DNA. Finally the plasmids themselves were 
purified and restriction digests used to identify the specific amplified and recovered 
promoter regions. The final advantage of using recovery vectors was for the 
incorporation of specific restriction sites into the amplified promoter regions to allow 
insertion into the promoter less reporter vector.
The introduction of specific restriction sites into each promoter region by PCR had a 
number of advantages. Originally the transcriptional start site of each gene of interest 
was amplified along with the upstream region. The transcriptional start site if retained 
would interfere with the transcriptional start site of the reporter so had to be removed. 
The introduction of a restriction site just upstream of the transcriptional start site of 
the gene of interest ensured that the upstream promoter regions were as close to the 
reporter proteins transcriptional start site as possible. The introduced restriction sites 
allowed the direction of the promoter regions insertion into the final reporter vector to 
be determined with only one possible orientation.
The transfection of the completed reporter constructs for GAPDH, ID1 and TM4SF1 
into immortalised NF and CWF was carried out using FuGene transfection reagent. 
The reporter construct contained a resistance cassette imparting resistance to the
264
antibiotic G418 to transfected cells. This allowed selection of transfected cells, 
however after 4 weeks of selection the cells appeared to loose G418 resistance and 
died. It was decided that for these preliminary experiments transient transfections 
without selection would be used.
The comparison between gene expression levels determined by QRT-PCR and the 
changes in fluorescence in the reporter cells identified a potential problem with the 
fluorescent protein based reporter system. Though the pattern of fluorescent levels 
between NF and CWF did match the differences seen by QRT-PCR analysis the time 
course data was less convincing. Fluorescence did increase over time after stimulation 
with FCS however not to the extent expected from the QRT-PCR data. The lag time 
between changes in gene expression and changes in fluorescence from reporter 
proteins has been identified as a problem with this system with a delay of between 2 
and 4 hours observed in GFP (Cubitt et al., 1995) (Matz et al., 1999). To fluoresce 
ZsGreen must first assemble itself into a tetramer, this occurs auto-catalytically 
however as in GFP this process takes a number of hours (Matz et al., 1999). The 
supplier Clontech (www.clontech.comi suggest an initial delay of between 8-12 hours 
after transfection before fluorescence is detectable but do not give specific details on 
maturation time of the fluorescent protein.
To control/normalise for cell division over the time of the experiment a way of 
determining cell number in real time was required. Commercial systems to label and 
track cells are available. Cell tracker dyes such as the green dye 5- 
chloromethylfluorescein diacetate (CMFDA) (www. invitro gen .com) label living cells 
giving up to 72 hours of trackable labelling. Nanocrystals can also be used to label 
cells over a period of time in culture the Qdot® nanocrystal system 
(www. invitro gen, com) offers 7 different colours of crystal with labelling covering 6
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generations of cells. These commercially available systems would not allow for a 
determination of cell number in real time as the dye or nanocrystals remain constant 
and are equally divided between daughter cells. Methods for quantifying cell numbers 
such as the Cell Titre Glo system (www.promega.com) require cell lysis before cell 
number can be determined. To allow for non-lethal determination of cell number the 
GAPDH promoter driven reporter construct was constructed. GAPDH has been 
shown to be stably expressed in CWF and NF by microarray analysis (Chapter 4) and 
was used as a housekeeping gene in all QRT-PCR reactions carried for Chapter 5. 
The GAPDH gene expression was not altered between NF and CWF, and was not 
altered by the presence or absence of serum. Fluorescence from the GAPDH reporter 
construct should therefore increase with cell number allowing a normalisation of 
fluorescence. In these experiments the GAPDH reporter was expressed in separate 
cells to the ID1 and TM4SF1 reporters. The GAPDH reporter cells were treated in the 
same way as the ID1 and TM4SF1 cells in order for them to act as a control. The 
choice for separate reporter cell lines was determined by antibiotic resistance cassettes 
available in the Clontech promoter-less reporter plasmids. Although Red Green and 
Yellow fluorescent proteins are available in promoter-less reporter plasmids they all 
contain the same resistance cassettes. This would make selection of cells containing 2 
different reporter constructs impossible. Future work with this system should focus on 
replacing the G418 resistance cassette with one for Zeomycin or Hygromycin 
allowing co-transfection of a housekeeping reporter construct and the reporter 
construct for the gene of interest.
These proof of principle experiment demonstrated that the reporter constructs work, 
and that with further refinement they may become useful tools fom studying chronic 
wounds. These reporter constructs demonstrate the potential for studying changes in
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gene expression in real time. While the constructs developed in this Chapter contained 
only one reporter it may be possible to place multiple reporters in a single construct. 
This would allow the transfection of reporters for both the gene of interest as well as a 
housekeeping control at the same time. With the diverse range of fluorescent proteins 
now available (Trzaska et al., 2005) multiple fluorophores may be detected in the 
same cell without cross talk. With a larger panel of reporter constructs covering the 
genes of interest identified in previous Chapters new treatments for chronic wounds 
could be screened. High throughput assays for new therapeutics based on plates 
containing CWF with various reporter constructs would allow the rapid screening of 
potential therapeutics. Indeed, fluorescent reporter constructs have previously been 
developed to screen chemicals. An immunotoxicity test based on multiple cell types 
derived from lymphocytes has been developed, with these cells transfected with GFP 
based cytokine reporter gene constructs (Jones et al., 2007). The assay was proposed 
as a simple way to screen chemicals for immunotoxic effect. In order to study latent 
HIV in memory T cells a dual fluorescence reporter cell line has been developed. The 
assay uses green fluorescence as a marker for HIV activity and red fluorescence as a 
marker of cell viability. The reporter cells have been used in a high throughput screen 
for potential HIV therapeutics (Cahill et al., 2004). The Yeast based ‘GreenScreen® 
assay’, a DNA repair reporter assay based on detection of changes in the expression of 
the S.cerevisiae RAD54 through a GFP reporter has also been described (Cahill et al., 
2004). DNA damage leads to an increase in fluorescence however, other stresses such 
as oxidative stress does not lead to an increase in fluorescence. The GreenScreen 
assay was developed as a high throughput screen for genotoxic compounds (Cahill et 
al., 2004, Knight et al., 2007, Van Gompel et al., 2005). The GreenScreen® assay in 
commercially available from Gentronix (www.gentronix.co.uk) and has been assessed
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by pharmaceutical companies as a potentially useful drug screen (Hastwell et al., 
2006, Billinton et al., 2008). A human cell version of the GreenScreen® genotoxicity 
assay has been developed, based on a GADD45a-GFP reporter (Graham et al., 2003, 
Moffatt et al., 2004). The assay is described as being useful for detecting mutagens, 
clastogens, aneugens, topoisomerase and polymerase inhibitors in a high throughput 
96 well microplate format. Reporter cell lines already play a role in biomedical 
research, immunotoxicity and DNA damage testing and could play a role in the study 
of chronic wounds. While cell based screening assays cannot replace the use of 
animal models for validation of novel therapeutic effects they can greatly reduce the 
number of animals used. A cell based real time reporter assay may be used to reduce 
the number of potential therapeutics prior to animal trails. This would not only speed 
up the screening process and reduce the number of animals required but it would also 
reduce the cost.
In conclusion, reporter constructs for a housekeeping gene and two genes of interest 
were generated. Previous work indicates that these genes may be important in the 
chronic wound phenotype. The reporter constructs were successfully transfected into 
CWF and NF fibroblasts with fluorescence observed with fluorescence microscopy. 
The generated reporter constructs were shown to be stimulated through addition of 
serum to the transfected cells. The scientific and commercial interest in cell based 
fluorescent reporters as useful tools in screening potentially harmful or useful 
chemicals has been demonstrated in the literature. The constructs described in this 
Chapter have the potential to be developed into a high throughput screen for the 
identification of novel therapeutic for the treatment of chronic venous leg ulcers.
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CHAPTER SEVEN
GENERAL DISCUSSION
7.1 General discussion and future work
In this Thesis, the characterisation of hTERT immortalised dermal fibroblast cell lines 
was described. These cell lines were based on primary cells taken from both chronic 
wounds and patient matched normal skin. Chronic wounds are a burden on the 
patients that suffer from them and on the health services that treat them. Within the 
UK, the NHS has approximately 200,000 individual patients with chronic non-healing 
wounds (Gunnel and Hjelmgren, 2005), with a treatment cost between £2.3bn and 
£3.1 bn per year (Menke et al., 2007). Though the underlying causes for chronic 
wounds varies, they are thought to have failed to resolve the inflammatory phase of 
the wound healing response (Agren et al., 1999a, Cook et al., 2000a, Raffetto et al., 
2001c, Stephens et al., 2003).
In order to study chronic wounds within controllable laboratory conditions several 
models of impaired wound healing have been developed. These models aim to 
recreate the chronic wound environment in laboratory animals either through a 
specific genetic background (diabetic mouse model) or through surgically generated 
tissue ischemia. These models do demonstrate impaired wound healing taking longer 
to heal than none ischemic wounds in the same animal however, they do eventually 
heal unlike chronic wounds in human patients. A second consideration when 
considering the use of the impaired wound healing models is the increased suffering 
of the experimental animals. The work in this thesis was funded by the Dr Hadwen 
Trust for Humane Research fhttp ://www. drhad wentrust. or g. uk) to develop a human 
cell based alternative to the animal models of impaired wounding. Whilst primary 
human cell strains taken from chronic wounds have been used in the past (Jiang et al., 
1999, Mondello et al., 2003) these cells have a limited life span and reproducibility in 
the laboratory and therefore new patient samples are required to continue work.
Therefore, the first aim of this thesis was to phenotypically characterise and compare 
hTERT immortalised fibroblast cell lines from chronic wound and patient matched 
normal with the primary cells from which they were derived. For the cells to be a 
useful research tool they must be able to escape replicative senescence, they must also 
retain their phenotypic differences both directly after immortalisation and after 
extended time in culture.
In Chapter 3 the growth potential of the CWF an NF cell lines was investigated along 
with their size, morphology, ability to repopulate a scratch wound and karyotype. It 
was demonstrated that all 6 hTERT infected cell lines had escaped replicative 
senescence, undergoing more than 100 population doublings with no marked 
reduction in proliferation rate. In two of the patients (H and K) there was a clear 
difference in proliferation rate between the CWF and NF. The CWF underwent fewer 
population doublings per week than the patient matched NF over the entire time in 
culture. In the third patient (I) there was no difference in the average population 
doubling rate between the CWF and NF cell lines. The hTERT infected cell lines were 
imaged over their extended time in culture to compare cellular morphology not only 
between NF and CWF cell lines but also between early and late passage cells. Both 
the morphology of the cells and their cell area were analysed looking for indications 
of senescence. No changes in cellular morphology were observed between the NF and 
CWF cell lines or between early and late passage cells within the same cell line. 
Differences in cell size were observed with CWF cells generally larger than patient 
matched NF however, no increase in cell size was observed with increased time in 
culture. While cellular proliferation, morphology and size by themselves are not
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sufficient to confirm that cells have escaped replicative senescence when taken 
together they are more convincing.
To confirm that the hTERT infected cell lines were expressing active telomerase RT- 
PCR was used to identify transcripts for hTERT and hTR in all six cell lines. Active 
telomerase was identified using the TRAP assay with telomerase activity identified in 
all six cell lines. This data suggest that the hTERT infected cells had successfully 
escaped replicative senescence through the introduction of active telomerase. 
Additionally in Chapter 3, a simplified wound model was used to study the ability of 
the hTERT infected cell lines to repopulate a wound. The repopulation of a wound by 
fibroblasts is an essential part of the wound healing process. In this model the CWF 
demonstrated a reduced ability to repopulate monolayer scratch wounds in all three 
patients compared to the patient matched NF. This phenotype was observed at both 
the early and late time point in culture. Whilst time-lapse microscopy allowed the 
automated documentation of the wound repopulation, variability between the size of 
the initial wound and limitations in access to the time-lapse microscope restricted the 
data collected. Scratch wounding machines such as the Essen Woundmaker™ offer 
the potential to generate reproducible wounds and to analyse multiple plates at a time. 
In this assay wound repopulation is through cellular migration and proliferation 
however, it may be useful to study wound repopulation in these cell through migration 
alone. This can be achieved by the use of an anti proliferative agent such as 
mitomycin c.
To address potential cross talk between CWF and NF a co-culture model using the 
fluorescent cell tracker dyes (www.invitrogen.com") CMFDA (green) and CMTPX 
(red) was designed. The CWF were labelled with CMFDA and the NF with CMTPX, 
an equal number of cells were used to generate a confluent monolayer which was then
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wounded. Through the use of fluorescent time-lapse microscopy the cells repopulating 
the wound area could be identified and counted. Results from this model were initially 
inconclusive but with further more in-depth work it may provide an insight into the 
importance of cell-cell communication in chronic wounds. The final phenotypic 
analysis carried out on the cell lines was to determine their karyotype. Since 
chromosomal abnormalities are often seen in hTERT immortalised cell lines 
(Mondello et al., 1999, Broberg et al., 2001, Broberg et al., 1998, Dahlen et al., 2001). 
NF and CWF cell lines were karyotyped after more than a year in continuous culture. 
Many of the cell lines had either a sub population or the entire population with 
chromosomal abnormalities. The mixed nature of many of the cells karyotypes, with a 
small population of the cells demonstrating an altered chromosome number or 
translocations suggests that the chromosomal alterations have been picked up over 
time in culture rather than being present at the point of transfection. Interestingly all 
the CWF populations analysed showed some levels of trisomy 7, which has 
previously been seen in aged patient samples or in cells taken from areas of prolonged 
inflammation (Scott et al., 1998, Bell et al., 1979). Comparison between the 
karyotypes seen in the late passage immortalised cells and primary cell strains at very 
early passage would indicate if the chromosomal abnormalities have been picked up 
during culture. If detected in the primary cells the trisomy 7 seen in all the CWF cell 
lines may prove to play a role in the failure of chronic wounds to heal.
Overall the analysis carried out in Chapter 3 indicated that the hTERT infection of 
CWF and patient matched NF had allowed them to escape replicative senescence. 
Importantly the immortalised cell lines retained phenotypic differences in growth rate 
and wound repopulation rate after immortalisation. An experiment to assesses the 
response of the fibroblasts in 3D culture were not carried out on the hTERT
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immortalised cell lines due to understandable restrictions set in place by the funding 
charity with respect to the use of rat tail collagen. Free floating fibroblast populated 
collagen lattices generated from rat tail type I collagen determine the ability of 
fibroblasts to remodel extracellular matrix. Lattice reorganisation is caused by the 
rearrangement of collagen fibrils by the fibroblasts within the lattice (Paul Ehrlich et 
al., 2006a). Tethered collagen lattices may also be used to study the ability of 
fibroblasts to generate tension as may be observed within a wound (Wall et al., 
2008b). These experiments would give important phenotypic information about the 
ability of the cell lines to remodel the wound environment which cannot be obtained 
by 2D assays such as the scratch wound model.
The second aim of this Thesis was to characterise genotypic responses of CWF and 
NF cell lines to wounding and to compare this response to that of the primary cells. 
In Chapter 4, a microarray analysis of cellular responses to serum stimulation was 
conducted with responses compared with those of primary cells (Iyer et al., 1999). 
Cells were serum starved for 48 hours synchronising them in Go of the cell cycle 
(Quiescence), this mimics their state in the undamaged dermis (Wall et al., 2008b). 
The addition of serum back onto the cells stimulates cellular proliferation, mimicking 
the exposure of fibroblasts within the dermis to serum from damaged blood vessels 
which occurs upon wounding. As well as mimicking the in vivo wound response the 
synchronisation of all the cells within the culture makes the identification of up or 
down regulated gene expression simpler. A limitation set on the microarray 
experiment carried out was the need to compare the data generated with the primary 
cells. The same Affymetrix™ U133A 2.0 GeneChip® technology that had been used 
previously (Romagnani et al., 2004, Smith et al., 2005, Gillitzer and Goebeler, 2001)
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was therefore used to measure gene expression at 0 and 6 hours after serum 
stimulation. Comparisons between the immortalised and primary cells identified a 
number of genes that had been altered by hTERT infection. Overrepresentation 
analysis of these genes identified pathways relating to the cell cycle and glycolysis up 
regulated in immortalised cells as well as genes linked with protein sequencing. These 
findings correlate with the increased proliferative ability the immortalised cells show. 
The number of genes altered by immortalisation was small and few known pathways 
appear to have been effected, genotypically the hTERT immortalised cell lines appear 
to be a good model of the primary cell strains from which they were generated. 
Comparisons between the CWF and NF identified a number of individual genes and 
pathways that were differentially expressed between CWF and NF. Among these 
genes were a number of members of the CXC chemokine family whose expression 
was down in CWF. This family of chemokines is responsible for the recruitment of 
neutrophils to the wound area controlling the inflammatory response, seen in acute 
wounds (Huang et al., 2006). As previously mentioned chronic wounds fail to resolve 
the inflammatory phase of wound healing, the reduced expression of these 
chemokines may in part be responsible for this.
Microarray analysis identified pro-inflammatory components of the toll like receptor 
pathway to be up regulated in CWF compared to NF. The cytokines IL6, IL1B and 
IL8 were up regulated in CWF. In a wound toll like receptors detect the presence of 
bacterial and viral infection and instigate an inflammatory response, however, CWF 
are cultured in aseptic conditions free from bacterial and viral stimuli. The up 
regulated cytokines are downstream, of the TLR pathway and may indicate miss- 
signalling by the TLR. As with the CXC family of cytokines the over expression of 
pro inflammatory cytokines by CWF may play a role in the failure of chronic wounds
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to heal. Further studies in this area looking at the ability of CWF and NF to induce the 
migration of inflammatory cells would be interesting. As the TLR pathway is well 
understood specific inhibitors could be used to confirm that this is in fact the cause of 
the altered gene expression seen in the CWF. Genes linked with cell motility were 
also identified as being differentially expressed between CWF and NF. Components 
of signalling pathways linked to the actin cytoskeleton were identified and may play a 
role in the reduced wound repopulation rates seen in the CWF. Genes such as CD9 
which inhibits signalling through the WAVE2 pathway (Jones et al., 2007) and whose 
expression is increased in CWF may be the target for gene silencing using siRNA. 
The knock down of specific genes through the introduction of siRNA into cells is a 
useful tool for studying the role of individual genes within a cell. In the case of CWF 
it may be possible to reverse some of the chronic wound phenotype described in 
chapter 3 by the specific inhibition of genes identified by microarray analysis 
discussed in chapter 4.
Microarray data from this thesis has been archived in MADRAS 
(http://madras.uwcm.ac.uki where it is fully searchable. This data adds value to the 
CWF and NF cell lines and increases their usefulness for future experiments. Gene 
expression in the cell lines over extended time in culture was demonstrated to be 
stable. The data also demonstrates that they retain not only phenotypic but also 
genotypic differences after hTERT infection.
The third aim of this Thesis was to generate promoter based reporter constructs using 
genes whose expression was identified as being altered in CWF. From the lists of 
genes differentially expressed between the CWF and NF a subset of genes of interest 
were manually selected. These genes demonstrated differences in expression between
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CWF and NF across all three patients. The differences in expression between NF and 
CWF were thought to be large enough for detection with a promoter based reporter 
system. To allow for testing of the reporter constructs a set of genes which were not 
only differentially expressed between CWF and NF but were also induced or 
repressed by the addition of serum to the cells were selected.
For this subset of genes of interest quantitative real time PCR was used to confirm the 
microarray results. As well as confirming expression changes seen in the microarray 
data this allowed for the analysis of more time points after serum stimulation (lh and 
24h) giving a broader picture of gene expression after stimulation. The cDNA used in 
the confirmation of the microarray data was generated from the same RNA that was 
used for microarray analysis. With more time repeats of the serum 
starvation/stimulation experiments and the generation of multiple RNA samples for 
each cell line would have been carried out. These experimental repeats would give 
more data about the reliability of the changes in gene expression observed in chapter 5 
and allow statistical analysis to be carried out on the data. As with the phenotypic 
analysis, variations were seen between the three patients in gene expression for each 
gene under investigation. The QRT-PCR data demonstrated the same changes in gene 
expression observed in the microarray data. From the 3 patients studied Patient I 
showed the most consistent maintenance of gene expression profile across the 
different time points in culture. Further validation of the changes in gene expression 
by analysis of protein levels were not carried out in this thesis. The reporter constructs 
rely only on the promoter driven mRNA transcription of their targeted genes. 
Therefore changes in mRNA level detected by both microarray and QRT-PCR are 
sufficient to generate changes in reporter expression. With more time the study of 
changes in protein expression on an individual gene level by western blotting, or at a
277
proteome level by 2D gel electrophoresis would have been carried out. This data 
would confirm that changes in gene expression identified by microarray and QRT- 
PCR translate to changes in protein level. As the proteins expressed by CWF play an 
important part in the altered phenotype this information would be useful in targeted 
chronic wound treatments.
The generation of reporter constructs initially required the cloning of the promoter 
regions for the selected genes of interest. Whilst this was successfully carried out for 
the majority of the genes of interest not all promoter regions were successfully cloned. 
With more time to redesign primers and optimise the long range PCR reactions the 
remaining promoters may be successfully cloned. After cloning restriction sites were 
introduced at the ends of the promoter regions and used to insert the promoter regions 
into a promoterless reporter vector. As with the initial cloning it was not possible to 
introduce restriction sites into each of the promoter regions by PCR. Further 
optimisation or redesign of the primers used would allow this to be achieved in the 
future. Another approach could include the use of commercially available promoter 
driven reporter constructs such as the GENOME-WIDE PROMOTER LIBRARY ™ 
(www.switchgeargenomics.comT This system uses approximately 1Kb of the 
upstream region of genes of interest to drive expression of a luciferase reporter.
The completed reporter constructs were successfully transfected into NF and CWF 
cell lines from patient I, as this patient displayed the most consistent maintenance of 
gene expression profile across the different time points in culture. The cells were 
tested and expression of the green fluorescent reporter protein was detected by 
microscopy and its controlled induction by a fluorescent plate reader. These reporter 
cell lines were however, generated by transient transfection. For the reporter cell lines 
to be a useful tool in the investigation of chronic wounds the creation of stable
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reporter cell lines is required. Unlike the transient reporter lines a stable line would be 
a consistent platform for the screening of therapeutic agents. Stable reporter cell lines 
may be generated through viral transduction, an efficient and widely used technique. 
Using a system such as the ViraPower™ Promoterless Lentiviral Gateway Vector 
Expression system (www. invitro gen, com) stable reporter cell lines could be 
generated. This technology would also allow for the introduction of more than one 
reporter per cell. This would allow a housekeeping gene reporter construct to be in the 
same cell as the reporter construct for the gene of interest. The presence of both 
reporters in the same cell controls for changes in global gene expression. If the chosen 
housekeeping gene is constitutively expressed it may also act as a control for cell 
number. Other controls looking at cross talk between the different fluorphores used, 
oxidative stress levels within the cells and cellular phototoxicity caused by exposure 
of the cells to light must also be carried out.
From the proof of principle work carried out in this Thesis the potential of a chronic 
wound reporter cell line is clear. With further development, screening of potential 
therapeutic agents could be carried out using such a cell line (Wall, 2006, Colwell et 
al., 2006), with the cells in a 96 well plate format. While such a cell line would not 
entirely replace the use of animal models in the testing of novel wound healing 
therapeutics it may play a part in reducing their use in large scale drug screening.
In this Thesis an attempt was made to establish hTERT immortalised cell lines 
generated from chronic wounds, as well as patient matched normal skin as a potential 
replacement for animals in chronic wound research. The cell lines were shown to be 
immortalised through retroviral infection by hTERT and to be expressing active 
telomerase. The CWF cell were shown to retain phenotypic and genotypic difference 
after immortalisation compared to patient matched NF. The phenotypic and genotypic
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changes seen in CWF relate to changes seen in chronic wounds. Cell lines with 
detailed gene expression data are now available for use in future studies of chronic 
wound healing and are currently being used in a number of other research projects. 
Reporter constructs were generated for two disease genes and a housekeeping gene, 
these reporter constructs were successfully transfected into NF and CWF cell lines 
and tested. Work on the generation of stable reporter cell lines is ongoing, using 
immortalised fibroblasts taken from diabetic foot ulcers as well as the chronic wound 
fibroblasts discussed in this Thesis. It is envisaged that these cell lines may eventually 
offer a real alternative to the use of animal models in chronic wound research.
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Appendix 1 
Promoter Sequences
ACTC Promoter
1 AATCAACCTG ATTCTTTAAA AGGCAGAGCT ACTACTGCCT CCAAAAGTAT CATTATTACA
TTAGTTGGAC TAAGAAATTT TCCGTCTCGA TGATGACGGA GGTTTTCATA GTAATAATGT
101 TTGTTTCTAA CTATTACAAT ACACAATAAC TTCTGCAACA AGTGTTATGG TATCACTTTT
AACAAAGATT GATAATGTTA TGTGTTATTG AAGACGTTGT TCACAATACC ATAGTGAAAA
201 CTCAAGACCA AACAGATAGT TAGTAAGTGA TAAAGGCAGC ATTTGAGCCC AGTTCTGTCT
GAGTTCTGGT TTGTCTATCA ATCATTCACT ATTTCCGTCG TAAACTCGGG TCAAGACAGA
301 TCTATATTTT CACGAGACAA GGCAGTTCTA CTCTTGGCAT CCTGTCAATA AACATTTTCA
AGATATAAAA GTGCTCTGTT CCGTCAAGAT GAGAACCGTA GGACAGTTAT TTGTAAAAGT
4 01 AGGTCTCTTA CCCGACCCCA CCACACAGCT GCCCATCGCG TTTCTTCTCC AGACCAACCC
TCCAGAGAAT GGGCTGGGGT GGTGTGTCGA CGGGTAGCGC AAAGAAGAGG TCTGGTTGGG
501 CCCAGTCGGG ACAAGTATCT AATCAGCAGG CCTCCTCAGC ATATCAGCCC AAGACCACTC
GGGTCAGCCC TGTTCATAGA TTAGTCGTCC GGAGGAGTCG TATAGTCGGG TTCTGGTGAG
601 GTGTGAACTG GAGGAAAAAC ACAAGCATTA AAAATCAAAG CTCCAGTCAA GAACTGAGAA
CACACTTGAC CTCCTTTTTG TGTTCGTAAT TTTTAGTTTC GAGGTCAGTT CTTGACTCTT
701 TTACATCTCC CTCTTCCTTC TCCCTCTCCT CATTTCATGT CATTTTTCTT TTTCCTTCTC
AATGTAGAGG GAGAAGGAAG AGGGAGAGGA GTAAAGTACA GTAAAAAGAA AAAGGAAGAG
801 GATGATATCT GTCATTTATG CCAATGCTTC TCACACTTTA ATGTACATAC CAAGCAAATG
CTACTATAGA CAGTAAATAC GGTTACGAAG AGTGTGAAAT TACATGTATG GTTCGTTTAC
901 TGCATTTCTA GCTCATTTCC AGGTTATGAC AATACTGCTT GTCCATGGGC TGCACTTTGA
ACGTAAAGAT CGAGTAAAGG TCCAATACTG TTATGACGAA CAGGTACCCG ACGTGAAACT
1001 TATGTTCTCC ATCAAAGTAT TTGCCTTTGC AGTCTTGTCT CCACCTGGAG TGAGGGCCTC
ATACAAGAGG TAGTTTCATA AACGGAAACG TCAGAACAGA GGTGGACCTC ACTCCCGGAG
1101 GGGCAAGCTA CTTTTGGCAT TTGTTCCTTT ATTCACTTTG GCAGCAGGGG ATCCTTTTCT
CCCGTTCGAT GAAAACCGTA AACAAGGAAA TAAGTGAAAC CGTCGTCCCC TAGGAAAAGA
1201 GCATGGATGA GGGCTACCCA ATAACTGGGC TGGGGTAAAC CTGGTCCCTT CTCCAGCAAG
CGTACCTACT CCCGATGGGT TATTGACCCG ACCCCATTTG GACCAGGGAA GAGGTCGTTC
1301 CCTGGCCAGA CCCTGATCCA TGCATGGGTT GGAACTCGGG TGGCCTTGGT TAATCTCAGC
GGACCGGTCT GGGACTAGGT ACGTACCCAA CCTTGAGCCC ACCGGAACCA ATTAGAGTCG
14 01 AGCCATTCAG GCTGGCGGGG ACTAGACCAG AAGGGTGCCC TGTCCTGGGT GCCCCTTTTG
TCGGTAAGTC CGACCGCCCC TGATCTGGTC TTCCCACGGG ACAGGACCCA CGGGGAAAAC
1501 TGGCAGCCCT GGAAGATGAG AAGCCGCTGT TGCTCCCCTG CTGCCCTGGC CCAGCTGTCA
ACCGTCGGGA CCTTCTACTC TTCGGCGACA ACGAGGGGAC GACGGGACCG GGTCGACAGT
1601 GCATGTGGCT TATTGTCCCC AAGGCTGGCA GGGCTGCGGA GGACCGAATC CACAGACCAT
CGTACACCGA ATAACAGGGG TTCCGACCGT CCCGACGCCT CCTGGCTTAG GTGTCTGGTA
1701 TGGCGTCACT TAGTCTTCCC CTGCCCCCTA CCCTTCAGCG CCTGCCCCTC CCCAGCTCCC
ACCGCAGTGA ATCAGAAGGG GACGGGGGAT GGGAAGTCGC GGACGGGGAG GGGTCGAGGG
1801 ATGGTCTGGG GGCTCCCTGG CTGATCCTCT CCCCTGCCCT TGGCTCCATG AATGGCCTCG
TACCAGACCC CCGAGGGACC GACTAGGAGA GGGGACGGGA ACCGAGGTAC TTACCGGAGC
1901 TGGCAGACCG GGCCCCCCAC CCCTGCCCCC GGCTGCTCCA ACTGACCCTG TCCATCAGCG
ACCGTCTGGC CCGGGGGGTG GGGACGGGGG CCGACGAGGT TGACTGGGAC AGGTAGTCGC
2001 CGCTGCCGCC GGAGCCGAGC CGACCCGCCC CGCCGACGGT GAGTCAGCGC CCGGCCCTCC
GCGACGGCGG CCTCGGCTCG GCTGGGCGGG GCGGCTGCCA CTCAGTCGCG GGCCGGGAGG
2101 CAGCCCCGCG CCGCCACCTG GCCAGCCCGG CCCGCATTCA GCCAAGGCCC CAGCTCCTGC
GTCGGGGCGC GGCGGTGGAC CGGTCGGGCC GGGCGTAAGT CGGTTCCGGG GTCGAGGACG
2201 CACTTTTTGA TTTGGTTCTA ACTTGTTTTG TCCTGGG
GTGAAAAACT AAACCAAGAT TGAACAAAAC AGGACCC
323
CD9 promoter
1 GCCTTCATTC ATTCTTCTCT CACCTGAACT ACTCCACAGC CTCCTAGCAG ATTTGCACCT
CGGAAGTAAG TAAGAAGAGA GTGGACTTGA TGAGGTGTCG GAGGATCGTC TAAACGTGGA
101 ATTACCTGAT TGCGTCTCCC CAAATACAAC ATCTCCATGT TCCATGCAAT CCCGTAAAGC
TAATGGACTA ACGCAGAGGG GTTTATGTTG TAGAGGTACA AGGTACGTTA GGGCATTTCG
201 ctcaaggggc TTCCTACCTG CCCCTCCGGC CTTCCCCCAC CCAACTACCT AAAACACAGG
GAGTTCCCCG AAGGATGGAC GGGGAGGCCG GAAGGGGGTG GGTTGATGGA TTTTGTGTCC
301 TGCTTGAACC TTTCGGTGGC CCCTAATGCT CAGAGTGCAA AGTCCAGGAG CACAAGGCTC
ACGAACTTGG AAAGCCACCG GGGATTACGA GTCTCACGTT TCAGGTCCTC GTGTTCCGAG
401 CAGCCCAGAG CCCGGACAGC CCCTGCCCCA GCCTTTGCCC AGGATTCTCC CTTGGCGGCA
GTCGGGTCTC GGGCCTGTCG GGGACGGGGT CGGAAACGGG TCCTAAGAGG GAACCGCCGT
501 TCAGAGGCCT CTCCTTAGCC TCTTAGCCCC CAAGCCTCTC CCCGTAACTG CACCTATCAC
AGTCTCCGGA GAGGAATCGG AGAATCGGGG GTTCGGAGAG GGGCATTGAC GTGGATAGTG
601 GTCCCTGAGC AGAAACAAGG ACTAATCCAT GTTTTTCAGC TCCTACCCCT AATGAAATAC
CAGGGACTCG TCTTTGTTCC TGATTAGGTA CAAAAAGTCG AGGATGGGGA TTACTTTATG
701 AGTCTACTGA TAATAAACAG GCAAATAACA GCAATGTGCT AACAGTGGCT GTTTCTGGTG
TCAGATGACT ATTATTTGTC CGTTTATTGT CGTTACACGA TTGTCACCGA CAAAGACCAC
801 TCGGTTGTTT CTGTAATGAC TGTATCTTGC TTTTGTAATC ATAAAGGACA GTAAAGGAAA
AGCCAACAAA GACATTACTG ACATAGAACG AAAACATTAG TATTTCCTGT CATTTCCTTT
901 AAAGAAGGTG ACTCTCCTCG TCCACTCCAG AGAATCAGGA AAGGAGTGTT TAAAGACCCA
TTTCTTCCAC TGAGAGGAGC AGGTGAGGTC TCTTAGTCCT TTCCTCACAA ATTTCTGGGT
1001 CAGGGCGCAT GCCGGCCAGC GAGTGGGGTG GGCTCTGGGT CCGGGAGAAG TCAGATCAGT
GTCCCGCGTA CGGCCGGTCG CTCACCCCAC CCGAGACCCA GGCCCTCTTC AGTCTAGTCA
1101 CTTAGGTCCT TGAATCTGGA GAGCTACAGA AAGTTTGTGA GCTCAGGAGA AGCGCTCCGA
GAATCCAGGA ACTTAGACCT CTCGATGTCT TTCAAACACT CGAGTCCTCT TCGCGAGGCT
1201 CCAAAGACGC AGGAGGGAGG GTGGGGTGGA GGAGTAGAGA GAAAACAGAA GCCGTCTACA
GGTTTCTGCG TCCTCCCTCC CACCCCACCT CCTCATCTCT CTTTTGTCTT CGGCAGATGT
1301 GAAGCGCTTG GGGACTGCCC AGCCCTCAGC TGTGTTATTA TTCGGTGATA GGTATTTGCT
CTTCGCGAAC CCCTGACGGG TCGGGAGTCG ACACAATAAT AAGCCACTAT CCATAAACGA
1401 CTGCGCGCTT CTAATTCCTC CTACCCCACA TGCTGTGCCC AATGAAAAGT ATGGTCAGCG
GACGCGCGAA GATTAAGGAG GATGGGGTGT ACGACACGGG TTACTTTTCA TACCAGTCGC
1501 CCAGGCGGCT TCCCTTTAAA TCCTCGCAAA GCAGAAGGGC CCCTCACTCT GGCAGCAGGC
GGTCCGCCGA AGGGAAATTT AGGAGCGTTT CGTCTTCCCG GGGAGTGAGA CCGTCGTCCG
1601 GTCTCCCAAA GCAGAACGCC CGGTCCGGCG CCCAGACCAA ACGCGGGGGA ACCGGAAGGG
CAGAGGGTTT CGTCTTGCGG GCCAGGCCGC GGGTCTGGTT TGCGCCCCCT TGGCCTTCCC
1701 TGGCTGCCTG CAAAGACCCC AAGACGGCTT GAAGAAGGAG TGGGTGGCGG GTGGGGGTTA
ACCGACGGAC GTTTCTGGGG TTCTGCCGAA CTTCTTCCTC ACCCACCGCC CACCCCCAAT
1801 CGGGGCAGCT GGGGCCGGGG CTCGCCGACC TGGGCGGGGG CGGGGGGCGG GGGGGGTGCG
GCCCCGTCGA CCCCGGCCCC GAGCGGCTGG ACCCGCCCCC GCCCCCCGCC CCCCCCACGC
1901 GGGGAGTGGG GGCGGCTTTT CCCGGCACAT GCGCACCGCA GCGGGTCGCG CGCCCTAAGG
CCCCTCACCC CCGCCGAAAA GGGCCGTGTA CGCGTGGCGT CGCCCAGCGC GCGGGATTCC
2001 GCCGCCTGCA TCTGTATCCA GCGCCAGGTC CCGCCAGTCC CAGCTGCGCG CGCCCCCCAG
CGGCGGACGT AGACATAGGT CGCGGTCCAG GGCGGTCAGG GTCGACGCGC GCGGGGGGTC
2101 TGCCGGTCAA AGGAGGCACC AAGTGCATCA AATACCTGCT GTTCGGATTT AAC
ACGGCCAGTT TCCTCCGTGG TTCACGTAGT TTATGGACGA CAAGCCTAAA TTG
324
CXCL1 promoter
1 TCAGGAAGAT GTGAAAAGAG AAATAATTGA AAAAGACTGG AGTACATATA CTATCTACAG
AGTCCTTCTA CACTTTTCTC TTTATTAACT TTTTCTGACC TCATGTATAT GATAGATGTC
1 0 1 CCCTTGACTA AGATTACTGT AATGAGAGCA CCAGTACCCC TGAGTAACCG AAAGGGCATT
GGGAACTGAT TCTAATGACA TTACTCTCGT GGTCATGGGG ACTCATTGGC TTTCCCGTAA
2 0 1 TTCCAGGACC TGCCTTGATT TATTCAAGAC TCATACTGCT GTATATGGTG TTGTATACAT
AAGGTCCTGG ACGGAACTAA ATAAGTTCTG AGTATGACGA CATATACCAC AACATATGTA
3 0 1 AAATGTAAAA AACACTGGGG AGTGAACCTT TCCATTATAT ATATATATAT ATATATATAT
TTTACATTTT TTGTGACCCC TCACTTGGAA AGGTAATATA TATATATATA TATATATATA
4 0 1 ACATCAGGAT GAGTTTCTGT TTAGGCAATG TTGGAAAACG CTATTTCCAT TTTTTTTTTA
TGTAGTCCTA CTCAAAGACA AATCCGTTAC AACCTTTTGC GATAAAGGTA AAAAAAAAAT
5 0 1 TGCTGGCTCT TACAAATGTT GACTCATTTC TCATAACCAC CTTGGGGTAG AAACGGAGAG
AC GAC C GAGA ATGTTTACAA CTGAGTAAAG AGTATTGGTG GAACCCCATC TTTGCCTCTC
6 0 1 GTGGCAGCCT TGCCTGTGTT CTCTGCTTGG CTAGGAACAC AGGTCTTACC TATTGAGCTG
CACCGTCGGA ACGGACACAA GAGACGAACC GATCCTTGTG TCCAGAATGG ATAACTCGAC
7 0 1 GCAGAAGCCT CTGCTTTTTC CCCCTCCTCC CATCTTACTC CATGTCTCAG AGAGCTCTGA
CGTCTTCGGA GACGAAAAAG GGGGAGGAGG GTAGAATGAG GTACAGAGTC TCTCGAGACT
8 0 1 AATGATGAAT AAAAATAAGT TCTCTAGAAC TTCTGGAGAA AAAAGTAATA AAGCTACCAG
TTACTACTTA TTTTTATTCA AGAGATCTTG AAGACCTCTT TTTTCATTAT TTCGATGGTC
9 0 1 TGTTTCTCTA GAAAGGGGGC CCAATACTGA ATACCAGGAA GTCCTATAGT AAATGGAATG
ACAAAGAGAT CTTTCCCCCG GGTTATGACT TATGGTCCTT CAGGATATCA TTTACCTTAC
1 0 0 1 GCATGTCTGC TGCTTCAGTG GGAAGGGTGC TTGCACACCA GGTACCCACT CCCTGGTGTC
CGTACAGACG ACGAAGTCAC CCTTCCCACG AACGTGTGGT CCATGGGTGA GGGACCACAG
1 1 0 1 CCCATGAGCC TGCTGGACCC AGCCCCTCCG AGGTCCGGAG TGACAACCAG TGCCGTATTT
GGGTACTCGG ACGACCTGGG TCGGGGAGGC TCCAGGCCTC ACTGTTGGTC ACGGCATAAA
1 2 0 1 CAGGGGATTT TGAAAGTTCC AACATTTTAC AGGGAAGAAG GAAGATAAG C AGGATATGAA
GTCCCCTAAA ACTTTCAAGG TTGTAAAATG TCCCTTCTTC CTTCTATTCG TCCTATACTT
1 3 0 1 TAACACTGGA TTCAGCTTTT GACACTGATA ATCTGTTGCC ACCAAATGGA AAACGTAAAC
ATTGTGACCT AAGTCGAAAA CTGTGACTAT TAGACAACGG TGGTTTACCT TTTGCATTTG
1 4 0 1 AACAAGCAGA ACATTCTTCT CTGGAATCTG ACATAATGGA CTGTACTTTC ACAGACAGCA
TTGTTCGTCT TGTAAGAAGA GACCTTAGAC TGTATTACCT GACATGAAAG TGTCTGTCGT
1 5 0 1 AGAAAGGCTG AGGCAGAGAG GATAATATAG CTCCAGCCTA TCTCCCAGCA CCTTGTTAAT
TCTTTCCGAC TCCGTCTCTC CTATTATATC GAGGTCGGAT AGAGGGTCGT GGAACAATTA
1 6 0 1 TTCCTCCAAA GAGGTCGCGC CTTCTCTGTG GTGGTTCTCA GGGATCCGCC CCAGCTCCTT
AAGGAGGTTT CTCCAGCGCG GAAGAGACAC CACCAAGAGT CCCTAGGCGG GGTCGAGGAA
1 7 0 1 AAGATCCCAC CTCTCAGGTG GTATCTTCAG CGCAGGCTGC CACTCAGCCC CCCTCCAGGG
TTCTAGGGTG GAGAGTCCAC CATAGAAGTC GCGTCCGACG GTGAGTCGGG GGGAGGTCCC
1 8 0 1 ACAGGAGTTA CTCTGAAGGG CGAGGCGCGG GCTGCATCAG TGGACCCCCA CACCCCACCC
TGTCCTCAAT GAGACTTCCC GCTCCGCGCC CGACGTAGTC ACCTGGGGGT GTGGGGTGGG
1 9 0 1 TCCTTCCGGA CTCGGGATCG ATCTGGAACT CCGGGAATTT CCCTGGCCCG GGGGCTCCGG
AGGAAGGCCT GAGCCCTAGC TAGACCTTGA GGCCCTTAAA GGGACCGGGC CCCCGAGGCC
2 0 0 1 CTCGGAGAGC CACAGAGCCC GGGCCGCAGG CACCTCCTCG CCAGCTCTTC CGCTCCTCTC
GAGCCTCTCG GTGTCTCGGG CCCGGCGTCC GTGGAGGAGC GGTCGAGAAG GCGAGGAGAG
2 1 0 1 TGCTCTCTCC GCCGCCCCCA GCAATCCCCG GCTCCTGCGA GTGGCACTGC TGCTCCTGCT
ACGAGAGAGG CGGCGGGGGT CGTTAGGGGC CGAGGACGCT CACCGTGACG ACGAGGACGA
2 2 0 1 CGCCCTGGGG TCCCCGGGCC GGACGCGGCT GGGGTAGGCA CCCAGCGCCG ACAGCCTCGC
GCGGGACCCC AGGGGCCCGG CCTGCGCCGA CCCCATCCGT GGGTCGCGGC TGTCGGAGCG
325
CXCL12 promoter
1 CAGCGGCCAG GCCTGAATCC CTGGTTCGCC CTCGACTCAG CCCACGCGGG CCTTTCAGGC
GTCGCCGGTC CGGACTTAGG GACCAAGCGG GAGCTGAGTC GGGTGCGCCC GGAAAGTCCG
101 GTGGCAAAGA AAAAAAGAAG AAGAAGAAGC GAGAGGCGAT GGCGTTTGCT TTGGCCAGAT
CACCGTTTCT TTTTTTCTTC TTCTTCTTCG CTCTCCGCTA CCGCAAACGA AACCGGTCTA
201 GATCTCCGAG CTCCAGGGCG CCCCTCCACC CGGGTGTAGA TTTCCCGCGG ACCCCTTCGC
CTAGAGGCTC GAGGTCCCGC GGGGAGGTGG GCCCACATCT AAAGGGCGCC TGGGGAAGCG
301 AGAGCTCTGG GAGCGGGGAG GGAGGCGCCG CCACCAGAGG GCGCCGGAGC CCCAGCGCTG
TCTCGAGACC CTCGCCCCTC CCTCCGCGGC GGTGGTCTCC CGCGGCCTCG GGGTCGCGAC
4 01 AGGCCTGGGG ACGCCCGACG GCTGCCTTCT TCACTGGACC TCACTGCCTT CAGTTCTTTA
TCCGGACCCC TGCGGGCTGC CGACGGAAGA AGTGACCTGG AGTGACGGAA GTCAAGAAAT
501 AGTGCCCAGG GTGGGTGGGT GGGTGGGTGG GTGGGTGGAT GGATGGATGG ATGGATGGAT
TCACGGGTCC CACCCACCCA CCCACCCACC CACCCACCTA CCTACCTACC TACCTACCTA
601 TGGAAAAAAA ATGCACAGAA GACACCTACT CCCACCAGCG GAGTTCCGGA GCCCTCGCAG
ACCTTTTTTT TACGTGTCTT CTGTGGATGA GGGTGGTCGC CTCAAGGCCT CGGGAGCGTC
701 CCCACTCCCC GACGGCCAGG ACTCCCCAGG GACAGGGACG TGTCCCCAGG GCAGGCCCCT
GGGTGAGGGG CTGCCGGTCC TGAGGGGTCC CTGTCCCTGC ACAGGGGTCC CGTCCGGGGA
801 GCTGGGAAGG ACACAGAGAG GTGGCTGGGG CAGCCTGCGG TCACAAAGCG AGGCCCAAAG
CGACCCTTCC TGTGTCTCTC CACCGACCCC GTCGGACGCC AGTGTTTCGC TCCGGGTTTC
901 GCACCCTCCC TTCGCCACCG GACTGGGGCC ATCTGGGATG TCTCGGGGGT ATCCGGAGGG
CGTGGGAGGG AAGCGGTGGC CTGACCCCGG TAGACCCTAC AGAGCCCCCA TAGGCCTCCC
1001 TGGACCCAGA AGGCAGACGC CAGTAGTACT GTCCTAGGAG TCGGAGGTCG GGGTGGGGGA
ACCTGGGTCT TCCGTCTGCG GTCATCATGA CAGGATCCTC AGCCTCCAGC CCCACCCCCT
1101 AGGCAGTAAG TACTTAGGTT TAAAGGACTT ACTTACAGCT ACCATTTATT GAGTACTGTC
TCCGTCATTC ATGAATCCAA ATTTCCTGAA TGAATGTCGA TGGTAAATAA CTCATGACAG
1201 CGGGTCTCAT TGAATCTCCC GTCCCACTCC GCGGGGTGGG CCTGTGATTA GCTCATTTCA
GCCCAGAGTA ACTTAGAGGG CAGGGTGAGG CGCCCCACCC GGACACTAAT CGAGTAAAGT
1301 ACTGAGAGCC GCCGGCGCCT TCTGCTTTGT TTGTACAGGC GAGGAAACTG AGGCTCGGCT
TGACTCTCGG CGGCCGCGGA AGACGAAACA AACATGTCCG CTCCTTTGAC TCCGAGCCGA
1401 AAAGACGGGT CTCATTCCCG CAGATCGAGC TCTGCCGGCG GCTGCGCCGC AAGCCGGGCA
TTTCTGCCCA GAGTAAGGGC GTCTAGCTCG AGACGGCCGC CGACGCGGCG TTCGGCCCGT
1501 CCTCGGCTGC CTTGGGCCGC CACCGCCAGC AGGCCCTCCG CCCGGGACTA ACTTGTTTGC
GGAGCCGACG GAACCCGGCG GTGGCGGTCG TCCGGGAGGC GGGCCCTGAT TGAACAAACG
1601 CCGTCCCGCA GCTTTCCACG CGCGCCCCAC TTTACGCCTA AGGTCCTCAG TCTCTCCAGT
GGCAGGGCGT CGAAAGGTGC GCGCGGGGTG AAATGCGGAT TCCAGGAGTC AGAGAGGTCA
1701 CGTCGCTCAG GCTGCGGACC TCACTGCAGA CCGGGCCAGC GGTGCGGGGC CCAGCGGAGC
GCAGCGAGTC CGACGCCTGG AGTGACGTCT GGCCCGGTCG CCACGCCCCG GGTCGCCTCG
1801 CACAGAGGGA GCGGAGGAGG GGCGAAGGGG ATGGGTGGGG GGTGCCGCCG AGGGAGTCGC
GTGTCTCCCT CGCCTCCTCC CCGCTTCCCC TACCCACCCC CCACGGCGGC TCCCTCAGCG
1901 CCCGCCCCTC ACCGCGCGCC CCGCCCCGCC CCGCCTGGCT CTCCCCTCTA AAGCGCCCGG
GGGCGGGGAG TGGCGCGCGG GGCGGGGCGG GGCGGACCGA GAGGGGAGAT TTCGCGGGCC
2001 GCATTGCCCG CTCGGCGTCC GGCCCCCGAC CCGCGCTCGT CCGCCCGCCC GCCCGCCCGC
CGTAACGGGC GAGCCGCAGG CCGGGGGCTG GGCGCGAGCA GGCGGGCGGG CGGGCGGGCG
2101 GTGCTGACCG CGCTCTGCCT CAGCGACGGT AAGTGCGCTC GGCGGGGAGG CCCTGGCGAG
CACGACTGGC GCGAGACGGA GTCGCTGCCA TTCACGCGAG CCGCCCCTCC GGGACCGCTC
2201 CCTCTGCCTG CGCCCGCAGT TTGCGCCGCC CGACACAGTG GGGGTGGAGG CAGCTCGCTT
GGAGACGGAC GCGGGCGTCA AACGCGGCGG GCTGTGTCAC CCCCACCTCC GTCGAGCGAA
326
CXCL3 promoter
1 AATGACCTCC CATCTATGTG CATCTCCTGG TAAAGTACAG ATGTGTCTTC CTTTCTGAAA
TTACTGGAGG GTAGATACAC GTAGAGGACC ATTTCATGTC TACACAGAAG GAAAGACTTT
101 TAAATTCCCA ATTGAACTTT ATTTTTCATT TATAAGTTTG CAGCATTTAT TACAGCTTGA
ATTTAAGGGT TAACTTGAAA TAAAAAGTAA ATATTCAAAC GTCGTAAATA ATGTCGAACT
201 GGGTCAATGT TTTTTCTGTA TCTATCCTTT CTTTCAAGGA ATTTAAGTAG TCAGGGAGAT
CCCAGTTACA AAAAAGACAT AGATAGGAAA GAAAGTTCCT TAAATTCATC AGTCCCTCTA
301 TTACCTATAG TGTCTATTTT AAAGTAACAG GACATTCTAG CACACCTTTC TATCCCTTGT
AATGGATATC ACAGATAAAA TTTCATTGTC CTGTAAGATC GTGTGGAAAG ATAGGGAACA
401 CAGTAACTAC AAGACCATTT TGGAAACTGG GATTGTGGTG TTTATATGAA CATTCTTCTT
GTCATTGATG TTCTGGTAAA ACCTTTGACC CTAACACCAC AAATATACTT GTAAGAAGAA
501 TATATCAGTT AGAGACAGGG AGAGTTGGGT GGCAGTAAGG GATACAGAAA ATTTTAAATG
ATATAGTCAA TCTCTGTCCC TCTCAACCCA CCGTCATTCC CTATGTCTTT TAAAATTTAC
601 TTTTTTCCTT TACAGAATTC ATAGCAGGCT GAGTTTTTGT TCAGGCAATG TCGGGAAAGA
AAAAAAGGAA ATGTCTTAAG TATCGTCCGA CTCAAAAACA AGTCCGTTAC AGCCCTTTCT
701 TAACAACCAT TAATAAGGCA CTTAATCCAT GTTGTCTCTT ACAAATGTTA ACTCATTTCT
ATTGTTGGTA ATTATTCCGT GAATTAGGTA CAACAGAGAA TGTTTACAAT TGAGTAAAGA
801 TGCAAGTGAT ACTCTGCAAC TAAATACAGG CAGCACAGTT GCACGCTCTG TGTTTGGTTA
ACGTTCACTA TGAGACGTTG ATTTATGTCC GTCGTGTCAA CGTGCGAGAC ACAAACCAAT
901 CCCTGTGCTT CAGGCAGATG CCATTCCTTT CTCCTCTCCT CCATCCTACT CCACGTCTCA
GGGACACGAA GTCCGTCTAC GGTAAGGAAA GAGGAGAGGA GGTAGGATGA GGTGCAGAGT
1001 TCTAAAACCT AATGACAAAT CAAAATACAT TATCTAAAAC TAGAAAAAGG GACAAAGGTG
AGATTTTGGA TTACTGTTTA GTTTTATGTA ATAGATTTTG ATCTTTTTCC CTGTTTCCAC
1101 GCCCTGTTAA TGTTTCCAGA GAAAGATCCC CCAGTGCTGA ATACCAGAAA ATTCTATAGT
CGGGACAATT ACAAAGGTCT CTTTCTAGGG GGTCACGACT TATGGTCTTT TAAGATATCA
1201 TCATCAGCAG GCAGCTGTTT GCTCCTTCAG TGGGAATGGT GTTTGCACAC CAGGTACCTA
AGTAGTCGTC CGTCGACAAA CGAGGAAGTC ACCCTTACCA CAAACGTGTG GTCCATGGAT
1301 AGCCCATGAT CCTGCTGGAC CCAGCCCCTC CACAGCTTCA GAGTGACAGC CAGTGTCATA
TCGGGTACTA GGACGACCTG GGTCGGGGAG GTGTCGAAGT CTCACTGTCG GTCACAGTAT
1401 CTCCAGGGGA TTTAGGAAGT TCCAACATTT CAGAGGGAGG AAGGACGTTA TGCAGGATAC
GAGGTCCCCT AAATCCTTCA AGGTTGTAAA GTCTCCCTCC TTCCTGCAAT ACGTCCTATG
1501 CACTAACACT GAATTCAAAT TTTGACACTG ATAATCTGTT GCCACCAAAT GGAAAACGTA
GTGATTGTGA CTTAAGTTTA AAACTGTGAC TATTAGACAA CGGTGGTTTA CCTTTTGCAT
1601 AGGAACAAGT AGAACATTCT TCTCTGGAAT CCGAGACGAT GGCTGTACTT TCACAGAGAG
TCCTTGTTCA TCTTGTAAGA AGAGACCTTA GGCTCTGCTA CCGACATGAA AGTGTCTCTC
17 01 TGAGAGAGGC AGAGACCGGG AGGTTAACAT AGAGGATAGA CTATATAGAG AGAGGATAGC
ACTCTCTCCG TCTCTGGCCC TCCAATTGTA TCTCCTATCT GATATATCTC TCTCCTATCG
1801 GATAACTAAG GAGACAAAGC TCTCTTCCTC TAAAGAAGTC GTGCCTTTCC TGTCCTGGTT
CTATTGATTC CTCTGTTTCG AGAGAAGGAG ATTTCTTCAG CACGGAAAGG ACAGGACCAA
1901 TACGCGGGGG GTCATCGGGG ACCTAAGGTC CCCCCTCACA GGCTGTATCT TCAGCGAGGT
ATGCGCCCCC CAGTAGCCCC TGGATTCCAG GGGGGAGTGT CCGACATAGA AGTCGCTCCA
2001 TATCCCAAAG TCCCAGAGTG CACGGGGGTT ACTCTGGAGG GCGAGGCGTA GGCGTCACCA
ATAGGGTTTC AGGGTCTCAC GTGCCCCCAA TGAGACCTCC CGCTCCGCAT CCGCAGTGGT
2101 GGGGCCGTCG CCTTCCTTCG GGACTCCGGA TCGATCTGGA GCTCCGGGAA TTTCCCTGGC
CCCCGGCAGC GGAAGGAAGC CCTGAGGCCT AGCTAGACCT CGAGGCCCTT AAAGGGACCG
2201 AGGGTTCGCC GATCTTGGG
TCCCAAGCGG CTAGAACCC
327
CXCL5 promoter
1 CTTTTCTCAT GATCCATCTC AGATTTCACC ATTTGGCGCC AAAAACAAAT TCGTGTGTTC
GAAAAGAGTA CTAGGTAGAG TCTAAAGTGG TAAACCGCGG TTTTTGTTTA AGCACACAAG
101 CACACACACA CACACAGTTT AAAAGTCAAT AACCTATGTA ATTAAACTTC TTTTAAAAGA
GTGTGTGTGT GTGTGTCAAA TTTTCAGTTA TTGGATACAT TAATTTGAAG AAAATTTTCT
201 GAATTTAATT GCCCAAGATT TTTTGAAGTG TTATCACTTC ACCTAGGCTT AACTTTTGTC
CTTAAATTAA CGGGTTCTAA AAAACTTCAC AATAGTGAAG TGGATCCGAA TTGAAAACAG
301 TCTGCAGGCT GTTTTCTACA GATTACCACT CCCCAGAAAG ATGAAGAATT ACATTTTCTG
AGACGTCCGA CAAAAGATGT CTAATGGTGA GGGGTCTTTC TACTTCTTAA TGTAAAAGAC
401 CTTCTCATTT AGTTTCCCAC AGAGTAAGGC CCATACCACC AAACCTTACT CAGCCAGTGA
GAAGAGTAAA TCAAAGGGTG TCTCATTCCG GGTATGGTGG TTTGGAATGA GTCGGTCACT
501 TATGACATCT CTTTCTTGCT CACCAATGGA GGTGATGGAT GGGGGAGTTA ATAAAATTCC
ATACTGTAGA GAAAGAACGA GTGGTTACCT CCACTACCTA CCCCCTCAAT TATTTTAAGG
601 CTGGTTTCTC ATTGCCATCA TGTTTACTGA TTACCTTTGC TGGTCTGCTG TGAGGGCAAG
GACCAAAGAG TAACGGTAGT ACAAATGACT AATGGAAACG ACCAGACGAC ACTCCCGTTC
701 CATGAAAGAA AGCCTATGTG TCATTCCAAT ACAATAACCC ATTCCTGCCA TGGAGCAAGA
GTACTTTCTT TCGGATACAC AGTAAGGTTA TGTTATTGGG TAAGGACGGT ACCTCGTTCT
801 ACAGATAACA GAAGGAGAGA GGGAGAGGAA GCTGGAAACT ACTTCACCCT TCAATTTCAG
TGTCTATTGT CTTCCTCTCT CCCTCTCCTT CGACCTTTGA TGAAGTGGGA AGTTAAAGTC
901 GGAAACAGCG TTGGTCACCA GTAATCATGA AACTCGATGG TTCCAGAAAC CTGTGGGGAG
CCTTTGTCGC AACCAGTGGT CATTAGTACT TTGAGCTACC AAGGTCTTTG GACACCCCTC
1001 GGGTGCTGTT GTGCTGCCAA ATTGATACAA ACCCCTACAA GAAGCTTTCA CATGAGCCCT
CCCACGACAA CACGACGGTT TAACTATGTT TGGGGATGTT CTTCGAAAGT GTACTCGGGA
1101 AAATACATAT CTGGGGCTGG GAACAGAGCT GGGGCAGGCC TGGGATCCCT GGCAAGCTTT
TTTATGTATA GACCCCGACC CTTGTCTCGA CCCCGTCCGG ACCCTAGGGA CCGTTCGAAA
1201 CAAAACCTCT TCCAATTCAA TAGCATAGCA ACTGCCAATA GCAAGGTATC TTCCATGGCA
GTTTTGGAGA AGGTTAAGTT ATCGTATCGT TGACGGTTAT CGTTCCATAG AAGGTACCGT
1301 GGACACACGT ATACTTGCTA TATACTACAA GTACAGAATT CTCAGTAAGC GGACTTACCA
CCTGTGTGCA TATGAACGAT ATATGATGTT CATGTCTTAA GAGTCATTCG CCTGAATGGT
1401 CCTTTCAGGC CACTGACTTC AAGTGGCAAG AGACAAGGGT CTCTTGTTAT CATGTTATCT
GGAAAGTCCG GTGACTGAAG TTCACCGTTC TCTGTTCCCA GAGAACAATA GTACAATAGA
1501 CATTCAAGAA ACCTAGAATG ACCTGCCTGC AAGGAAGACA GGAAGGACTT TCAGTTTATA
GTAAGTTCTT TGGATCTTAC TGGACGGACG TTCCTTCTGT CCTTCCTGAA AGTCAAATAT
1601 AATAATTAGA AAGGATTGAC TTTCAGAAAT TTTTCTCAAA TCAAGGCTCC TGTTACTTTG
TTATTAATCT TTCCTAACTG AAAGTCTTTA AAAAGAGTTT AGTTCCGAGG ACAATGAAAC
1701 CCAGAGGGCT GCGTGCCTCA GAAAAGCCGG CATCCCTAGC CCGCTCTGGC ACAGGCCATG
GGTCTCCCGA CGCACGGAGT CTTTTCGGCC GTAGGGATCG GGCGAGACCG TGTCCGGTAC
1801 CTGGAGCCAC AGCTCCCTCC ACCGCGGAGC AGGGTTACAA CGTCCCTCTC GGTAGAGGTG
GACCTCGGTG TCGAGGGAGG TGGCGCCTCG TCCCAATGTT GCAGGGAGAG CCATCTCCAC
1901 TGTCTGGCCC CCCTCCCCCA ACCTCTTCTT TCCACACTGC CCCATGAGTT CAGGGAATTT
ACAGACCGGG GGGAGGGGGT TGGAGAAGAA AGGTGTGACG GGGTACTCAA GTCCCTTAAA
2001 AGATGAGTGT AGATAAAAGG AGTGCAGAAG GCACGAGGAA GCCACAGTGC TCCGGATCCT
TCTACTCACA TCTATTTTCC TCACGTCTTC CGTGCTCCTT CGGTGTCACG AGGCCTAGGA
2101 CAGGAACCCG CGACCGCTCG CAGCGCTCTC TTGACCACTA TGAGCCTCCT GT
GTCCTTGGGC GCTGGCGAGC GTCGCGAGAG AACTGGTGAT ACTCGGAGGA CA
328
GALNAC promoter
1 GTATAAATAC CTTTGGAAAG TCCCTGGTGG AATTCATATC AAAGCGGCAC CGTGATTTTT
CATATTTATG GAAACCTTTC AGGGACCACC TTAAGTATAG TTTCGCCGTG GCACTAAAAA
101 ACACCTGAAT TTGAAAGTGA TCTGGGTGGG CCCAGCGCCA TCTCCATAAC GGAGTTATGT
TGTGGACTTA AACTTTCACT AGACCCACCC GGGTCGCGGT AGAGGTATTG CCTCAATACA
201 CAGTATGTGT GGCCCTGGAA TAATGTTCCA CACACCCTTA CAGAAGGGGA TTTCCTCCTT
GTCATACACA CCGGGACCTT ATTACAAGGT GTGTGGGAAT GTCTTCCCCT AAAGGAGGAA
301 TTGCACACTG GTCTGACAGC TGCCTGGCCC AGGGCCTTCC TTGCAGACGC ATGTACAACC
AACGTGTGAC CAGACTGTCG ACGGACCGGG TCCCGGAAGG AACGTCTGCG TACATGTTGG
401 AATTACTCGA GTATATAAAC CTCACTGAAA GGCAGGCTTT TCTTGGGAGC TAATAAATAA
TTAATGAGCT CATATATTTG GAGTGACTTT CCGTCCGAAA AGAACCCTCG ATTATTTATT
501 ATCATCATCT ATTGGGAATT GTGAACCCTG CAAAAAGCAG CTCGTTGTAT TTTCAGAAAT
TAGTAGTAGA TAACCCTTAA CACTTGGGAC GTTTTTCGTC GAGCAACATA AAAGTCTTTA
601 AAGTGGAGTC TATATGGAAA AAGCAATCTA GTCTGAGATT CTAAGGCAAG TCTCTTTGCT
TTCACCTCAG ATATACCTTT TTCGTTAGAT CAGACTCTAA GATTCCGTTC AGAGAAACGA
701 TTTGCAGGAA AACAAGACAG GATTTTAAAG AACTCCCCTC TCATCCCGGT TTCCCATCTG
AAACGTCCTT TTGTTCTGTC CTAAAATTTC TTGAGGGGAG AGTAGGGCCA AAGGGTAGAC
801 ATGGGTGCTG AGCAGAAGTT TATGACCTCA GGGTGGACTG TAGCTTCAGG GGGGCGAGAT
TACCCACGAC TCGTCTTCAA ATACTGGAGT CCCACCTGAC ATCGAAGTCC CCCCGCTCTA
901 GTCAGGAATG ACCCTTCGGT GGCATGTAGT CTACAGTTAA CGGAGCACTT TCATTTCCAC
CAGTCCTTAC TGGGAAGCCA CCGTACATCA GATGTCAATT GCCTCGTGAA AGTAAAGGTG
1001 CGGGGACACA GGCCGGCAAG AGACTGCAGA TTCTTTTTGT CCCTTGGACC TCAGTTTCCT
GCCCCTGTGT CCGGCCGTTC TCTGACGTCT AAGAAAAACA GGGAACCTGG AGTCAAAGGA
1101 TCTGCCAGAA TTTCATGTGT CTTTTCTTTA ACTGATGGCA TCTTCAGCCC AGAGTCAGTG
AGACGGTCTT AAAGTACACA GAAAAGAAAT TGACTACCGT AGAAGTCGGG TCTCAGTCAC
1201 CAGGTGGTTC CCTGGGGCAG CCGACTCCAG GCCACTGCGG CAGGCCGTGG CGATCGGGGT
GTCCACCAAG GGACCCCGTC GGCTGAGGTC CGGTGACGCC GTCCGGCACC GCTAGCCCCA
1301 GGGCCAAAGA GCCGGGCCAG CCTTCCCGGG ATGCAAAAAT ACAACAGAGG GCGCCGAACT
CCCGGTTTCT CGGCCCGGTC GGAAGGGCCC TACGTTTTTA TGTTGTCTCC CGCGGCTTGA
1401 TCCAGACCGC CAAGTTCCTT AAAGATGTCT CTGGCGGCCG GGCGCGGTGG CTTACGCCTG
AGGTCTGGCG GTTCAAGGAA TTTCTACAGA GACCGCCGGC CCGCGCCACC GAATGCGGAC
1501 TGAGGTCGGG AGTTCGAGAC CAGCCTGACC AACATGGAGA AACCCCGTCT GTACTAAAAA
ACTCCAGCCC TCAAGCTCTG GTCGGACTGG TTGTACCTCT TTGGGGCAGA CATGATTTTT
1601 ATCCCGGCTA CTCGGGAGGC TGAGGCAGGA GACTCTCTTG AACCCGGGAG GCTGAGGCAG
TAGGGCCGAT GAGCCCTCCG ACTCCGTCCT CTGAGAGAAC TTGGGCCCTC CGACTCCGTC
1701 CGAGATCGCG CCATTGCATT CCAGCCTGGG CAACAAGAGC GAAACTCTGT CTTTAAAAAA
GCTCTAGCGC GGTAACGTAA GGTCGGACCC GTTGTTCTCG CTTTGAGACA GAAATTTTTT
1801 TTTCGATGTG CTTTTATTTG GAATCACCGC AACACACAAG CAGTGTTGAC TCGGAGGGGG
AAAGCTACAC GAAAATAAAC CTTAGTGGCG TTGTGTGTTC GTCACAACTG AGCCTCCCCC
1901 TGATCTCACA TTCCAGACTG GAGCTGATGT GTGTCAGCGC GACATGGGGC GGGGGGAGGG
ACTAGAGTGT AAGGTCTGAC CTCGACTACA CACAGTCGCG CTGTACCCCG CCCCCCTCCC
2001 CAAACTTTTC CTCCCAGCGC TCGGGGAGTC AGGTTGACGC GCCCTGGATG CGGGGCTAGA
GTTTGAAAAG GAGGGTCGCG AGCCCCTCAG TCCAACTGCG CGGGACCTAC GCCCCGATCT
2101 GAGGCTCCCG GGCTGGACTC AGGCTTCTCA GGTACAAGTT AGGT
CTCCGAGGGC CCGACCTGAG TCCGAAGAGT CCATGTTCAA TCCA
329
GAPDH promoter
1 ACTCGTGTTC CCTAATCCCA TCTCCAAAGG TTGGCAGCAG ACCGGCCCAG GCTCGTGGAA
TGAGCACAAG GGATTAGGGT AGAGGTTTCC AACCGTCGTC TGGCCGGGTC CGAGCACCTT
101 CCTGTCTCCC AGCATTCCTC ATTGTTCCCG GGTCTGCAGA GGGCGTGAGC TATGCTGCAG
GGACAGAGGG TCGTAAGGAG TAACAAGGGC CCAGACGTCT CCCGCACTCG ATACGACGTC
201 CTCAAGTCTT CTCTGCTGAG TCACCTTCGA ACCGGAGGCT GTGAGCTGGC TGTCGTGACC
GAGTTCAGAA GAGACGACTC AGTGGAAGCT TGGCCTCCGA CACTCGACCG ACAGCACTGG
301 CAGTAGTGCT CCCTGGGCAC TGAGCTCCCT CTTTGCGGGG AGAAGACAGT AATGAAAAAT
GTCATCACGA GGGACCCGTG ACTCGAGGGA GAAACGCCCC TCTTCTGTCA TTACTTTTTA
401 GCAGGAGCAT GGAGGTGCTC TTAATGCTCT CAAT GAGAAA GGGTTAACGG TCCTGGTTGC
CGTCCTCGTA CCTCCACGAG AATTACGAGA GTTACTCTTT CCCAATTGCC AGGACCAACG
501 CACCCCACCC CTTTCACCAT TAGGGACCTT CTTGCCTTGC TCTTGCTACT CTGCTCTGGG
GTGGGGTGGG GAAAGTGGTA ATCCCTGGAA GAACGGAACG AGAACGATGA GACGAGACCC
601 GCCAGACGAG GACACAGCCT GGCTCTGGGT CCCAGCAGGA AAGGCAATCC CAGAAAGGCA
CGGTCTGCTC CTGTGTCGGA CCGAGACCCA GGGTCGTCCT TTCCGTTAGG GTCTTTCCGT
701 GATTATCACC AGGCAGGCTA AACTTAGCAA CCGGCTTTTA GCTAGAAGGG CAGGGGGCTG
CTAATAGTGG TCCGTCCGAT TTGAATCGTT GGCCGAAAAT CGATCTTCCC GTCCCCCGAC
801 CCCTCCCATG CACCTGCTGA TGGGCCAAGG CCACCCCACC CCACCCCCTT CCTTACAAGT
GGGAGGGTAC GTGGACGACT ACCCGGTTCC GGTGGGGTGG GGTGGGGGAA GGAATGTTCA
901 CTGCCCTCCT ACCAGAAGAA TGGATCCCCT GTGGGAGGGG GCAGGGGACC TGTTCCCACC
GACGGGAGGA TGGTCTTCTT ACCTAGGGGA CACCCTCCCC CGTCCCCTGG ACAAGGGTGG
1001 GACTCACCCT GCCCTCAATA TCCCCCGGCG CAGCCAGTGA AAGGGAGTCC CTGGCTCCTG
CTGAGTGGGA CGGGAGTTAT AGGGGGCCGC GTCGGTCACT TTCCCTCAGG GACCGAGGAC
1101 TCACGTCCCG CTCTTCGCCC CAGGCTGGAT GGAATGAAAG GCACACTGTC TCTCTCCCTA
AGTGCAGGGC GAGAAGCGGG GTCCGACCTA CCTTACTTTC CGTGTGACAG AGAGAGGGAT
1201 AGGCCTCTGG GCCCCCACCA GCCATCCTGT CCTCCGCCTG GGGCCCCAGC CCGGAGAGAG
TCCGGAGACC CGGGGGTGGT CGGTAGGACA GGAGGCGGAC CCCGGGGTCG GGCCTCTCTC
1301 TCAGGTCCAG GCTACAGGGC TGCAGGACAT CGTGACCTTC CGTGCAGAAA CCTCCCCCTC
AGTCCAGGTC CGATGTCCCG ACGTCCTGTA GCACTGGAAG GCACGTCTTT GGAGGGGGAG
1401 CCCAGTGCCC AGTGCCCAGT GCCCAGCCCA GGCCTCGGTC CCAGAGATGC CAGGAGCCAG
GGGTCACGGG TCACGGGTCA CGGGTCGGGT CCGGAGCCAG GGTCTCTACG GTCCTCGGTC
1501 GGCCCCCGCC CGAGGCCCAT GGGCCCCTCC TAGGCCTTTG CCTGAGCAGT CCGGTGTCAC
CCGGGGGCGG GCTCCGGGTA CCCGGGGAGG ATCCGGAAAC GGACTCGTCA GGCCACAGTG
1601 CTCTCAGCCT TTGAAAGAAA GAAAGGGGAG GGGGCAGGCC GCGTGCAGCC GCGAGCGGTG
GAGAGTCGGA AACTTTCTTT CTTTCCCCTC CCCCGTCCGG CGCACGTCGG CGCTCGCCAC
1701 AGTCCTCCTG TTTCATCCAA GCGTGTAAGG GTCCCCGTCC TTGACTCCCT AGTGTCCTGC
TCAGGAGGAC AAAGTAGGTT CGCACATTCC CAGGGGCAGG AACTGAGGGA TCACAGGACG
1801 CCATCGGGCC AATCTCAGTC CCTTCCCCCC TACGTCGGGG CCCACACGCT CGGTGCGTGC
GGTAGCCCGG TTAGAGTCAG GGAAGGGGGG ATGCAGCCCC GGGTGTGCGA GCCACGCACG
1901 GAAAGTAGGG CCCGGCTACT AGCGGTTTTA CGGGCGCACG TAGCTCAGGC CTCAAGACCT
CTTTCATCCC GGGCCGATGA TCGCCAAAAT GCCCGCGTGC ATCGAGTCCG GAGTTCTGGA
2001 AGTCACCGCC TGCCGCCGCG CCCCCGGTTT CTATAAATTG AGCCCGCAGC CTCCCGCTTC
TCAGTGGCGG ACGGCGGCGC GGGGGCCAAA GATATTTAAC TCGGGCGTCG GAGGGCGAAG
2101 TTTGCGTCGC CAGGTGAAGA CGGGCGGAGA GAAACCCGGG AGGCTAGGGA CGGCCTGAAG
AAACGCAGCG GTCCACTTCT GCCCGCCTCT CTTTGGGCCC TCCGATCCCT GCCGGACTTC
2201 GCGGGGTGGG CCCGGGCGGC CTCCGCATTG CAGGGGCGGG CGGAGGACGT GATGCGGCGC
CGCCCCACCC GGGCCCGCCG GAGGCGTAAC GTCCCCGCCC GCCTCCTGCA CTACGCCGCG
2301 CGTGTGTGTC GGCCGGGGCC ACTAGGCGCT CACTGTTCTC TCCCTCC
GCACACACAG CCGGCCCCGG TGATCCGCGA GTGACAAGAG AGGGAGG
330
ID1 promoter
1 GTCGTGTGGA GCCTCAGTTT CCTTTGTATA AAGAAACCAA AGAGCTCCTT TCTTTAGAGT
CAGCACACCT CGGAGTCAAA GGAAACATAT TTCTTTGGTT TCTCGAGGAA AGAAATCTCA
1 0 1  AGTAAGACCC TGTATCATTA TTATTTTATT TTGAAACAGA GTCCCACTCT GTCGCCCAGG
TCATTCTGGG ACATAGTAAT AATAAAATAA AACTTTGTCT CAGGGTGAGA CAGCGGGTCC
2 0 1  GCCTCCTGGG TTCCAGCGAG TCTCCTGCCT CAGCCTCCTG AGTAGCTGGG GTATTACAGG
CGGAGGACCC AAGGTCGCTC AGAGGACGGA GTCGGAGGAC TCATCGACCC CATAATGTCC
3 0 1  AGACGGGATT TCACCATGTT GGTCAGGCTG GTCTCGAACT CCTGACCTCG TGATCTGCCC
TCTGCCCTAA AGTGGTACAA CCAGTCCGAC CAGAGCTTGA GGACTGGAGC ACTAGACGGG
4 01 ACTGCGCCCG GCCCCCTGTA TCCTTTTTTT TTTTTTTTTT TTTGAGACGA GTCTCACTCT
TGACGCGGGC CGGGGGACAT AGGAAAAAAA AAAAAAAAAA AAACTCTGCT CAGAGTGAGA
5 0 1  GCAACCTCCG CCTCCCAGGT TCAAGCAATT CTCCTGTCTC AGCCTCCCGA GTAGCTGGGA
CGTTGGAGGC GGAGGGTCCA AGTTCGTTAA GAGGACAGAG TCGGAGGGCT CATCGACCCT
6 0 1  TTTAGTAGAG ATGGGGTTTC ACCATATTGG TCAGGCTGGT CTCGAACTCC TGACCTCAGG
AAATCATCTC TACCCCAAAG TGGTATAACC AGTCCGACCA GAGCTTGAGG ACTGGAGTCC
7 01 GGCGTGAGCC ACCGCGCAGC CCTTCATTTT TTAAAATAAG AAATAAATGA AAAAAGATGA
CCGCACTCGG TGGCGCGTCG GGAAGTAAAA AATTTTATTC TTTATTTACT TTTTTCTACT
8 01 AGAAATTAAT AATGGTCACG TTTGTGATTA TTATTTAAAC ACCAAGCAGA TATTAAATAT
TCTTTAATTA TTACCAGTGC AAACACTAAT AATAAATTTG TGGTTCGTCT ATAATTTATA
9 0 1  AGCTGCAGAG CTGGAAAGAG AACTCAGGCC TTTTTCCCCA CGCTGGAAGG GGTAGCTGGG
TCGACGTCTC GACCTTTCTC TTGAGTCCGG AAAAAGGGGT GCGACCTTCC CCATCGACCC
1 0 0 1  CCAAGCTGTG GGTCTGGGTT GGGAGACTCG CAGGTGTGGG GCGGGGAGGT AAGGTGACCC
GGTTCGACAC CCAGACCCAA CCCTCTGAGC GTCCACACCC CGCCCCTCCA TTCCACTGGG
1 1 0 1  CTCCCGCCCG GGGTCTGCAG GTGACGGGCT GGGGGGAGCA CGGGAACTAG CTAGACCAGT
GAGGGCGGGC CCCAGACGTC CACTGCCCGA CCCCCCTCGT GCCCTTGATC GATCTGGTCA
1 2 0 1  ACAGTCCGTC CGGGTTTTAT GAATGGGTGA CGTCACAGGC CTGGCGTCTA ACGGTCTGAG
TGTCAGGCAG GCCCAAAATA CTTACCCACT GCAGTGTCCG GACCGCAGAT TGCCAGACTC
1 3 0 1  AGGGGGGAGA CTGTAGCTCC GCAGCTGCCG CGCCGTGGGA GGGAGACCCT GCTCTGAGGT
TCCCCCCTCT GACATCGAGG CGTCGACGGC GCGGCACCCT CCCTCTGGGA CGAGACTCCA
14 01 AAACATTAAA AAATCACGAA CTGTTGCAGG TTCAGGAAAT TTTTGCAAGG AGCTGCAAAT
TTTGTAATTT TTTAGTGCTT GACAACGTCC AAGTCCTTTA AAAACGTTCC TCGACGTTTA
1501  ATCTAGTTCA CTTCCCAGCC ACCCAGCCCC AAACTTACTA GACTTTCCCG AATTAATTGC
TAGATCAAGT GAAGGGTCGG TGGGTCGGGG TTTGAATGAT CTGAAAGGGC TTAATTAACG
1601  GGAACACGAA CAGCAACATT ATTTAGGAAT TGAGAAAGCC CAGGGGAGCA GATGTAAAGG
CCTTGTGCTT GTCGTTGTAA TAAATCCTTA ACTCTTTCGG GTCCCCTCGT CTACATTTCC
17 01 GGGTCCGAGA AGCATCTTCC AAGAGGGTCC GGAAACCCAG GCTCTCTGGG CTATCCAGAG
CCCAGGCTCT TCGTAGAAGG TTCTCCCAGG CCTTTGGGTC CGAGAGACCC GATAGGTCTC
1 8 0 1  TGAAATGGAG CTGGAGAAGT GAGAAAGTGA ATATGGGAAA AACTGATTCC TGAGGTCTTT
ACTTTACCTC GACCTCTTCA CTCTTTCACT TATACCCTTT TTGACTAAGG ACTCCAGAAA
1 9 0 1  CCAGAGGAGC CCAGTGCGGC CCTCGCCTCT ACCCGCTGCC CTGCCCGGTG CCCTGCCACC
GGTCTCCTCG GGTCACGCCG GGAGCGGAGA TGGGCGACGG GACGGGCCAC GGGACGGTGG
2 0 0 1  CACTGCGAGC AGGCACTAGA CGAGCAGGAG GCTGGACCTA GGAGCGCGGG TCACGCCCCC
GTGACGCTCG TCCGTGATCT GCTCGTCCTC CGACCTGGAT CCTCGCGCCC AGTGCGGGGG
2 1 0 1  CCTCCGGGGG CCGTGGCGTG TTTATAAAAG ACAAGCTGTG GCTCCGCACT CTCATTCCAC
GGAGGCCCCC GGCACCGCAC AAATATTTTC TGTTCGACAC CGAGGCGTGA GAGTAAGGTG
2 2 0 1  CACCTCATTT TTTTCGCTTT GCCCATTCTG TTTCAGCCAG TCGCCAAGAA TC
GTGGAGTAAA AAAAGCGAAA CGGGTAAGAC AAAGTCGGTC AGCGGTTCTT AG
331
IGSF4 promoter
1 AGGATTCTTG CCATATAGGA CCTGCCTTTA TAGTTTACAT ATCACTTTCA GCATACATAT
TCCTAAGAAC GGTATATCCT GGACGGAAAT ATCAAATGTA TAGTGAAAGT CGTATGTATA
101 TCGCCCAGGC TGGAGTGCAA TGATGCGATC TCAGCTCACT GCAACCTCCG CCTCCTGGGT
AGCGGGTCCG ACCTCACGTT ACTACGCTAG AGTCGAGTGA CGTTGGAGGC GGAGGACCCA
201 TTACAGGTGT GTGTCATCAC GCCTGGCTAA TTTTTGTATT TTTATTAGAG ACGGAGTTTC
AATGTCCACA CACAGTAGTG CGGACCGATT AAAAACATAA AAATAATCTC TGCCTCAAAG
301 TGATCCATCT GCCTCAACCT CCCAAAGTGC TGGGATTACA GGCATCAGTC AGCGTGCCCG
ACTAGGTAGA CGGAGTTGGA GGGTTTCACG ACCCTAATGT CCGTAGTCAG TCGCACGGGC
4 01 GCTCTCTATT TGGTCCGACC CAGGTACCTC ACTGCCAGAG GTAGTAAGAA CGGGTAGGAC
CGAGAGATAA ACCAGGCTGG GTCCATGGAG TGACGGTCTC CATCATTCTT GCCCATCCTG
501 GTTTCCTGTC TCCTGTAGTG CTGTTCTCCT GTTGGAGCTT TCCCCACTTC TGAAGGACTG
CAAAGGACAG AGGACATCAC GACAAGAGGA CAACCTCGAA AGGGGTGAAG ACTTCCTGAC
601 ATATCCAGGG CTGTGAAGAC CGGGCAGTCT CGAAATTAGT TTATGCATAA TGGATAATAG
TATAGGTCCC GACACTTCTG GCCCGTCAGA GCTTTAATCA AATACGTATT ACCTATTATC
7 01 ATCATGACTT CCTTTTTGAT ATGTATTATT TATTTATTTT ATAGCAAGAT GAGGACAGAA
TAGTACTGAA GGAAAAACTA TACATAATAA ATAAATAAAA TATCGTTCTA CTCCTGTCTT
801 CTCAGACTTA GCAATTTACA TTCAGTAATC TCTTGGTCAT TTAGCCACAG ATAATTTGTC
GAGTCTGAAT CGTTAAATGT AAGTCATTAG AGAACCAGTA AATCGGTGTC TATTAAACAG
901 CAAATTGTAT TTCCTACATC TTATTGTTCT GCATTCTATG AATACTTAAA TTATTATAAA
GTTTAACATA AAGGATGTAG AATAACAAGA CGTAAGATAC TTATGAATTT AATAATATTT
1001 GAGCAACAGA GGGTCAGAGC GCACACGATC TTCTAGAGGG GAAGAAAATA AGTAATTAAA
CTCGTTGTCT CCCAGTCTCG CGTGTGCTAG AAGATCTCCC CTTCTTTTAT TCATTAATTT
1101 AAGCAAAGAG AATTTCGGGG AGGGAGAGTG AGTCCGGAGA TGCAAGTCGC TTTAGCAGGA
TTCGTTTCTC TTAAAGCCCC TCCCTCTCAC TCAGGCCTCT ACGTTCAGCG AAATCGTCCT
1201 GGTCCCCAGC TTCCTTAGGA AGGGCTGGGG GCGCAGAGGA GGAGTGAGAG GGTTTGAGCC
CCAGGGGTCG AAGGAATCCT TCCCGACCCC CGCGTCTCCT CCTCACTCTC CCAAACTCGG
1301 CCTCTCCCCA ACTCCCACCA CCCCCGCTCT TCACCTGAAG CCTTGACTAA TTTTTTCCGT
GGAGAGGGGT TGAGGGTGGT GGGGGCGAGA AGTGGACTTC GGAACTGATT AAAAAAGGCA
1401 CACATATATT CAACACACAC CTATATATTA AAACCAGGGA GGAGACCCTC GACAAGCGGA
GTGTATATAA GTTGTGTGTG GATATATAAT TTTGGTCCCT CCTCTGGGAG CTGTTCGCCT
1501 TTCTGCCGCA AAAAGACCGA CTGGAAAATC TCAGAACCCG ACTCTACGGC TGCCTTCTCC
AAGACGGCGT TTTTCTGGCT GACCTTTTAG AGTCTTGGGC TGAGATGCCG ACGGAAGAGG
1601 TCCCGCTCCG CCGGACGTGC AAAGCACGCA TGCACTTCTC CCAGATTGTT TTGTCAATCC
AGGGCGAGGC GGCCTGCACG TTTCGTGCGT ACGTGAAGAG GGTCTAACAA AACAGTTAGG
17 01 GTTCCCAAAG ATCTATTCCT TCGGTGCAAG GTGAGTGACG GAAATTTGCA ACGTCTGGTT
CAAGGGTTTC TAGATAAGGA AGCCACGTTC CACTCACTGC CTTTAAACGT TGCAGACCAA
1801 TCTTAAGGGA GATTCTCCAG TCGTCGGTCT GATACAGCGA TTGCTATAAA CATTCCTAAT
AGAATTCCCT CTAAGAGGTC AGCAGCCAGA CTATGTCGCT AACGATATTT GTAAGGATTA
1901 GTCCTTGCAC GCCAGGCGCC CGGGAGAACA CTTTTTCCTT GATCCGGGGA AAGCAAAACC
CAGGAACGTG CGGTCCGCGG GCCCTCTTGT GAAAAAGGAA CTAGGCCCCT TTCGTTTTGG
2001 TGGCCCCGCC CCTAGGTGGC GCGGGCGCGC CGCCGAACGC CAGCGCCAGG GGGCGGGGTG
ACCGGGGCGG GGATCCACCG CGCCCGCGCG GCGGCTTGCG GTCGCGGTCC CCCGCCCCAC
2101 CGGCGCTGTG ATTGGTCTGC CCGGACTCCG CCTCCAGCGC ATGTCATTAG CATCTCATTA
GCCGCGACAC TAACCAGACG GGCCTGAGGC GGAGGTCGCG TACAGTAATC GTAGAGTAAT
2201 CTGAGGCAGG TGCCCGACAT GGCGAGTGTA GTGCTGCCGA GCGGATCCCA GTGTGCGGCG
GACTCCGTCC ACGGGCTGTA CCGCTCACAT CACGACGGCT CGCCTAGGGT CACACGCCGC
2301 TTCTGCTGTT GCTCTTCTCC GCCGCGGCAC TGATCCCCAC AGGTAGGTGT GGGCACCGAC
AAGACGACAA CGAGAAGAGG CGGCGCCGTG ACTAGGGGTG TCCATCCACA CCCGTGGCTG
2401 GGCCACAGAG GGGGGAAACG TTTCCATGAC AACCTCCCCC CACTTCCTAC ATCCGAAGCG
CCGGTGTCTC CCCCCTTTGC AAAGGTACTG TTGGAGGGGG GTGAAGGATG TAGGCTTCGC
332
IL11 promoter
1 GAGAGAGAGC TCTTACCTGA GGCGATGAGG TCATGTCCCA CCGTGGGGGG GCTGTGACCT
CTCTCTCTCG AGAATGGACT CCGCTACTCC AGTACAGGGT GGCACCCCCC CGACACTGGA
1 0 1  CTGGATTGGG AAGGGGAAGC CTCCAACCAG CCCGGCAGTC TCGGAGGCTG ACACGAGGGG
GACCTAACCC TTCCCCTTCG GAGGTTGGTC GGGCCGTCAG AGCCTCCGAC TGTGCTCCCC
2 0 1  TCAGTCCCAT CCTGTCCTTC CCTGCCATCT AGGTCTGGGG GCTCTCGGGG ACATGGCTTG
AGTCAGGGTA GGACAGGAAG GGACGGTAGA TCCAGACCCC CGAGAGCCCC TGTACCGAAC
3 0 1  CTCCTCTGCC CCCATGCCTG GGGCTGGCCC ACTGTGAGCC TGGGTAGGCG TCGCTGCCTC
GAGGAGACGG GGGTACGGAC CCCGACCGGG TGACACTCGG ACCCATCCGC AGCGACGGAG
4 0 1  CTGCCTCCAC CTCTGTGCGG TGACGTCCAG GGCTCTGGCC CCGGTGGTTC TGGCCACTGT
GACGGAGGTG GAGACACGCC ACTGCAGGTC CCGAGACCGG GGCCACCAAG ACCGGTGACA
5 0 1  CTGCCCCATC TCTCTCGAAG GCGACATCTT TTTCTCTGTG TCCCTGATGT GTTCAGAAAA
GACGGGGTAG AGAGAGCTTC CGCTGTAGAA AAAGAGACAC AGGGACTACA CAAGTCTTTT
6 0 1  CTTCACGTGA ATGAGCTCGC TTTATCCTCA TCGTGGCATT TAGGCGGATG AGGGTGCATC
GAAGTGCACT TACTCGAGCG AAATAGGAGT AGCACCGTAA ATCCGCCTAC TCCCACGTAG
7 01  GGGGAGAGTC GCACATGGAG GTCTTGCCTC TATGGAGTGT CTCAGCGCCT CTTGGTCCTC
CCCCTCTCAG CGTGTACCTC CAGAACGGAG ATACCTCACA GAGTCGCGGA GAACCAGGAG
8 01 CTTTGAGAAA GGCTTTTCAA AAGGCCAGGC GTGGTGGTTC ACACCTGTAT TCCCACCACT
GAAACTCTTT CCGAAAAGTT TTCCGGTCCG CACCACCAAG TGTGGACATA AGGGTGGTGA
90 1  TTGAGACCAG CCTGGGCAAC ATGGCAAAAC CCTATCTCTA CTAAAAATAC AAAAAATAGC
AACTCTGGTC GGACCCGTTG TACCGTTTTG GGATAGAGAT GATTTTTATG TTTTTTATCG
1 0 0 1  AGGCTGAGGC ATGAGAATCA CTTGAACCTG GGAGGCGGAG GTTACAGTGA GCTGAGATCA
TCCGACTCCG TACTCTTAGT GAACTTGGAC CCTCCGCCTC CAATGTCACT CGACTCTAGT
1 1 0 1  TCTCAAAAAA ACCAAAAACG AGGCCAGGCA CGGTAGCTCA CACCTGTCAT CCCAGCACTT
AGAGTTTTTT TGGTTTTTGC TCCGGTCCGT GCCATCGAGT GTGGACAGTA GGGTCGTGAA
1 2 0 1  AGACCAGCCT GGCCAACATG GTAAGACCCC GTCTCTACTA AAAATACAAA ATTAGCCGGG
TCTGGTCGGA CCGGTTGTAC CATTCTGGGG CAGAGATGAT TTTTATGTTT TAATCGGCCC
1 3 0 1  TGAGGCAGGA GAATCGCTTG AACCCGGGAG GTGGAGGTTG CAGTGAGCTG AGATTGTGCC
ACTCCGTCCT CTTAGCGAAC TTGGGCCCTC CACCTCCAAC GTCACTCGAC TCTAACACGG
14 01 AGACTCAGTA CCAAAAAACA AACAAACAAA AAACAAACAA AAAATGAGAA AGGCTTTTAC
TCTGAGTCAT GGTTTTTTGT TTGTTTGTTT TTTGTTTGTT TTTTACTCTT TCCGAAAATG
1 5 0 1  CTGTCTTTCT AATATCTCTG TCTCCCCTTT TCTGTCCCTG GGGCCTCTCC GTCCCTGTCA
GACAGAAAGA TTATAGAGAC AGAGGGGAAA AGACAGGGAC CCCGGAGAGG CAGGGACAGT
1 6 0 1  CTGCGGCATC CTCTGTCTCA GAGTCTTGGT GTCTCTGTTC CTTTCCCCTC GGGGTCTCCC
GACGCCGTAG GAGACAGAGT CTCAGAACCA CAGAGACAAG GAAAGGGGAG CCCCAGAGGG
1 7 0 1  TCTGATCTCT GACTCCCAGA ACCTCTCCCT CTGTCTCCAG GGCTGCCCCT CTGATCCTCT
AGACTAGAGA CTGAGGGTCT TGGAGAGGGA GACAGAGGTC CCGACGGGGA GACTAGGAGA
1 8 0 1  TGGATCTCCA TCTCCCTGTC TCTGTCTCAG TCTGTCCTTC ACTCTGTGTG TGTGTGTGTC
ACCTAGAGGT AGAGGGACAG AGACAGAGTC AGACAGGAAG TGAGACACAC ACACACACAG
1 9 0 1  CTCCACCTCT CCAGGCCCCT GTCTTGTCCC TCCGTCCGGC CTTTCTCTGC CTTTCCGTCC
GAGGTGGAGA GGTCCGGGGA CAGAACAGGG AGGCAGGCCG GAAAGAGACG GAAAGGCAGG
2 0 0 1  GGACCCCCAC CCACAGTCGG GCCCCAGCGC TTGAGCCTGA GTGTCTGCTC CGGCCCGTGG
CCTGGGGGTG GGTGTCAGCC CGGGGTCGCG AACTCGGACT CACAGACGAG GCCGGGCACC
2 1 0 1  TCCGACCACC CCCCCCTTTC CCTTTTCAAC TTTTCCAACT TTTCCTTCCG TGCCCTCCTC
AGGCTGGTGG GGGGGGAAAG GGAAAAGTTG AAAAGGTTGA AAAGGAAGGC ACGGGAGGAG
2 2 0 1  CTGAATGGAA AAGGCAGGCA GGGAGGGTGA GTCAGGATGT GTCAGGCCGC CCTCCCCTGC
GACTTACCTT TTCCGTCCGT CCCTCCCACT CAGTCCTACA CAGTCCGGCG GGAGGGGACG
2 301  CCCCCAGGCG TCCACACTCC CTCACTGCCG CGGCCCTGCT GCTCAGGGCA CATGCCTCCC
GGGGGTCCGC AGGTGTGAGG GAGTGACGGC GCCGGGACGA CGAGTCCCGT GTACGGAGGG
24 01 GGCAGCGGAC AGGGAAGGGT TAAAGGCCCC CGGCTCCCTG CCCCCTGCCC TGGGGAACCC
CCGTCGCCTG TCCCTTCCCA ATTTCCGGGG GCCGAGGGAC GGGGGACGGG ACCCCTTGGG
333
MMP3 promoter
1 AAAATAGAGT AGCAGAGGCA GGTACAAGGT ACCATTGAAC AATGATTAAT GACTCTTCCT
TTTTATCTCA TCGTCTCCGT CCATGTTCCA TGGTAACTTG TTACTAATTA CTGAGAAGGA
101 TTTTAAAATA TAGCAAACTT TTGTATTTAG TTCAGGAACA GCATGGCCCA TTTTGCCAAT
AAAATTTTAT ATCGTTTGAA AACATAAATC AAGTCCTTGT CGTACCGGGT AAAACGGTTA
201 GGCTTTCCTC TAAACTTTAA ATATGTTTTA TAAGTTATAA CTCCAGAGAA AATTTACAAA
CCGAAAGGAG ATTTGAAATT TATACAAAAT ATTCAATATT GAGGTCTCTT TTAAATGTTT
301 TTCTACACTT TTAACCTCTC AATATTTTAT CTGTTGGGCT CCACTGTTTC TTCCTGGAAT
AAGATGTGAA AATTGGAGAG TTATAAAATA GACAACCCGA GGTGACAAAG AAGGACCTTA
401 CAATGTGGCC AAATATTTTC CCTGTATTTC AATCAGGACA AGACATGGTT TTTCCCCCCA
GTTACACCGG TTTATAAAAG GGACATAAAG TTAGTCCTGT TCTGTACCAA AAAGGGGGGT
501 TCTTTAGGCC AGGTGCCGTG ACCCATGTCT GTAATCCTAG CACTTTGAGA GGTTGAGGCA
AGAAATCCGG TCCACGGCAC TGGGTACAGA CATTAGGATC GTGAAACTCT CCAACTCCGT
601 AACATAGTGA AACCTCTGTC TCTATTTTTT AAATAAAATT TGAAAAAGTC TTTAGACATA
TTGTATCACT TTGGAGACAG AGATAAAAAA TTTATTTTAA ACTTTTTCAG AAATCTGTAT
701 CCCTGCCAAG TGGCTATCAA CTGTGTGGGC ATCTTCAGTC ATAGGGATCT TATTGCCACA
GGGACGGTTC ACCGATAGTT GACACACCCG TAGAAGTCAG TATCCCTAGA ATAACGGTGT
801 GTTTATTAAG AAACACACAA AAAATAAAGC AAAGAAGAAA ATGCAAAAGA GTTATAAATG
CAAATAATTC TTTGTGTGTT TTTTATTTCG TTTCTTCTTT TACGTTTTCT CAATATTTAC
901 GCACATTTGT ATCCATCATT CTACTGAGTT CTTACTCCCA AGATGTTCTT CCCTTTAGCA
CGTGTAAACA TAGGTAGTAA GATGACTCAA GAATGAGGGT TCTACAAGAA GGGAAATCGT
1001 AATGTGGTGA TCAGGGAAGC ATTGAGGAGA TGGATGGTGG CAGGTGGCAA GAGGACTATA
TTACACCACT AGTCCCTTCG TAACTCCTCT ACCTACCACC GTCCACCGTT CTCCTGATAT
1101 CTTGCATTCA AGCATTTATT ATACACCAAT AATGTGAGCA ACACTTTACT TGACAAAGAA
GAACGTAAGT TCGTAAATAA TATGTGGTTA TTACACTCGT TGTGAAATGA ACTGTTTCTT
1201 GAGAAAATTT AGGATGGATT CTGTTCTTCA ACTTCAAAGC ATCTGCTAAT TTGAATTTAG
CTCTTTTAAA TCCTACCTAA GACAAGAAGT TGAAGTTTCG TAGACGATTA AACTTAAATC
1301 GAAGACAAGG ACAGAGAGAA TTTCAGTCCG GTAAGCAATG TAATTCATTT CAATTCTACA
CTTCTGTTCC TGTCTCTCTT AAAGTCAGGC CATTCGTTAC ATTAAGTAAA GTTAAGATGT
14 01 TAAATTGGTT ACAGAATTAA AACCAACCCA AAGGGAATAT ACTTCCTTCT TTTTCACAGA
ATTTAACCAA TGTCTTAATT TTGGTTGGGT TTCCCTTATA TGAAGGAAGA AAAAGTGTCT
1501 AGAACCAGCA AATCCAACGA CAGTCAATAG CAGGCATTAC AAATCAGATT CAGAAAAATA
TCTTGGTCGT TTAGGTTGCT GTCAGTTATC GTCCGTAATG TTTAGTCTAA GTCTTTTTAT
1601 GTTTTGAGTA TAATTGTATA TAGTATAGAC TATAGCTATG TATGTACACT TTCCACTTAC
CAAAACTCAT ATTAACATAT ATCATATCTG ATATCGATAC ATACATGTGA AAGGTGAATG
1701 CTGCTTTTAG AAGTTCTGCA CAATTCTGAT TTTTACCAAG TCAACCTACT TCTTCTCTCA
GACGAAAATC TTCAAGACGT GTTAAGACTA AAAATGGTTC AGTTGGATGA AGAAGAGAGT
1801 TTTCCAGAAG AAAAAAAATG CTCCAGTTTT CTCCTCTACC AAGACAGGAA GCACTTCCTG
AAAGGTCTTC TTTTTTTTAC GAGGTCAAAA GAGGAGATGG TTCTGTCCTT CGTGAAGGAC
1901 GAGAGAAATT AGTAAAGTAG GTTGTATCAT CCTACTTTGA ATTTGGAATG TTTGGAAATG
CTCTCTTTAA TCATTTCATC CAACATAGTA GGATGAAACT TAAACCTTAC AAACCTTTAC
2001 TGCGGGTGAT CCAAACAAAC ACTGTCACTC TTTAAAAGCT GCGCTCCCGA GGTTGGACCT
ACGCCCACTA GGTTTGTTTG TGACAGTGAG AAATTTTCGA CGCGAGGGCT CCAACCTGGA
2101 AGAGCTAAGT AAAGCCAGTG GAAATGAAGA GTCTTCCAAT CCTACTGTTG CTGTGCGTGG
TCTCGATTCA TTTCGGTCAC CTTTACTTCT CAGAAGGTTA GGATGACAAC GACACGCACC
2201 TGAGGACACC AGCATGAACC TTGTTCAGGT AATTAACACT AACTGACCTG GCCAGGTGGG
ACTCCTGTGG TCGTACTTGG AACAAGTCCA TTAATTGTGA TTGACTGGAC CGGTCCACCC
334
THUMPD2 promoter
1 AAACAAGAGT AGCCCCGACC TTGCTGACCA AAGGCTCCTG GAGGGGAAAA GACATCAGAA
TTTGTTCTCA TCGGGGCTGG AACGACTGGT TTCCGAGGAC CTCCCCTTTT CTGTAGTCTT
101 AAACTGCAGC CTCAGCTCAG CTGTGGTTTC ACCCAGGCCA GCACACTGCT GGTCGGTGCT
TTTGACGTCG GAGTCGAGTC GACACCAAAG TGGGTCCGGT CGTGTGACGA CCAGCCACGA
201 TGTACTGACA TAACTGGGCC CCTACCCACC GCTCTACCGC ATCTCTATCT ACTCCACTCA
ACATGACTGT ATTGACCCGG GGATGGGTGG CGAGATGGCG TAGAGATAGA TGAGGTGAGT
301 TTTCCTGTTC CCCACCCCCC ACACGCCGTC TCATTTTCAT CTGCTGCTTC TCCCTCTTAC
AAAGGACAAG GGGTGGGGGG TGTGCGGCAG AGTAAAAGTA GACGACGAAG AGGGAGAATG
401 AGCCCTCCCT GCCTCCTTTT TGTCGGTGCT GTCATAGCTT CCCGGGTATG TCCTCAGTGA
TCGGGAGGGA CGGAGGAAAA ACAGCCACGA CAGTATCGAA GGGCCCATAC AGGAGTCACT
501 ACCCTTGCTT ACCCATCTTT GAATCCTCAA GACAGGGTGG TGACTGGCGG AGAATAGGTG
TGGGAACGAA TGGGTAGAAA CTTAGGAGTT CTGTCCCACC ACTGACCGCC TCTTATCCAC
601 ATACTTAACA TCTTGGGCAC AGAATGTAGA GAGAACTAAA GAGGGTTCCT GTCCTCCCCA
TATGAATTGT AGAACCCGTG TCTTACATCT CTCTTGATTT CTCCCAAGGA CAGGAGGGGT
7 01 AAAATGAACT ACGGCAGTAG CCCAGAAAAG GAAAACATGT GTCTGAGGGC AAGAAAAGAA
TTTTACTTGA TGCCGTCATC GGGTCTTTTC CTTTTGTACA CAGACTCCCG TTCTTTTCTT
801 TCCCAGCACT TTGGGAGGCC GAGGCAGGCG GATCGCTTGA TCTCAGGAGT TCGAGACCAG
AGGGTCGTGA AACCCTCCGG CTCCGTCCGC CTAGCGAACT AGAGTCCTCA AGCTCTGGTC
901 AAAAATTAGC CCGGTGTGGT GGGGCTTGCC TGTGGTCCCA GCTACTGGAC AGGCTGAGGT
TTTTTAATCG GGCCACACCA CCCCGAACGG ACACCAGGGT CGATGACCTG TCCGACTCCA
1001 GCCAAGATCA CGTCACTGCG CTCCAGCCTG GGCGACAGAG GGAGACCCTG TCGCAAAAAA
CGGTTCTAGT GCAGTGACGC GAGGTCGGAC CCGCTGTCTC CCTCTGGGAC AGCGTTTTTT
1101 ACCTTGGAAA AGCTCATGTT ATGTGACTCC ATGAAGAATT TTTACTGTAC GGCCCAGTAG
TGGAACCTTT TCGAGTACAA TACACTGAGG TACTTCTTAA AAATGACATG CCGGGTCATC
1201 CGGGGGAGGT GAGGGAGTAT CAGTTCTTCA CCTTAACATC CCATTCTGAA GCACAGGACA
GCCCCCTCCA CTCCCTCATA GTCAAGAAGT GGAATTGTAG GGTAAGACTT CGTGTCCTGT
1301 TAACTGACTC AATATACAGC TACAGAGCTA ATTTCACGCT GTTTATCTTG TAACATGGAT
ATTGACTGAG TTATATGTCG ATGTCTCGAT TAAAGTGCGA CAAATAGAAC ATTGTACCTA
1401 AAAATTCAGA GTTTAGAAAA ATGCCTTCAA ATACCGTTAG GAGAACCATT CAAATCAGGT
TTTTAAGTCT CAAATCTTTT TACGGAAGTT TATGGCAATC CTCTTGGTAA GTTTAGTCCA
1501 TGGTTAACTA AGTAGTGCAA GAAATATGAG CTGTTTCAGA ACGCAGACGT TTGTTAGAGA
ACCAATTGAT TCATCACGTT CTTTATACTC GACAAAGTCT TGCGTCTGCA AACAATCTCT
1601 GGCCCGATTC TTTGTGAAAA CAGACCAGGG CTCCTTCTAT GAGAAGAGTA GAGGAGAGGA
CCGGGCTAAG AAACACTTTT GTCTGGTCCC GAGGAAGATA CTCTTCTCAT CTCCTCTCCT
17 01 AAAAGGCATT ATGTTAGATA GGGAGAAATC TAGGCTCCAG CCTCAGCTGT GCTGCTAACT
TTTTCCGTAA TACAATCTAT CCCTCTTTAG ATCCGAGGTC GGAGTCGACA CGACGATTGA
1801 TACAAAATAA GGCAACTGGA CTGAATTATC AATTCTAACC CTTCCACCTG TGATTCTAAC
ATGTTTTATT CCGTTGACCT GACTTAATAG TTAAGATTGG GAAGGTGGAC ACTAAGATTG
1901 CAGGAAGACC CATAGGGGCC ACAGAGGGCT GATGCGACCC TCCCAGGCTC TCCGTCTCTC
GTCCTTCTGG GTATCCCCGG TGTCTCCCGA CTACGCTGGG AGGGTCCGAG AGGCAGAGAG
2001 CCTCTCCCTC TCCCTCTCCC CTTTGGCATC ACACGCCCCT GCGCGCCGCC TCCAGGAGCG
GGAGAGGGAG AGGGAGAGGG GAAACCGTAG TGTGCGGGGA CGCGCGGCGG AGGTCCTCGC
2101 GGCGCGCCTG AGCCGCCATG TCGGAGGCGC GTGGAGAGCC AGGGTCCGGG CCTGAGGCTG
CCGCGCGGAC TCGGCGGTAC AGCCTCCGCG CACCTCTCGG TCCCAGGCCC GGACTCCGAC
2201 GTTCGTAATG CGAGAGGTG
CAAGCATTAC GCTCTCCAC
335
TM4SF1 promoter
1 GTAGTTTAAG CATCACTTTC CCCCATTTTG GCCCCAGGTG GGATAGATCA GCAGACAGGA
CATCAAATTC GTAGTGAAAG GGGGTAAAAC CGGGGTCCAC CCTATCTAGT CGTCTGTCCT
101 CACCCATAGG CTCTGTCACC AGTGGAATCC TGTCTCTAAG CCATCGGGCC AAACACACGT
GTGGGTATCC GAGACAGTGG TCACCTTAGG ACAGAGATTC GGTAGCCCGG TTTGTGTGCA
201 TTATGAGGAT TTGCCTGCCT CCGCCTGAGC AGGTGGGTGG TTCCACGCTT CCCAACTCCA
AATACTCCTA AACGGACGGA GGCGGACTCG TCCACCCACC AAGGTGCGAA GGGTTGAGGT
301 CCCTGTTAGT GTGCTGAGGC CACACTTCTT GGGCCCTCCT CCGGTCCCAT GCCACATCAC
GGGACAATCA CACGACTCCG GTGTGAAGAA CCCGGGAGGA GGCCAGGGTA CGGTGTAGTG
4 01 CCTCTAGTTC CGGGCCAAAT CCTTCAGACT CTAGATTCGT GAACCTCATT CACCTTCTTC
GGAGATCAAG GCCCGGTTTA GGAAGTCTGA GATCTAAGCA CTTGGAGTAA GTGGAAGAAG
501 TCTGTACTCT CTATCTTGTC CTGGTGACAA GGCCCTCCAG GCCTGGCCCC ACCCGGCCAC
AGACATGAGA GATAGAACAG GACCACTGTT CCGGGAGGTC CGGACCGGGG TGGGCCGGTG
601 TGCTGTTCAA GGCATAAATT TATTCAGTGC CCAGCCCCTC CTTCTGCAAG GTAACCACCT
ACGACAAGTT CCGTATTTAA ATAAGTCACG GGTCGGGGAG GAAGACGTTC CATTGGTGGA
701 AGCCTGTGGA AGCTGGTCTC AGGATCTGGC TGGGTAAACC ATCTGTTTAC CTCTGTGTGG
TCGGACACCT TCGACCAGAG TCCTAGACCG ACCCATTTGG TAGACAAATG GAGACACACC
801 TTTCTCCACT CTGCTTGCCA AGTCCCTTTG TCTTATTTTT TTCTCCCTCT CCCTCCTTCC
AAAGAGGTGA GACGAACGGT TCAGGGAAAC AGAATAAAAA AAGAGGGAGA GGGAGGAAGG
901 TTCCTCCCTC CCTCCCTTCC TCCCTTTTTC CCTCTCTCCT TCTCTCCCTC CTTCTCTTCT
AAGGAGGGAG GGAGGGAAGG AGGGAAAAAG GGAGAGAGGA AGAGAGGGAG GAAGAGAAGA
1001 TCCCATTCTC TTCCTCCCCC TCTCTTCTTC CTCTTTTTAT TTTTGTCCCA TGCTTTAGGC
AGGGTAAGAG AAGGAGGGGG AGAGAAGAAG GAGAAAAATA AAAACAGGGT ACGAAATCCG
1101 CACTCAATAA TTTTTAAAAA GCACCTGAGC CCTTTGTGTT GACTGATGCC ACCTCTGTTG
GTGAGTTATT AAAAATTTTT CGTGGACTCG GGAAACACAA CTGACTACGG TGGAGACAAC
1201 GAACACTGAA ATCCATCCTG CAGAGCTTGC TGTAGGCAGA GTAAAGAAGT TTGCTCTGTA
CTTGTGACTT TAGGTAGGAC GTCTCGAACG ACATCCGTCT CATTTCTTCA AACGAGACAT
1301 AGACACCTTG TATTTAATAG ACAAGGAAAT GAGCTCAGGA GATTTGCCCC AGGTTGTAAA
TCTGTGGAAC ATAAATTATC TGTTCCTTTA CTCGAGTCCT CTAAACGGGG TCCAACATTT
14 01 GATTGGAAGC TGTCCAGACA GCTGCATGGA GCAGGGGCAC AGCTCACTGT CTTTCAAAGC
CTAACCTTCG ACAGGTCTGT CGACGTACCT CGTCCCCGTG TCGAGTGACA GAAAGTTTCG
1501 TGGAAAGTCA TGTTAGGCTT TCCTGTTGAT TCTTTATCTT GTGGAGGAGT TGCACAGTCA
ACCTTTCAGT ACAATCCGAA AGGACAACTA AGAAATAGAA CACCTCCTCA ACGTGTCAGT
1601 ACTGAGGCTG TTTCTCACAT CCTGCCCCTG GTTTTGCCTG TCCCAAGGAT TTCGTCTGAA
TGACTCCGAC AAAGAGTGTA GGACGGGGAC CAAAACGGAC AGGGTTCCTA AAGCAGACTT
1701 GCCTGCCATT AGGACCAATG AAAGCAAAGT ACCTCATCCC CTCAGTGACT AAGAATCGCA
CGGACGGTAA TCCTGGTTAC TTTCGTTTCA TGGAGTAGGG GAGTCACTGA TTCTTAGCGT
1801 GCTTTCTCCA CCAGAAGGGC ACACTTTCAT CTAATTTGGG GTATCACTGA GCTGAAGACA
CGAAAGAGGT GGTCTTCCCG TGTGAAAGTA GATTAAACCC CATAGTGACT CGACTTCTGT
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